<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006242.pub2" GROUP_ID="BREASTCA" ID="596105062304092846" MERGED_FROM="" MODIFIED="2014-05-15 00:58:54 +0100" MODIFIED_BY="Melina Willson" REVIEW_NO="68" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.12">
<COVER_SHEET MODIFIED="2014-05-15 09:55:23 +1000" MODIFIED_BY="Melina Willson">
<TITLE MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">Trastuzumab-containing regimens for metastatic breast cancer</TITLE>
<CONTACT>
<PERSON ID="19748" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Lorenzo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moja</LAST_NAME>
<SUFFIX>MD, MSc, Dr Pub Health</SUFFIX>
<POSITION/>
<EMAIL_1>lorenzo.moja@unimi.it</EMAIL_1>
<EMAIL_2/>
<URL>www.cochrane.it</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Biomedical Sciences for Health</DEPARTMENT>
<ORGANISATION>University of Milan - IRCCS Galeazzi Orthopaedic Institute</ORGANISATION>
<ADDRESS_1>Via Pascal 36</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20133</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390239014517</PHONE_1>
<PHONE_2/>
<FAX_1>+39023559048</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-05-15 09:55:23 +1000" MODIFIED_BY="Melina Willson">
<PERSON ID="70027863394252581072100427111233" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Sara</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Balduzzi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>sara.balduzzi@unimore.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine</DEPARTMENT>
<ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Modena</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1301210256018332930672354489367" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Stefania</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mantarro</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical and Experimental Medicine</DEPARTMENT>
<ORGANISATION>University of Pisa</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Pisa</CITY>
<ZIP>56125</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="31080024490424198366101207105525" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Valentina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Guarneri</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>valentina.guarneri@unipd.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Surgery, Oncology and Gastroenterology</DEPARTMENT>
<ORGANISATION>University of Padova, Istituto Oncologico Veneto IRCCS</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Padova</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6431969882E26AA2017F61BB201CBF66" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Ludovica</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tagliabue</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Doctor</POSITION>
<EMAIL_1>ludovica.tagliabue@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medical Staff Directory</DEPARTMENT>
<ORGANISATION>San Luca Hospital, Auxologic Institute</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6389" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Vanna</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pistotti</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>vanna.pistotti@marionegri.it</EMAIL_1>
<EMAIL_2/>
<URL>www.cochrane.it</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Italian Cochrane Centre and IRCCS Mario Negri Institute for Pharmacological Research</ORGANISATION>
<ADDRESS_1>Via La Masa, 19</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20156</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390239014301</PHONE_1>
<PHONE_2/>
<FAX_1>+390239000420</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19748" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Lorenzo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moja</LAST_NAME>
<SUFFIX>MD, MSc, Dr Pub Health</SUFFIX>
<POSITION/>
<EMAIL_1>lorenzo.moja@unimi.it</EMAIL_1>
<EMAIL_2/>
<URL>www.cochrane.it</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Biomedical Sciences for Health</DEPARTMENT>
<ORGANISATION>University of Milan - IRCCS Galeazzi Orthopaedic Institute</ORGANISATION>
<ADDRESS_1>Via Pascal 36</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20133</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390239014517</PHONE_1>
<PHONE_2/>
<FAX_1>+39023559048</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11485" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Roberto</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>D'Amico</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant professor</POSITION>
<EMAIL_1>roberto.damico@unimore.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+39 3316213042</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine</DEPARTMENT>
<ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION>
<ADDRESS_1>Via del Pozzo 71</ADDRESS_1>
<ADDRESS_2/>
<CITY>Modena</CITY>
<ZIP>41124</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 059 4223865</PHONE_1>
<PHONE_2/>
<FAX_1>+39 059 4223235</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-05-13 17:23:22 +1000" MODIFIED_BY="Sara Balduzzi">
<UP_TO_DATE>
<DATE DAY="17" MONTH="1" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="1" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="1" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="8" YEAR="2014"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2013-01-21 14:29:33 +1100" MODIFIED_BY="Melina L Willson"/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2014-05-12 18:34:39 +1000" MODIFIED_BY="sara ">
<INTERNAL_SOURCES MODIFIED="2014-05-12 18:34:00 +1000" MODIFIED_BY="sara ">
<SOURCE MODIFIED="2014-05-12 18:34:00 +1000" MODIFIED_BY="sara ">
<NAME>Italian Cochrane Centre, University of Modena and Reggio Emilia</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Mario Negri Institute</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-05-12 18:34:39 +1000" MODIFIED_BY="sara ">
<SOURCE MODIFIED="2014-05-12 18:34:39 +1000" MODIFIED_BY="sara ">
<NAME>Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco) - CUP H95E07000130005</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-05-07 18:30:37 +1000" MODIFIED_BY="sara ">
<SUMMARY MODIFIED="2014-05-01 02:14:44 +1000" MODIFIED_BY="sara ">
<TITLE MODIFIED="2013-08-06 21:47:37 +1000" MODIFIED_BY="sara ">Efficacy and safety of trastuzumab in metastatic breast cancer</TITLE>
<SUMMARY_BODY MODIFIED="2014-05-01 02:14:44 +1000" MODIFIED_BY="sara ">
<P>Tumours characterised by the presence of the HER2 protein are found in about one in five women with metastatic breast cancer. These tend to be more aggressive and the prognosis and choice of treatment are affected. Trastuzumab (Herceptin®) is a targeted biological drug (a monoclonal antibody) that attaches to the HER2 protein, blocking the growth of malignant cells.</P>
<P>We included seven trials with 1497 women who had HER2-positive metastatic breast cancer in this review. They were assigned by chance to receive trastuzumab with or without chemotherapy (taxane, anthracycline or capecitabine in four studies), hormonal therapy (aromatase inhibitors including letrozole or anastrozole in two studies) or targeted therapy (lapatinib in one study). Women treated with trastuzumab were followed up until disease progression in five studies and beyond disease progression in two studies. The length of trastuzumab administration varied between 8.7 and 30 months, and follow-up averaged two years after starting trastuzumab.</P>
<P>All studies found that trastuzumab extends time to disease progression, with gains varying between two and 11 months, and in five studies it extended time to death by between five and eight months. However, some patients develop severe heart toxicity (congestive heart failure) during treatment. While trastuzumab reduces breast cancer mortality by one-fifth, the risk of heart toxicity is between three and four times more likely. If 1000 women were given standard therapy alone (with no trastuzumab) about 300 would survive and 10 would have heart toxicities. With the addition of trastuzumab to this treatment, an additional 73 would have their lives prolonged, and an additional 25 would have severe heart toxicity. Omitting the anthracycline-trastuzumab arms (which would not be regarded as standard of care) 21 patients would have severe heart toxicity (11 more than the chemotherapy alone group). These heart toxicities are often reversible if the treatment is stopped once heart disease is discovered. Women with advanced disease might choose to accept this risk. On balance, this review shows that with trastuzumab the time to disease progression and survival benefits outweigh the risk of heart harm.</P>
<P>Trastuzumab does not increase the risk of haematological toxicities, such as neutropenic fever and anaemia; however, it seems to raise the risk of neutropenia. There were insufficient data on the impact of trastuzumab on quality of life, treatment-related deaths and brain metastases to reach a conclusion for these outcomes.</P>
<P>We rated the overall quality of the evidence as moderate, with the main weaknesses being the fact that all studies included were open-label (not blinded), which may have affected the outcome assessments for time to disease progression and toxicities, and that two studies have not published their results for mortality. Furthermore, the recruitment in three out of seven studies was stopped early and in three trials more than 50% of patients in the control groups were permitted to switch to the trastuzumab arms at disease progression, making it more difficult to understand the real net benefit of trastuzumab on mortality. The evidence to support the use of trastuzumab beyond disease progression is limited.</P>
<P>It is important to highlight that, although trastuzumab is used for women with HER2-positive early breast cancer, the women enrolled in these metastatic trials were not previously treated with trastuzumab. The effectiveness of trastuzumab for women relapsing after adjuvant trastuzumab is still an open issue, although it is likely that it is offered to the majority of them.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-04-29 17:15:29 +1000" MODIFIED_BY="sara ">
<ABS_BACKGROUND MODIFIED="2014-04-18 21:25:45 +1000" MODIFIED_BY="[Empty name]">
<P>Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as HER2-positive) or not (HER2-negative). Typically, patients with HER2-positive disease have a worse prognosis. Trastuzumab is a selective treatment that targets the HER2 pathway. The available evidence supporting trastuzumab regimens mostly relies upon surrogate endpoints and, although the efficacy results seem to support its use, other uncertainties have been raised about its net benefit in relation to transient cardiac toxicity and a long-term increased risk of metastasis to the central nervous system.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-04-29 17:15:29 +1000" MODIFIED_BY="sara ">
<P>To assess the evidence on the efficacy and safety of therapy with trastuzumab (overall) and in relation to the type of co-administered regimen and the line of treatment, i.e. first-line or beyond progression, in women with HER2-positive metastatic breast cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-04-29 11:14:55 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Breast Cancer Group's (CBCG) Specialised Register and used the search strategy developed by the CBCG to search for randomised controlled trials (RCTs) in CENTRAL (2013, Issue 1), MEDLINE, EMBASE, BIOSIS, the WHO International Clinical Trials Registry Platform (ICTRP) search portal and ClinicalTrials.gov (up to 17 January 2013).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>RCTs comparing the efficacy and safety of trastuzumab alone or in combination with chemotherapy, hormonal therapy or targeted agents in women with HER2-positive metastatic breast cancer.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>We collected data from published trials. We used hazard ratios (HRs) for time-to-event outcomes and risk ratio (RRs) for binary outcomes. Subgroup analyses included type of regimen (taxane-containing, anthracycline-containing, aromatase inhibitor-containing or other) and treatment line (first-line, beyond progression).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-04-18 21:28:45 +1000" MODIFIED_BY="[Empty name]">
<P>The review found seven trials, involving 1497 patients, which met the criteria to be included. The trials were generally of moderate methodological quality; two studies have not published their results on overall survival so the presence of selective outcome reporting bias cannot be ruled out. None of the studies used blinding to treatment allocation, though this is unlikely to have biased the results for overall survival. Studies varied in terms of co-administered regimen and in terms of treatment line. In four studies, trastuzumab was administered with a chemotherapy, such as a taxane-containing, anthracycline-containing or capecitabine-containing regimen. Two studies considered postmenopausal women and administered trastuzumab with hormone-blocking medications, such as an aromatase inhibitor. One study administered trastuzumab in addition to lapatinib. Five studies out of seven included women treated with trastuzumab administered until progression as first-line treatment and two studies considered trastuzumab beyond progression. The combined HRs for overall survival and progression-free survival favoured the trastuzumab-containing regimens (HR 0.82, 95% confidence interval (CI) 0.71 to 0.94, P = 0.004; and HR 0.61, 95% CI 0.54 to 0.70, P &lt; 0.00001, respectively; moderate-quality evidence). Trastuzumab increased the risk of congestive heart failure (RR 3.49, 90% CI 1.88 to 6.47, P = 0.0009; moderate-quality evidence) and left ventricular ejection fraction (LVEF) decline (RR 2.65, 90% CI 1.48 to 4.74, P = 0.006). For haematological toxicities, such as neutropenic fever and anaemia, there was no clear evidence that risks differed between groups, while trastuzumab seemed to raise the risk of neutropenia. The overall survival improvement was maintained when considering patients treated as first-line or patients receiving taxane-based regimens. The progression-free survival improvement was maintained when considering patients receiving taxane-based regimens, and patients treated as first-line or subsequent lines. Few data were collected on central nervous system progression. Similarly, few studies reported on quality of life and treatment-related deaths.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-04-18 21:30:17 +1000" MODIFIED_BY="[Empty name]">
<P>Trastuzumab improved overall survival and progression-free survival in HER2-positive women with metastatic breast cancer, but it also increased the risk of cardiac toxicities, such as congestive heart failure and LVEF decline. The available subgroup analyses are limited by the small number of studies. Studies that administered trastuzumab as first-line treatment, or along with a taxane-based regimen, improved mortality outcomes. The evidence to support the use of trastuzumab beyond progression is limited. The recruitment in three out of seven studies was stopped early and in three trials more than 50% of patients in the control groups were permitted to switch to the trastuzumab arms at progression, making it more difficult to understand the real net benefit of trastuzumab.</P>
<P>Trastuzumab is generally used for women with HER2-positive early breast cancer in clinical practice, while women enrolled in most of the trials in the metastatic setting were naive to trastuzumab. The effectiveness of trastuzumab for women relapsing after adjuvant trastuzumab is therefore still an open issue, although it is likely that the majority are being offered it again.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-05-07 09:20:40 +1000" MODIFIED_BY="sara ">
<BACKGROUND MODIFIED="2014-04-18 21:37:45 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-04-18 21:26:05 +1000" MODIFIED_BY="[Empty name]">
<P>Breast cancer is the most commonly diagnosed cancer in women (<LINK REF="REF-Ferlay-2010" TYPE="REFERENCE">Ferlay 2010</LINK>), and the second leading cause of cancer-related death. Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as HER2-positive) or not (HER2-negative). The gene encoding the HER2 is amplified and the protein is over-expressed in 20% to 25% of women with metastatic breast cancer (<LINK REF="REF-Slamon-1987" TYPE="REFERENCE">Slamon 1987</LINK>). Patients with HER2-positive disease typically have a worse prognosis (<LINK REF="REF-Gschwind-2004" TYPE="REFERENCE">Gschwind 2004</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>The antibody trastuzumab (Herceptin®) was developed as a means of blocking the tyrosine kinase-linked human epidermal growth factor receptor-2 (HER2) (<LINK REF="REF-Coussens-1985" TYPE="REFERENCE">Coussens 1985</LINK>). The study by Baselga et al provided the first clinical evidence of the antitumour activity of this recombinant human monoclonal antibody against HER2 in patients with HER2 over-expressing breast carcinomas (<LINK REF="REF-Baselga-1996" TYPE="REFERENCE">Baselga 1996</LINK>). Research by Baselga et al and other follow-up studies have documented an important difference between trastuzumab and most standard chemotherapy agents due to its tolerability, with a favourable risk-benefit profile in patients with metastatic breast cancer (<LINK REF="REF-Cobleigh-1999" TYPE="REFERENCE">Cobleigh 1999</LINK>; <LINK REF="REF-Vogel-2001" TYPE="REFERENCE">Vogel 2001</LINK>). The most common adverse events are fever, chills and other acute and self limiting symptoms that may accompany the initial infusion of trastuzumab. Cardiac dysfunction has been reported with trastuzumab, particularly when used in combination with anthracycline-based chemotherapy, but many patients will recover with standard treatment for congestive heart failure (<LINK REF="REF-Seidman-2002" TYPE="REFERENCE">Seidman 2002</LINK>). Furthermore, it has been observed that patients with HER2 over-expressing metastatic breast cancer receiving trastuzumab are at an increased risk for isolated central nervous system progression (<LINK REF="REF-Burstein-2005" TYPE="REFERENCE">Burstein 2005</LINK>; <LINK REF="REF-Pestalozzi-2006" TYPE="REFERENCE">Pestalozzi 2006</LINK>), possibly because they are living longer with improved systemic disease control.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-04-18 21:37:45 +1000" MODIFIED_BY="[Empty name]">
<P>Due to reported improvements in time to disease progression and survival, the US Food and Drug Administration rapidly approved trastuzumab in 1998 for the treatment of women with metastatic breast cancer (<LINK REF="REF-FDA-1998" TYPE="REFERENCE">FDA 1998</LINK>). Other drug regulatory agencies approved trastuzumab following a longer period of scrutiny of the evidence - the UK National Institute for Health and Clinical Excellence recommended trastuzumab for women with HER2-positive advanced breast cancer in 2002 (<LINK REF="REF-NICE-2002" TYPE="REFERENCE">NICE 2002</LINK>). The evidence supporting trastuzumab regimens mostly relied upon surrogate endpoints (e.g. progression-free survival). The strength of this evidence has been questioned (<LINK REF="REF-Apolone-2005" TYPE="REFERENCE">Apolone 2005</LINK>; <LINK REF="REF-Joppi-2005" TYPE="REFERENCE">Joppi 2005</LINK>), and other uncertainties have been raised about the net benefit of trastuzumab, particularly related to transient cardiac toxicity and secondly to a long-term increased risk of metastasis to the central nervous system.</P>
<P>The purpose of this review is to systematically evaluate the evidence for the efficacy and safety of the use of trastuzumab alone or in combination with chemotherapy in women with metastatic breast cancer using evidence from randomised controlled trials. We recognise that since some of the adverse events of interest are rare but serious, and occur during long-term use of trastuzumab, we need to look also at non-randomised studies to address our question fully. We plan to carry out a systematic review of non-randomised studies as a second phase of this project.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-04-29 17:15:45 +1000" MODIFIED_BY="sara ">
<P>To assess the evidence on the efficacy and safety of therapy with trastuzumab (overall) and in relation to the type of co-administered regimen and the line of treatment, i.e. first-line or beyond progression, in women with HER2-positive metastatic breast cancer.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-04-29 11:16:12 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-04-29 11:15:55 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-08-19 14:53:55 +1000" MODIFIED_BY="Melina L Willson">
<P>Randomised controlled trials (RCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Women with HER2-positive metastatic breast cancer, of any age, menopausal status or hormone receptor status.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Intervention group: trastuzumab alone or in combination with chemotherapy, hormonal therapy or targeted agents.</LI>
<LI>Comparator: the same regimen used in the intervention group without trastuzumab.</LI>
</OL>
<P>Trials could include both women with metastatic disease and women with locally advanced/recurrent disease, as long as the data on the patients with metastatic disease could be extracted from the data reported.</P>
<P>Trials could or could not specify recommended treatment upon disease progression or initial treatment failure. We included trials where patients crossed over to the other treatment arm at the time of progression or received other treatment off-study in this review, and analysed these according to the treatment they were originally randomised to receive.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-04-29 11:15:55 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Overall survival on intention-to-treat analysis.</LI>
<LI>Progression-free survival.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-04-29 11:15:55 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Overall response rate.</LI>
<LI>Cardiac toxicity per protocol analysis (all patients who received the experimental treatment, regardless of compliance).</LI>
<LI>Other toxicities (defined and graded according to the World health Organization (WHO)/National Cancer Institute (NCI) toxicity Criteria.</LI>
<LI>Recurrence in central nervous system.</LI>
<LI>Treatment-related deaths.</LI>
<LI>Quality of life.</LI>
</UL>
<P>We applied the following definitions of the outcomes:</P>
<UL>
<LI>Overall survival: time from randomisation to death (from any cause).</LI>
<LI>Progression-free survival: time from randomisation to date of progression or death (from any cause). We considered time to progression (TTP - time from randomisation to date of progression) when progression-free survival was not reported.</LI>
<LI>Overall response rate: the proportion of patients with a complete or partial response. Partial response is defined as a decrease in the size of a tumour, or in the extent of cancer in the body, in response to treatment.</LI>
<LI>Cardiac toxicity: congestive heart failure and decline of left ventricular ejection fraction (LVEF). We considered the following definitions of congestive heart failure: cardiac dysfunction New York Heart Association class III-IV; severe, symptomatic or confirmed congestive heart failure. The decline of LVEF was defined as reported by the authors, as different thresholds were used.</LI>
<LI>Other toxicities: neutropenic fever (grade 3/4),; anaemia (grade 3/4) and neutropenia (grade 3/4).</LI>
<LI>Recurrence in central nervous system (CNS): the proportion of patients with disease progression due to metastases to CNS. Time to recurrence (also referred to as disease-free interval): time from date randomised to date of first CNS recurrence. Isolated metastasis to CNS confirmed radiologically by computed tomography (CT) or magnetic resonance imaging (MRI) scanning in patients with new brain or leptomeningeal metastasis.</LI>
<LI>Treatment-related death is defined as death due to drug toxicity not due to disease progression, reported as 'treatment-related', 'toxic death' or 'lethal toxicity'.</LI>
<LI>Quality of life: expression of well-being, measured through a validated scale (i.e. SF-36, European Organisation for Research and Treatment of Cancer (EORTC), Functional Assessment of Cancer Therapy (FACT)).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-04-29 11:16:12 +1000" MODIFIED_BY="[Empty name]">
<P>We limited our search to articles published after 1 January 1996; this is the date when Baselga and colleagues first presented data on the efficacy of trastuzumab in humans (<LINK REF="REF-Baselga-1996" TYPE="REFERENCE">Baselga 1996</LINK>).</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-04-29 11:16:12 +1000" MODIFIED_BY="[Empty name]">
<P>For RCTs, see: Cochrane Breast Cancer Group search strategy (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html">http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html</A>).</P>
<P>We searched the following databases:</P>
<OL>
<LI>Cochrane Breast Cancer Group (CBCG) Specialised Register on 14 January 2013. Details of the search strategy applied to create the register and the procedure used to code references are described in the Group's module in <I>The Cochrane Library</I>. The register includes both published and unpublished trials (including ongoing). We applied the CBCG codes 'advanced' and 'immunotherapy' to the Specialised Register and combined with the following keywords (imported with the references from MEDLINE): 'trastuzumab' [Substance Name], and a search of all non-indexed fields for the following text words: Trastuzumab, Herceptin or monoclonal antibod* AND HER2.</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>) on 17 January 2013 (Issue 1). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the search strategy;</LI>
<LI>MEDLINE (via OVID) (searched on 17 January 2013). Refer to <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</LI>
<LI>EMBASE (via EMBASE.com) (searched on 17 January 2013). Refer to <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</LI>
<LI>WHO International Clinical Trials Registry Platform (ICTRP) search portal (<A HREF="http://apps.who.int/trialsearch/AdvSearch.aspx">http://apps.who.int/trialsearch/AdvSearch.aspx</A>), for all prospectively registered and ongoing trials (searched on 17 January 2013). Refer to <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
<LI>ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">http://www.clinicaltrials.gov/</A>) (searched on 23 January 2013). Refer to <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</LI>
<LI>BIOSIS (host: ISI Web of Knowledge), January 1996 to current (searched on 23 January 2013). Refer to <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</LI>
</OL>
<P>We used the medical subject headings 'Breast Neoplasms', 'Antineoplastic Agents', 'Adverse effects' and 'Toxicity', and the text words 'Trastuzumab', 'Herceptin', 'Adverse effect', 'Side effect', 'Toxic effect', 'Drug toxicity', 'Drug tolerance', 'Causality', 'Risk', 'Adverse event', 'Adverse drug reaction', 'Breast cancer', 'Breast tumour', 'Breast tumor' and 'Breast neoplasm'. We included reports irrespective of the language in which they were reported.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Health Technology Assessment (HTA) Database and the Database of Abstracts of Reviews of Effects (DARE) to identify existing systematic reviews. We scanned the lists of studies included in these systematic reviews to assemble a list of known RCTs.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-04-18 21:42:45 +1000" MODIFIED_BY="[Empty name]">
<P>The methods of this systematic review partially overlap with another Cochrane review exploring the efficacy and safety of trastuzumab in early breast cancer (<LINK REF="REF-Moja-2012" TYPE="REFERENCE">Moja 2012</LINK>).</P>
<STUDY_SELECTION MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Three review authors (SB, SM and LT) independently screened the titles and abstracts of articles that were found for inclusion. We also assessed information available from conference proceedings on unpublished studies. We resolved disagreements by discussion. We obtained a copy of the full article for each reference reporting a potentially eligible trial. We sought further information from the authors where papers contained insufficient information to make a decision about eligibility. We applied the selection criteria described above to each trial. We recorded reasons for exclusion. We entered the characteristics and outcomes of the included trials, and details of the excluded trials, into our database.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Three review authors (SB, SM and LT) independently extracted information from the included trials using the pro-forma process piloted on a random sample of papers investigating other chemotherapy agents. Another review author (LM) checked data for correctness. We recorded details of study design, participants, setting, interventions, follow-up, quality components, efficacy outcomes and side effects. The extraction form is available from the review authors upon request. We also recorded details of previous therapies given to patients (including endocrine or other therapy). For studies with more than one publication, we extracted data from all of the publications. However, we considered the final or updated version of each trial to be the primary reference for efficacy and toxicity unless otherwise specified (i.e. a large part of the included patients crossed over to the other treatment arm during follow-up). We included trials where patients crossed over to the other treatment arm at the time of progression, or received the other treatment off-study and were managed according to the arm where they were originally randomised.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-04-18 21:42:45 +1000" MODIFIED_BY="[Empty name]">
<P>We based the 'Risk of bias' assessment on the data provided in the publications included. If a study was reported in more than one publication, we used the publication with the most complete reporting.</P>
<SUBSECTION>
<HEADING LEVEL="4">Randomised controlled trials</HEADING>
<P>We classified the generation of allocation sequence, allocation concealment, completeness of outcome data and selective outcome reporting as 'adequate' (low risk of bias), 'inadequate' (high risk of bias) or 'unclear' following the criteria specified in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Three review authors (SB, SM and LT) independently assessed trials according to the predefined quality criteria. Another review author (LM) checked data for correctness. We evaluated the impact of methodological quality only on the primary outcomes by considering the allocation concealment item.</P>
<P>We assessed the overall quality of evidence using the GRADE approach (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Randomised trials start as high-quality evidence, but may be downgraded due to: risk of bias (methodological quality), indirectness of evidence, unexplained heterogeneity, imprecision (sparse data) and publication bias. We determined the overall quality of the evidence for each outcome after considering each of these factors and judged this as follows.</P>
<UL>
<LI>High: further research is very unlikely to change our confidence in the estimate of effect.</LI>
<LI>Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</LI>
<LI>Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</LI>
<LI>Very low: any estimate of effect is very uncertain.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality assessment for observational studies</HEADING>
<P>In future updates of this review, we will separately assess the methodological quality of observational studies by using a component approach considering: concurrent, concomitant treatment; how allocation occurred; any attempt to balance groups by design; blinding of outcome assessment; completeness of follow-up; identification of prognostic factors (e.g. cardiovascular risk factors) and case-mix adjustment. These components are part of a list of quality items identified through a systematic review of the literature (<LINK REF="REF-Deeks-2003" TYPE="REFERENCE">Deeks 2003</LINK>). We will not assess the quality of case series or single case reports.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Survival-type outcomes</HEADING>
<P>The measure of association chosen for overall survival and progression-free survival was the hazard ratio (HR). A HR less than 1.0 favoured regimens containing trastuzumab and ratios larger than 1.0 favoured regimens that do not contain trastuzumab.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous outcomes</HEADING>
<P>The measure of association chosen for combining overall response rate and toxicities was the risk ratio (RR). For overall response rate, a RR greater than 1.0 favoured regimens containing trastuzumab, and less than 1.0 favoured regimens that do not contain trastuzumab. For toxicities, a RR greater than 1.0 indicated that the experimental treatment was more toxic than the control, and less than 1.0 suggested that the control was more toxic than the experimental treatment.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Where possible, we sought any missing data or unclear information using the Internet, by contacting the authors and by checking for the best available resource or publication.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity using the Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The I<SUP>2</SUP> statistic indicates the percentage of the overall variability that is due to between-study (or inter-study) variability, as opposed to within-study (or intra-study) variability. We assumed that latent clinical heterogeneity was ubiquitous, therefore we combined the studies using the random-effects model, regardless of statistical evidence for heterogeneity in the effect sizes. We classified an I<SUP>2</SUP> value greater than 50% as having substantial heterogeneity and discussed this accordingly (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>We evaluated the risk of outcome reporting bias for overall survival and progression-free survival. In each study, we assessed the absence of these outcomes and discussed its possible impact on the overall estimates.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>We directly extracted the HRs and their variances for overall survival and progression-free survival from the papers. If not reported, we indirectly obtained the HRs by using the methods described in <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>, employing either other available summary statistics or data extracted from published Kaplan-Meier curves.</P>
<P>For all adverse events and brain metastases, treated as binary data, we used the RR as the measure of association and fixed a higher type I error (&#945; = 0.10, two-sided) (<LINK REF="REF-Shadish-2002" TYPE="REFERENCE">Shadish 2002</LINK>).</P>
<P>We pooled the HRs and RRs on the log scale through the generic inverse variance approach, using the random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>We pre-specified two subgroup analyses:</P>
<OL>
<LI>analysis by type of regimen (anthracycline-based, taxane-based, other chemotherapy-based, other targeted agents-based);</LI>
<LI>line of chemotherapy for metastatic breast cancer (first-line versus other).</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>We conducted a sensitivity analysis in order to assess the impact of methodological quality on the primary outcomes, i.e. overall survival and progression-free survival, by considering the allocation concealment item.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-05-01 02:15:02 +1000" MODIFIED_BY="sara ">
<STUDY_DESCRIPTION MODIFIED="2014-04-18 21:50:29 +1000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2014-04-18 21:44:51 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised trials evaluating the efficacy of the therapy with trastuzumab in metastatic breast cancer therapy first started accruing patients in the early 1990s, as the first study on this topic was published in 1996<I> </I>(<LINK REF="REF-Baselga-1996" TYPE="REFERENCE">Baselga 1996</LINK>). Since then, research has rapidly moved forward on the treatment of metastatic and early breast cancer with this drug, judging from the number of articles reporting results from randomised and observational trials in PubMed. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for the results of the search strategy.</P>
<P>Search results from MEDLINE, EMBASE, CENTRAL, the CBCG's Specialised Register, BIOSIS databases and trial registers provided 7660 citations. After removing duplicates, there were 6407 citations remaining. Of these, we discarded 6368 after reviewing the titles and abstracts because they clearly did not meet the inclusion criteria. We examined the full text of the remaining 39 citations: three references did not meet the inclusion criteria (see: <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>) and we excluded 12 references as we could not find the full text. Twenty-four publications (corresponding to seven trials) met the inclusion criteria and we included them in this systematic review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-04-18 21:50:29 +1000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>We identified and defined seven eligible studies evaluating the efficacy or safety of trastuzumab in patients with HER2-over-expressing metastatic breast cancer as RCTs (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>; <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>). All studies were fully published in peer-reviewed journals. For two trials additional unpublished data were provided by the investigators or obtained from regulatory agency reports or trial registries (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>).</P>
<P>The study by <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> had four arms; two of them were experimental (anthracyclines or taxane plus trastuzumab) and two were control arms (anthracyclines or taxane alone). Data were reported for all arms, allowing us to lump together the two arms in which trastuzumab was administrated and the other two control arms.</P>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of patients</HEADING>
<P>The seven studies randomised a total of 1497 HER2-positive women; 752 women were allocated to the trastuzumab-containing arm and 745 to the non-trastuzumab-containing arm. All studies included women aged between 24 and 88 years and the reported median ages ranged from 51 to 59 years.</P>
<P>Five studies enrolled untreated metastatic patients and excluded those with brain metastases (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>). Previous adjuvant treatment with anthracyclines was permitted in <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> and <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>. <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> also included patients previously treated with taxanes. <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> considered eligible patients treated with tamoxifen or anastrozole. <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>, <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> and <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> did not clearly report the inclusion criteria with respect to prior treatment with anthracyclines or taxanes. <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> enrolled postmenopausal women with newly diagnosed hormone receptor (HR)-positive metastatic breast cancer or locally advanced breast cancer; none of the patients in this trial received aromatase inhibitors or trastuzumab in the adjuvant setting.</P>
<P>Two studies enrolled metastatic breast cancer patients who progressed during prior trastuzumab-based therapy (<LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>). In the von Minckwitz trial, the median duration of previous trastuzumab treatment was 45 weeks (range: 7 to 235 weeks) in the control arm and 44 weeks (range: 10 to 284 weeks) in the trastuzumab arm. In the trial by Blackwell, both groups had received a median of three prior trastuzumab regimens for metastatic disease. In the study by von Minckwitz, 3% of patients in the control arm and 1% of the patients in the trastuzumab arm had central nervous system metastases. <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> did not clearly report the inclusion criteria with respect to patients with central nervous system metastases.</P>
<P>As an inclusion criterion all the trials required normal heart function, with the exception of <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>, although patients were monitored for cardiac dysfunction.</P>
<P>Six RCTs included only HER2-positive patients (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>). In the study by Huober, an amendment for German sites permitted the implementation of a third arm where patients with HER2-negative and HR-positive tumours were assigned to receive letrozole alone as first-line treatment (<LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>). We only considered the data from HER2-positive patients for our analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions used in the trials</HEADING>
<P>Five trials evaluated trastuzumab as first-line treatment and administered it until progression (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>). Three trials combined trastuzumab with a taxane (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>). A second arm of <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> combined trastuzumab with an anthracycline plus cyclophosphamide. <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> used the regimen of trastuzumab with anastrozole. <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> used the regimen of trastuzumab with letrozole.</P>
<P>Two studies evaluated trastuzumab in patients with metastatic breast cancer who progressed after treatment with trastuzumab (<LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>); von Minckwitz combined trastuzumab with capecitabine while Blackwell combined trastuzumab with lapatinib. In the von Minckwitz study, patients could have received up to one chemotherapy drug for metastatic disease: 4% of patients in the trastuzumab arm received first-line treatment during the study; all the remaining included patients received second-line treatment. Blackwell combined trastuzumab in a heavily pretreated patient population (median number of prior trastuzumab-based regimens: three). In this trial, patients were randomised to receive either oral lapatinib 1500 mg daily or oral lapatinib 1000 mg daily in combination with trastuzumab. Although the treatment regimen in the control arm was not the same as in the trastuzumab arm (i.e. a 30% relative increase in the lapatinib dose), we decided to include the study in the meta-analysis and to exclude it in a sensitivity analysis.</P>
<P>In five studies the protocol prescribed trastuzumab at 2 mg/kg weekly doses (with a loading dose of 4 mg/kg) (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>). In the study by <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>, trastuzumab was administered at a dose of 6 mg/kg every three weeks (after a loading dose of 8 mg/kg). In the study by <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>, the protocol prescribed trastuzumab at 2 mg/kg weekly doses (with a loading dose of 4 mg/kg), but approximately two years after the start of the study trastuzumab was allowed to be given as a three-weekly application with a dose of 6 mg/kg (after a loading dose of 8 mg/kg).</P>
<P>The median number of doses of trastuzumab differed among studies: <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> prescribed a median of 36 doses, <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> 39 doses and <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> and <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> 25 doses each; for <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK> the median number of doses was nine. <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> and <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> did not clearly report information on the number of administered doses.</P>
<P>All studies reported detailed safety data with details of toxicities encountered in each arm.</P>
<P>Quality of life data were properly reported in two papers only, referring to the studies by <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> and <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK> (see Osoba 2002 and Wu 2011 sub-references).</P>
<P>All the trials were funded by pharmaceutical companies.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded three studies as ineligible for the reasons reported in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-04-18 21:53:37 +1000" MODIFIED_BY="[Empty name]">
<P>See: <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> ('Risk of bias' summary table).</P>
<P>Since the trials were conducted at multiple sites, it is likely that these trials had unbiased central randomisation procedures, protocol integrity and rigorous and reliable data registration, in order to satisfy regulatory authorities and human investigation committees. We could not directly assess methodological quality because details of the methods used (such as the mechanism of allocation concealment) were not always provided in the published reports or alternative presentations (i.e. meeting proceedings or regulatory agency reports). None of the studies used blinding to treatment allocation, a common practice in phase III oncological trials, because of the difficulty in concealing different infusion times, schedules and toxicities. This was unlikely to bias the results of the studies where overall survival was measured, as this outcome was not subject to observer or patient bias in interpretation.</P>
<ALLOCATION MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>All studies were described as randomised. We assessed the generation of a random sequence as adequate for three trials (<LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>); four studies did not report sufficient details (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005;</LINK> <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>; <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>). We assessed allocation concealment as adequate in one trial (<LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>).</P>
<P>Treatment groups were well balanced in four studies (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>). Clinically relevant imbalances were reported by:</P>
<UL>
<LI>
<LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>: compared to the trastuzumab group, the control group had more patients with positive oestrogen and progesterone receptors (56% versus 41%) and fewer patients receiving prior adjuvant anthracyclines (55% versus 64%);</LI>
<LI>
<LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>: more patients in the control arm (71%) than in the trastuzumab arm (42%) had received adjuvant systemic treatment, and tamoxifen as adjuvant endocrine treatment was given in 65% and 31% of patients, respectively;</LI>
<LI>
<LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>: T3-4 stage at first diagnosis was more frequent in the capecitabine and trastuzumab arm than in the capecitabine alone arm (respectively: 34% and 14%).</LI>
</UL>
<P>These imbalances may have introduced some biases in the estimated intervention effect.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>All the studies were open-label, so performance bias cannot be ruled out. Outcome assessment may be influenced by unblinded investigators or patients. While overall survival is unlikely to be influenced by a lack of blinding, open-label trials might be at high risk of bias, particularly trials using subjective outcomes such as quality of life or pain reduction. However, in trials testing trastuzumab, outcomes were assessed by combining subjective and objective dimensions: progression-free survival or congestive heart failure were confirmed through imaging and biochemical tests. The independence that these tests ensure from the investigator's subjective assessment is difficult to predict. We reasoned that the risk of detection bias in open-label trials for progression-free survival, overall response rate and congestive heart failure was marginal: we decided to rate studies as having unclear risk of bias for these outcomes. We suggest that trialists use central independent adjudication committees to evaluate these outcomes independently from the study site and completely blinded to the treatment allocation of the patient. This would eliminate any subjective element from the outcome assessment, guaranteeing a low risk of bias for outcome determination. Only <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> declared that they relied upon a blinded Response Evaluation committee.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>The rate of loss to follow-up was minimal (less than 3%) and accounted for in all of the trials. In <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>, although 26 patients (9%) had withdrawn consent or were lost to follow-up before death, only eight patients (2.7%) were lost to follow-up before progression (progression-free survival is the primary outcome of the study).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>The protocols for the studies were not available for <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> and <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>.</P>
<P>At the moment, <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> and <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> have not published or released their results for overall survival, therefore the presence of selective outcome reporting bias cannot be ruled out. <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> reported that the total number of deaths occurring in both arms was 42, but they did not provide information on how many patients died in the treatment and the control arms. <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> reported that there was no significant difference in overall survival between arms, without showing data. If the overall survival data are released, we will include these data in the review update. <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> reported results for the primary and secondary outcomes: it is likely that reporting bias has not occurred. In the paper published in 2011, <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK> reported updated results only for overall survival.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-04-18 21:53:37 +1000" MODIFIED_BY="[Empty name]">
<P>Two trials were closed prematurely because of slow recruitment (<LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>). Another trial was stopped early because data from other trials suggested that only patients with strong HER2 over-expression (3+) gain benefit from trastuzumab (<LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>). Three trials allowed patients in the control arm experiencing progression to cross over to the trastuzumab arm: 52%, 56% and 57% of patients in the control arm crossed over to the experimental arm, respectively (<LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>). Sixty-six per cent of the patients in the <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> trial, upon documented disease progression, were entered into the extension study H0659g, a non-randomised, open-label study in which they could receive either trastuzumab alone or in combination with a chemotherapy of choice.</P>
<P>The possibility of switching from the control arm to the experimental arm at progression makes it more difficult to interpret the results for overall survival (<LINK REF="REF-Moja-2012" TYPE="REFERENCE">Moja 2012</LINK>).<BR/>
</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-05-01 02:15:02 +1000" MODIFIED_BY="sara ">
<P>See: <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Efficacy of trastuzumab</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Overall survival</HEADING>
<P>Overall survival was reported in five out of the seven included trials (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>). Trastuzumab extended time to death by between five and eight months. We indirectly estimated the hazard ratio (HR) for the <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> trial by using the number of events occurring in each arm and the P value of the log-rank test. We indirectly estimated the HR for the <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> trial as the ratio of the medians for the time to death in the trastuzumab and control groups; we estimated its variance by dividing the total number of deaths by four, as suggested in <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>. For <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>, we considered the analysis that censored patient data at the time of cross-over after progression, as reported in the paper published in 2012. For the study by <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>, we considered the data reported in the paper published in 2011, which focused on overall survival: 119 deaths were observed.</P>
<P>Although each single study reported a non-statistically significant difference between groups, our meta-analysis showed a statistically significant improvement in overall survival among patients treated with trastuzumab-containing regimens compared to the control group (HR 0.82, 95% confidence interval (CI) 0.71 to 0.94, P = 0.004; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was no heterogeneity among studies (I<SUP>2</SUP> = 0%). The results are reported in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>We conducted a sensitivity analysis by excluding <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>, because the lapatinib dose was higher in the control arm compared to the trastuzumab arm. The result did not change substantially (HR 0.82, 95% CI 0.70 to 0.95, P = 0.009; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Overall survival stratified by type of regimen</HEADING>
<P>The taxane-containing regimen subgroup consisted of two studies (<LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> and the paclitaxel arms of <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>), while the other subgroups included one study each: in the anthracycline-containing regimen subgroup, there was the anthracycline arms of <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; in the aromatase inhibitor-containing regimen subgroup, there was <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; and in the lapatinib-containing regimen subgroup, there was the study by <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>. The taxane-containing regimen reported a statistically significant improvement in overall survival (HR 0.80, 95% CI 0.65 to 0.99, P = 0.04; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Overall survival stratified by treatment line</HEADING>
<P>The studies that administered trastuzumab as first-line treatment were <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>, <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> and <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>. <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> and <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK> considered trastuzumab beyond progression. The analysis showed that trastuzumab as first-line treatment improved overall survival (HR 0.79, 95% CI 0.67 to 0.94, P = 0.006; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The difference in overall survival did not reach statistical significance in the studies administering trastuzumab beyond progression (P = 0.27). The test for differences between treatment line subgroups was not statistically significant (P = 0.55). The results are reported in <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Progression-free survival</HEADING>
<P>Progression-free survival was provided by or estimated from all seven included trials (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>; <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>). For <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>, <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> and <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> we considered the time to progression. Although there were some differences in the definitions of time to progression (i.e. not considering death as an event contributing to the composite outcome), we judged these to have a minor impact on the overall analysis of progression-free survival (in <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> and <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>), due to the lack of heterogeneity between studies. Indeed we decided to pool the data irrespective of the progression-free survival definition adopted. Trastuzumab extended time to disease progression with gains varying between two and 11 months. We indirectly estimated the HR for the <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> trial as the ratio of the medians for the time to progression in the trastuzumab and control groups; we estimated its variance by using the relationship between the Chi<SUP>2</SUP> test and the log HR. It was not possible to report the total number of progression-free survival events since <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> and <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> did not report this basic information. For the study by <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>, we considered the intention-to-treat (ITT) analysis reported in the paper published in 2012. The analysis showed a statistically significant improvement in progression-free survival among patients treated with trastuzumab-containing regimens compared to the control group (HR 0.61, 95% CI 0.54 to 0.70, P &lt; 0.00001; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). We found low heterogeneity among studies (I<SUP>2</SUP> = 12%). The results are reported in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>The sensitivity analysis excluding <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> provided a very similar benefit favouring trastuzumab (HR 0.58, 95% CI 0.50 to 0.66, P &lt; 0.00001; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Progression-free survival stratified by type of regimen</HEADING>
<P>The taxane-containing regimen subgroup was composed of three studies (the paclitaxel arms of <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>, <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> and <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>), with a significant difference in progression-free survival (HR 0.53, 95% CI 0.42 to 0.68). In the anthracycline-containing regimen subgroup there were the anthracycline arms of <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>, with a significant improvement in progression-free survival (HR 0.78, 95% CI 0.68 to 0.91). In the subgroup who received aromatase inhibitor-containing regimens, the pooled hazard ratio for the <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> and <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> trials was statistically significant (HR 0.64, 95% CI 0.49 to 0.83). In the subgroup who received other types of regimens, the pooled hazard ratio for the <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> and <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK> trials was statistically significant (HR 0.72, 95% CI 0.59 to 0.88). Heterogeneity was not detected among studies in each subgroup (I<SUP>2 </SUP>= 0%). The variability among subgroups was high (I<SUP>2 </SUP>= 60.8%). Refer to <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> for these results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Progression-free survival stratified by treatment line</HEADING>
<P>The studies that administered trastuzumab as first-line treatment were <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>, <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>, <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>, <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> and <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>. <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK> and <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> considered trastuzumab beyond progression. The analysis showed that trastuzumab significantly improved progression-free survival, both as first-line treatment (HR 0.56, 95% CI 0.49 to 0.65, P &lt; 0.00001) and beyond progression (HR 0.72, 95% CI 0.59 to 0.88, P = 0.001). No heterogeneity was found among studies in each subgroup (I<SUP>2</SUP> = 0%). As expected, the test for differences between treatment line subgroups showed that trastuzumab seems to be more effective as first-line treatment compared to beyond progression (P = 0.04). The results are reported in <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall response rate</HEADING>
<P>The seven included trials reported information on overall response rates (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> according to ITT analysis; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> according to per protocol analysis). There were 293 cases (41.3%) out of 710 in the trastuzumab group and 178 (25.1%) out of 709 in the control group who had an overall response. The overall response rate was higher in patients treated with trastuzumab (risk ratio (RR) 1.58, 95% CI 1.38 to 1.82, P &lt; 0.00001) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Overall response rate stratified by type of regimen</HEADING>
<P>The analysis showed an overall response rate favouring the trastuzumab group for all subgroups. In the taxane-containing groups, the RR was 1.71 (95% CI 1.23 to 2.38, P = 0.002). In the anthracycline-containing groups, the RR was 1.33 (95% CI 1.04 to 1.70, P = 0.02). In the aromatase inhibitor-containing groups, the RR was 2.55 (95% CI 1.23 to 5.27, P = 0.01). In the subgroup that administered other types of regimens, the RR was 1.70 (95% CI 1.16 to 2.49, P = 0.006). See <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK> for these results. There was no heterogeneity among studies in each subgroup, with the exception of the taxane-containing subgroup (substantial heterogeneity, I<SUP>2</SUP> = 62%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Overall response rate stratified by treatment line</HEADING>
<P>The analysis showed that trastuzumab significantly improved overall response rate both as first-line treatment (RR 1.57, 95% CI 1.34 to 1.84, P &lt; 0.00001) and beyond progression (RR 1.70, 95% CI 1.16 to 2.49, P = 0.006; see <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). We found low heterogeneity among studies in the first-line subgroup (I<SUP>2</SUP> = 5%); we found no heterogeneity among studies in the beyond progression subgroup (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety of trastuzumab</HEADING>
<P>Data on cardiac dysfunction were reported in different ways among the included studies. We decided to combine data on major cardiac toxicities (e.g. congestive heart failure and cardiac dysfunction NYHA class III and IV) under the outcome congestive heart failure and to combine data on left ventricular ejection fraction (LVEF) decline, considering definitions for relevant decline as reported in the original study irrespective of the threshold used, under the outcome LVEF decline.</P>
<SUBSECTION>
<HEADING LEVEL="4">Congestive heart failure</HEADING>
<P>All seven included trials reported data on congestive heart failure or severe cardiac events, totaling 1459 patients with HER2-positive metastatic breast cancer. <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> reported a fatal cardiac event in the trastuzumab arm. From <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> two events were reported, one acute myocardial infarction occurred in the control arm and one ischaemic heart attack occurred in the trastuzumab arm. No symptomatic congestive heart failure was observed in <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>. <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> reported one grade 3 cardiac failure and one grade 4 myocardial ischaemia in the trastuzumab arm, while one grade 3 sinus tachycardia and one grade 4 myocardial ischaemia occurred in the control arm. <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> reported two symptomatic congestive heart failures in the trastuzumab arm. <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> observed cardiac dysfunction NYHA class III/IV in 25 in the trastuzumab arms and five in the control arms. In <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>, four patients in the trastuzumab arm experienced severe cardiac events.</P>
<P>There were 35 cases (4.7%) of severe cardiac event out of 738 in the trastuzumab group and 8/721 (1.1%) in the control group. The overall result indicated an increased risk of severe cardiac event with trastuzumab (RR 3.49, 90% CI 1.88 to 6.47, P = 0.0009; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). We detected no heterogeneity (I<SUP>2</SUP> = 0%). The results are reported in <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Congestive heart failure stratified by type of regimen</HEADING>
<P>Based on two arms in <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>, trastuzumab in combination with an anthracycline significantly increased the risk of a severe cardiac event compared with an anthracycline alone (RR 5.43, 90% CI 2.28 to 12.94, P = 0.001). There was a trend for such an increase for the taxane-containing regimens (RR 1.98, 90% CI 0.54 to 7.26, P = 0.39) and in the subgroup of studies administering other types of regimens (RR 5.31, 90% CI 0.87 to 32.20, P = 0.13), with the possible exception of those including aromatase inhibitors (RR 1.01, 90% CI 0.20 to 5.15, P = 0.99). Where applicable, we found no heterogeneity among studies in each subgroup (I<SUP>2</SUP> = 0%). The test for subgroup differences showed that the observed cardiotoxicity does not depend on type of regimen used (P = 0.40). Excluding from the analysis the anthracycline-containing arms of <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>, the RR failed to reach statistical significance (RR 2.06, 90% CI 0.85 to 4.99, P = 0.18). The results are likely to be influenced by the low number of events observed in most subgroups and differences between regimens have not been ruled out. Refer to <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Congestive heart failure stratified by treatment line</HEADING>
<P>Trastuzumab as first-line treatment seemed to significantly increase the risk of a severe cardiac event (RR 3.30, 90% CI 1.71 to 6.37, P = 0.003). We observed a larger increase in the subgroup of studies which administered trastuzumab beyond progression (RR 5.31, 90% CI 0.87 to 32.20, P = 0.13), although it did not reach the threshold for statistical significance. We found no heterogeneity among studies in each subgroup (I<SUP>2 </SUP>= 0%). The test for subgroup differences showed that the observed cardiotoxicity does not depend on the treatment line (P = 0.68). Refer to <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Decline in left ventricular ejection fraction</HEADING>
<P>Data on decline in LVEF could be extracted from six trials (<LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>; <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>). <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> observed 10 events of grade &#8805; 3 left ventricular systolic dysfunction or decrease in LVEF &#8805; 20% relative to the baseline value and below the normal lower limit (as defined by the institution) in the trastuzumab arm and three such events in the control arm. <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> observed one confirmed decrease of &#8805; 15 LVEF percentage points from baseline to &lt; 50% in the trastuzumab arm. In the study by <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>, a decrease in LVEF to less than 40% (or by greater than 10% from baseline) was observed in one patient in the trastuzumab group. No cases of significant decrease in LVEF occurred in <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>. <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> observed a mean decrease of 3% for patients in the control arm and of 7% in the trastuzumab arm. The different reporting meant that we could not include the data from <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> in the pooled analysis.</P>
<P>Based on five trials (<LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>; <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>), there were 28 cases (5.9%) of LVEF decline out of 478 women in the trastuzumab group and nine (2.0%) out of 460 in the control group. The pooled analysis indicated an increased risk of decline in LVEF with trastuzumab (RR 2.65, 90% CI 1.48 to 4.74, P = 0.006; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). No heterogeneity was detected (I<SUP>2</SUP> = 0%).</P>
<SUBSECTION>
<HEADING LEVEL="5">Decline in left ventricular ejection fraction stratified by type of regimen</HEADING>
<P>The analyses for the taxane-containing subgroups and the other regimens (that is capecitabine and lapatinib) showed a statistically significant increase in the risk of LVEF decline (respectively RR 2.36, 90% CI 1.12 to 4.96, P = 0.06; RR 3.21, 90% CI 1.19 to 8.64, P = 0.05). The results are inconclusive for the aromatase inhibitor-containing subgroup (RR 3.03, 90% CI 0.21 to 44.02, P = 0.50). The results are likely to be influenced by the low number of events observed in most subgroups. Where applicable, we observed no heterogeneity (I<SUP>2 </SUP>= 0%). Refer to <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Decline in left ventricular ejection fraction stratified by treatment line</HEADING>
<P>Trastuzumab seemed to increase the risk of LVEF decline both as first-line treatment and administered beyond progression (respectively RR 2.40, 90% CI 1.17 to 4.91, P = 0.04; RR 3.21, 90% CI 1.19 to 8.64, P = 0.05; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). We found no heterogeneity among studies in both subgroups (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other toxicities</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Neutropenic fever</HEADING>
<P>Three studies reported information on neutropenic fever (<LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>). There were 24 cases (10.3%) out of 232 in the trastuzumab group and 17 (7.5%) out of 228 in the control group. The increased risk of neutropenic fever in patients treated with trastuzumab was not statistically significant (RR 1.38, 90% CI 0.86 to 2.21, P = 0.26; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). We detected no heterogeneity (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Neutropenic fever stratified by type of regimen/treatment line</HEADING>
<P>A low number of studies reported data on neutropenic fever, therefore the subgroup analysis by type of regimen and the subgroup analysis by treatment line were the same. The subgroup composed of <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> and <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>, which administered trastuzumab along with a taxane-containing regimen and as first-line treatment, reported an increased risk of neutropenic fever which failed to reach statistical significance (RR 1.32, 90% CI 0.82 to 2.13, P = 0.34). In <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>, which administered trastuzumab along with capecitabine and beyond progression, a non-significant increased risk of neutropenic fever was observed (RR 4.81, 90% CI 0.38 to 60.61, P = 0.31). Where applicable, we found no heterogeneity (I<SUP>2</SUP> = 0%). Refer to <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> and <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaemia</HEADING>
<P>Four studies reported information on anaemia (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>). No events occurred in <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>. There were six cases (1.3%) out of 466 in the trastuzumab group and seven (1.5%) out of 458 in the control group. There was no evidence of an increased risk of anaemia in patients treated with trastuzumab (RR 0.93, 90% CI 0.37 to 2.35, P = 0.90) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). We observed no heterogeneity (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaemia stratified by type of regimen</HEADING>
<P>There was no evidence of an increased risk of developing anaemia in any of the subgroups defined by different regimens. For the taxane-containing regimen, the RR was 1.03 (90% CI 0.20 to 5.30, P = 0.97). For the anthracycline-containing regimen, the RR was 1.26 (90% CI 0.36 to 4.35, P = 0.76). For the subgroup of studies administering other types of regimens, the RR was 0.19 (90% CI 0.02 to 2.42, P = 0.28). The results are likely to be influenced by the low number of events observed in each subgroup. Where applicable, there was no heterogeneity (I<SUP>2 </SUP>= 0%). Refer to <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anaemia stratified by treatment line</HEADING>
<P>There was no evidence of an increased risk of anaemia in either subgroup. For the first-line subgroup, the RR was 1.19 (90% CI 0.44 to 3.19, P = 0.77) and for the beyond progression subgroup, the RR was 0.19 (90% CI 0.02 to 2.42, P = 0.28). Where applicable, we found no heterogeneity (I<SUP>2 </SUP>= 0%). Refer to <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Neutropenia</HEADING>
<P>Three studies reported information on neutropenia (<LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>). There were 41 cases (17.7%) out of 232 in the trastuzumab group and 28 (12.3%) out of 228 in the control group. The increased risk of neutropenia in patients treated with trastuzumab was of borderline statistical significance (RR 1.46, 90% CI 1.02 to 2.08, P = 0.08; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). We detected no heterogeneity (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Neutropenia stratified by type of regimen/treatment line</HEADING>
<P>A low number of studies reported data on neutropenia, therefore the subgroup analysis by type of regimen and the subgroup analysis by treatment line were the same. The subgroup composed by <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> and <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>, which administered trastuzumab along with a taxane-containing regimen and as first-line treatment, reported an increased risk of neutropenia of borderline statistical significance (RR 1.48, 90% CI 1.02 to 2.14, P = 0.09). In <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>, which administered trastuzumab along with capecitabine and beyond progression, the observed increased risk of neutropenia was not significant (RR 1.28, 90% CI 0.38 to 4.37, P = 0.74). Where applicable, we found no heterogeneity (I<SUP>2 </SUP>= 0%). Refer to <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK> (type of regimen) and <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK> (treatment line).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Recurrence in central nervous system</HEADING>
<P>One study reported information on brain metastases (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>). There were 42 cases (17.9%) out of 235 in the trastuzumab-containing group and 21/234 (9.0%) in the control group (RR 1.99, 95% CI 1.32 to 3.01). <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK>, which allowed the accrual of patients with known brain metastases, reported that nine (6.2%) out of the 146 patients treated with trastuzumab experienced central nervous system progression, whereas 15 patients (10.3) out of the 145 treated with lapatinib alone experienced progression while on study (RR 0.60, 90% CI 0.31 to 1.16). We decided against pooling the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment-related deaths</HEADING>
<P>
<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> reported that two deaths, both in the trastuzumab arm, were possibly related to the therapy. In the <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK> trial, two drug-related deaths occurred in the control arm. <LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> reported that one patient died in the trastuzumab arm with cardiac failure (concurrent with pulmonary thromboembolism) considered to be treatment-related. No drug-related deaths were observed in the <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>, <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK> and <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK> trials. <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> did not report data on treatment-related deaths.</P>
<P>We decided against pooling these data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life</HEADING>
<P>Quality of life, measured by the European Organization for Research and Treatment Care Quality of Life Questionnaire, was assessed in the study by Osoba 2002, which used data previously published in <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>. The authors showed that higher proportions of patients treated with a combination of trastuzumab and chemotherapy achieved improvement in global quality of life than did patients treated by chemotherapy alone.</P>
<P>
<LINK REF="STD-Blackwell-2010" TYPE="STUDY">Blackwell 2010</LINK> reported results on quality of life, assessed using the Functional Assessment of Cancer Therapy&#8211;Breast (FACT-B) questionnaire (version 4). It was reported that changes from baseline in the combination arm were comparable to the changes from baseline in the monotherapy arm for all of the subscales, so none of the differences between the two treatment arms were statistically significant, but data were not shown. Quality of life was also assessed in the study by Wu 2011, which used data from the Blackwell study, using the Functional Assessment of Cancer Therapy&#8211;Breast (FACT-B) questionnaire (version 4). The analyses presented showed that comparable quality of life was maintained in both arms during the investigational treatment period.</P>
<P>We decided against pooling these data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analysis: trastuzumab efficacy according to allocation concealment</HEADING>
<P>We judged allocation concealment to be adequate only for <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>, which did not report data on overall survival. Thus, it was not possible to conduct a sensitivity analysis by allocation concealment for overall survival with unclear/inadequate allocation concealment. The HR for progression-free survival in <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK> was 0.70 (95% CI 0.42 to 1.16, P = 0.17); the HR in the unclear/inadequate subgroup, which represents 94.1% of the total weight in the meta-analysis, was 0.61 (95% CI 0.53 to 0.70, P &lt; 0.00001; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). There was no statistically significant difference between the two subgroups.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-05-07 09:20:40 +1000" MODIFIED_BY="sara ">
<SUMMARY_OF_RESULTS MODIFIED="2014-05-02 19:53:16 +1000" MODIFIED_BY="sara ">
<P>This systematic review allowed us to measure the benefits of trastuzumab-based therapy in terms of response, progression-free survival and overall survival, and to quantify the risk of cardiac toxicities. The majority of studies were of fairly long duration, with the median duration of follow-up being two years, and were of moderate quality, the main weaknesses being the lack of blinding for progression-free survival and toxicity, and the potential outcome reporting bias for overall survival in two studies. The results should therefore be considered with this background in mind. All studies reported that trastuzumab extends time to disease progression, with gains varying between two and 11 months, and in five studies it extended time to death by between five and eight months. The meta-analysis showed a significant improvement in overall survival and progression-free survival for trastuzumab-containing regimens, which is possibly greater when considering patients treated as first-line compared to its use beyond progression, or patients receiving taxane-based regimens. For severe cardiac toxicities, we combined data across studies according to the premise that the adverse event profile of trastuzumab would be similar irrespective of the specific toxicity definition. We found that compared with control treatments, trastuzumab was associated with statistically significantly higher rates of serious cardiac toxicity. Subgroup comparisons revealed that the regimens did not differ from each other with respect to the relative risk of serious cardiac toxicities. The overall result of the meta-analysis on cardiotoxicity is influenced by the study of <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>, which is the first one that evaluated trastuzumab in addition to an anthracycline-containing regimen. Cardiotoxicity was unexpected at that time. The other studies do not show the same levels of cardiotoxicity, mainly due to the adoption of stricter enrolment criteria with respect to the baseline cardiovascular risk of patients. Indeed, in the subsequent trastuzumab studies, a normal baseline cardiac function was mandatory for study entry.</P>
<P>Human epidermal growth factor receptor 2 (HER2) positivity is associated with poor prognosis. Trastuzumab represents the paradigm of successfully developed targeted agents. Indeed, the target is measurable, the presence of the target is associated with a poorer outcome and target inhibition led to increased activity of standard therapy (<LINK REF="REF-Gschwind-2004" TYPE="REFERENCE">Gschwind 2004</LINK>). Moreover, trastuzumab has shown synergistic interaction with several cytotoxic agents (<LINK REF="REF-Pegram-2004" TYPE="REFERENCE">Pegram 2004</LINK>), and its overall tolerability facilitated the combination of trastuzumab with the majority of agents registered for metastatic breast cancer, with the exception of anthracyclines. Trastuzumab used in combination therapies produced gains in absolute survival over older single agents and the magnitude of these gains was around 7%, as showed in our sensitivity analysis excluding the study by Blackwell. Strong survival benefits are also obtained in early breast cancer (<LINK REF="REF-Moja-2012" TYPE="REFERENCE">Moja 2012</LINK>). Other molecular targeted therapies, such as bevacizumab or lapatinib, did not produced similar gains (<LINK REF="REF-Mauri-2008" TYPE="REFERENCE">Mauri 2008</LINK>; <LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>; <LINK REF="STD-Gelmon-2012" TYPE="STUDY">Gelmon 2012</LINK>; <LINK REF="REF-Wagner-2012" TYPE="REFERENCE">Wagner 2012</LINK>). For instance, in 2008 the FDA granted the accelerated approval of bevacizumab plus paclitaxel for advanced breast cancer (<LINK REF="REF-Miller-2007" TYPE="REFERENCE">Miller 2007</LINK>), on the basis of a supposed progression-free survival benefit. However, in 2010 the FDA removed the indication due to the lack of overall survival benefit in light of the possible side effects. A recent interim analysis of a trial designed to compare lapatinib or trastuzumab in combination with taxane-based chemotherapy for patients with metastatic breast cancer revealed that patients receiving trastuzumab had a statistically significant increase in progression-free survival (<LINK REF="STD-Gelmon-2012" TYPE="STUDY">Gelmon 2012</LINK>). As a matter of fact, trastuzumab remains a key, milestone drug in routine clinical practice and should be preferred over other treatment choices.</P>
<P>The possibility of developing cardiac toxicity (left ventricular ejection fraction (LVEF) decline or congestive heart failure) is a well known side effect of trastuzumab-based regimens (<LINK REF="REF-Moja-2012" TYPE="REFERENCE">Moja 2012</LINK>), and should be balanced against the benefits. In advanced disease, however, where the majority of the patients will eventually die with progressive disease, patients and doctors are likely to accept a higher risk of toxicity even for a slight survival benefit (<LINK REF="REF-Simes-2001" TYPE="REFERENCE">Simes 2001</LINK>). The absence of a statistically significant difference in the risk of developing severe cardiac toxicity reported in our subgroup analyses for the combination of trastuzumab with taxanes, aromatase inhibitors, capecitabine and lapatinib should not be interpreted as evidence of lack of cardiac toxicities, particularly if compared with the significant increase when trastuzumab is combined with anthracyclines. The increased risk of developing significant cardiotoxicity means that the concomitant administration of anthracyclines and trastuzumab is not recommended in clinical practice. Indeed, more recently, relatively small neoadjuvant studies conducted in selected patients with an earlier disease stage were reassuring in terms of the cardiac safety of combining anthracycline-based regimens and trastuzumab (<LINK REF="REF-Guarneri-2012" TYPE="REFERENCE">Guarneri 2012</LINK>; <LINK REF="REF-Buzdar-2013" TYPE="REFERENCE">Buzdar 2013</LINK>; <LINK REF="REF-Schneeweiss-2013" TYPE="REFERENCE">Schneeweiss 2013</LINK>). However, the overall limited number of patients does not allow recommendation of the use of this combination outside a clinical trial. Moreover, in the Z1041 phase III randomised study, the concurrent administration of trastuzumab with anthracyclines resulted in no additional benefit as compared to the standard administration of anthracyclines followed by taxanes-trastuzumab (<LINK REF="REF-Buzdar-2013" TYPE="REFERENCE">Buzdar 2013</LINK>). Currently, the results from this review inform us about an overall increase of the risk ratio of congestive heart failure of 3.49 in patients receiving trastuzumab-based therapy in metastatic breast cancer, irrespective of type of regimen used in combination with trastuzumab. Excluding the anthracycline-containing regimens, the RR lowers to 2.06 and fails to reach statistical significance. This toxicity might be mainly reversible and overall has little clinical relevance in the setting of advanced disease. On the other hand, in a large cohort of patients with breast cancer treated with trastuzumab outside clinical trials, cardiotoxicity varied considerably across subgroups of patients (e.g. age and history of cardiac disease were strong predictors of cardiotoxicity) and the long&#8211;term safety profile was less favourable (<LINK REF="REF-Bonifazi-2013" TYPE="REFERENCE">Bonifazi 2013</LINK>).</P>
<P>Trastuzumab does not increase the risk of haematologic toxicities, such as neutropenic fever and anaemia; it seems to raise the risk of neutropenia.</P>
<P>Central nervous system (CNS) metastases are another important issue in HER2-positive disease. Breast cancer is the second most common cancer that can metastasise to the CNS (<LINK REF="REF-Tabouret-2012" TYPE="REFERENCE">Tabouret 2012</LINK>). Early studies reported an increased incidence of brain metastases in patients receiving trastuzumab. Historically, CNS progression has occurred late in the clinical course of the disease and survival has been mainly affected by the lack of systemic disease control. More recently, the availability of several lines of therapy, along with a better knowledge of the disease biology, has resulted in a substantial change in the natural history of the disease. Today, it is well known that breast cancer is a heterogeneous disease, with a distinct clinical behaviour and pattern of relapse (<LINK REF="REF-Kennecke-2010" TYPE="REFERENCE">Kennecke 2010</LINK>). The improvement in systemic control is increasing the prevalence of metastatic breast cancer patients who develop CNS recurrence while having good extra-CNS disease control. Only one study reported data on CNS progression, precluding the possibility of drawing definitive conclusions on this issue. This study showed an almost doubled incidence of CNS progression in trastuzumab-treated patients. The observed increase of brain metastases in trastuzumab-treated patients is reasonably a consequence of improved extra-CNS disease control along with low or no effect on CNS anatomical site.</P>
<P>Few data were found on treatment-related deaths or on quality of life, making it difficult to understand the impact of trastuzumab on these.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-05-07 09:20:40 +1000" MODIFIED_BY="sara ">
<P>The results of our meta-analysis cannot be generalised to all women with metastatic breast cancer in clinical practice. Most of the women in the studies included in our review were younger than women usually affected by the disease (median age ranging from 51 to 59 years). Furthermore, the present analysis combines the results from the registrative RCT, which included women with different baseline risks for cardiotoxicity, and the results from more recent RCTs, which instead included only women with a normal baseline risk. The overall results for congestive heart failure are influenced by the anthracycline-containing regimens of the registrative study, which would not be regarded as standard of care if in combination with trastuzumab, but the lack of generalisability of the other included studies may have an impact on the estimates and the risks may be slightly increased in real-practice settings (<LINK REF="REF-Bonifazi-2013" TYPE="REFERENCE">Bonifazi 2013</LINK>). Therefore, careful cardiac monitoring is required before and while on trastuzumab-based therapy.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Two trials were closed prematurely because of slow recruitment and another trial was stopped early for apparent benefit. Three trials allowed patients in the control arm experiencing progression to cross over to the trastuzumab arm and in one trial, upon documented disease progression, two-thirds of the patients were entered into an extension non-randomised study, in which they could receive either trastuzumab alone or in combination with chemotherapy of choice. This can have an impact on the estimates, since one arm has a continuous exposure to the biologic, whereas in the other arm the exposure is first to the control treatment and then the biologic. The consequences of the cross-over lead to problems in data analysis and the interpretation of results (<LINK REF="REF-D_x0027_Amico-2011" TYPE="REFERENCE">D'Amico 2011</LINK>), especially for overall survival in a metastatic setting, so the risk-benefit profile of trastuzumab might have been modified by the switch.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>This systematic review has several strengths. We asked a specific clinical question and the search strategy was comprehensive. We included any publication of all relevant trials irrespective of language. We investigated the potential interaction between the treatment effect and potential effect modifiers. Finally, we rigorously applied the GRADE criteria for each of the relevant outcomes (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>).</P>
<P>This review also has limitations. Some readers may question the pooling of different cardiac toxicities. Since the overall numbers are relatively small, even limited changes in the definition of severe congestive heart failure or in LVEF thresholds might be associated with a higher or lower RR for adverse events.</P>
<P>A limitation of the current subgroup analyses is that they are based on published group data, rather than individual patient information. Individual patient data might allow a more detailed appraisal of outcomes for each regimen and for patients with different baseline risks. Still, the power to detect effect modification might still be limited even with individual patient information, particularly for cardiac toxicities. Thus, strong inferences about the specific efficacy or safety superiority of one particular regimen over the others should be avoided.</P>
<P>For this review, we limited inclusion to RCTs and their open-label extensions. Long-term observational studies, including population-based registries, can provide realistic estimates of the risks of trastuzumab in real settings. We are completing the analyses of a second phase of this project, which will include observational studies, to address the issue of the frequency of cardiac events outside clinical trials, their cumulative incidence over a longer period and the potential for reversibility.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>We found four other systematic reviews evaluating trastuzumab for the treatment of HER2-positive metastatic breast cancer (<LINK REF="REF-Mannocci-2010" TYPE="REFERENCE">Mannocci 2010</LINK>; <LINK REF="REF-Fleeman-2011" TYPE="REFERENCE">Fleeman 2011</LINK>; <LINK REF="REF-Harris-2011" TYPE="REFERENCE">Harris 2011</LINK>; <LINK REF="REF-Liao-2011" TYPE="REFERENCE">Liao 2011</LINK>). Although the outcomes and the methods do not totally overlap, there are no major disagreements with the results and conclusions of our systematic review. <LINK REF="REF-Mannocci-2010" TYPE="REFERENCE">Mannocci 2010</LINK> considered trastuzumab beyond progression: the review included 12 observational studies and the only RCT published at that time (<LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>); safety was not evaluated. Quality assessment was not done. From analyses of the observational studies, the authors found no significant differences among subgroups defined by type of regimen (capecitabine or vinorelbine). <LINK REF="REF-Fleeman-2011" TYPE="REFERENCE">Fleeman 2011</LINK> considered lapatinib or trastuzumab in combination with an aromatase inhibitor as first-line treatment. This health technology report included three RCTs, one assessing the efficacy and safety of lapatinib, and two assessing the efficacy and safety of trastuzumab (<LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>, and a 2009 conference abstract of the trial by <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK>). The authors decided against pooling the data. <LINK REF="REF-Harris-2011" TYPE="REFERENCE">Harris 2011</LINK> evaluated only the efficacy of HER2-targeted agents. The meta-analysis included eight trials, three of them assessing lapatinib and five assessing trastuzumab (<LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK>; <LINK REF="STD-Marty-2005" TYPE="STUDY">Marty 2005</LINK>; <LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>; <LINK REF="STD-Kaufman-2009" TYPE="STUDY">Kaufman 2009</LINK>; <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK>). There were no subgroup analyses by type of drug. The results for efficacy were similar to the results of our systematic review in terms of overall survival (hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.67 to 0.91), progression-free survival (HR 0.63, 95% CI 0.53 to 0.74) and overall response rate (RR 1.67, 95% CI 1.46 to 1.90). <LINK REF="REF-Liao-2011" TYPE="REFERENCE">Liao 2011</LINK> reported the results in a letter to the editor. The meta-analysis included four trials, mixing metastatic and early breast cancer patients. Results on overall survival, overall response rate and cardiac toxicity did not differ from our results. None of the other reviews reported results in absolute terms.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>The included trials had limitations: recruitment in three out of seven studies was slow or stopped early, in three trials more than 50% of patients in the control groups were permitted to switch to the trastuzumab arms at progression, all studies were open-label and there is potential selective outcome reporting bias with regard to overall survival in two studies. There is therefore moderate-quality evidence that the use of trastuzumab for metastatic breast cancer: a) improves both overall survival and progression-free survival in HER2-positive women; and b) increases by between three and four times the risk of severe cardiac toxicities.</P>
<P>From seven trials involving nearly 1500 women with HER2-positive metastatic breast cancer, the overall finding was that overall mortality was reduced by one-fifth after an average of two years of follow-up, but the risk of heart toxicity was more than three times greater for women in the group receiving trastuzumab compared to those receiving standard therapy alone. In absolute terms, if 1000 women were given standard therapy without trastuzumab then about 300 would survive for at least two years, but if 1000 women were treated with standard chemotherapy and trastuzumab until or beyond progression, about 373 would be alive two years after their diagnosis. However, about 35 in every 1000 women taking trastuzumab would experience severe heart toxicity, which is 25 more than for 1000 women taking the standard therapy alone. These heart problems are often reversible if the treatment is stopped straight away and, in the context of advanced disease, patients might choose to accept this risk given the potential benefit.</P>
<P>Treatment beyond progression might involve a greater risk of severe heart toxicities than first-line treatment, although these results are based on only two studies and few events.</P>
<P>The review did not identify a trastuzumab-containing regimen that may have been more or less effective or toxic, with the exception of the combination with anthracyclines that raises the risk of severe cardiac toxicity.</P>
<P>The evidence to support the use of trastuzumab beyond progression in metastatic disease is limited.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Trastuzumab is widely used for women with early breast cancer.</P>
<P>However, despite adjuvant trastuzumab, between 61 and 340 patients so treated are predicted to relapse and be considered for further anti-HER2 directed therapy in the metastatic setting in the first three years (<LINK REF="REF-Moja-2012" TYPE="REFERENCE">Moja 2012</LINK>). The effectiveness of trastuzumab for these patients is still an open issue since patients enrolled in trials in the metastatic setting were naive to trastuzumab. It is likely that the majority of the patients relapsing after adjuvant trastuzumab will be offered trastuzumab again even if the evidence of benefit is indirect. In our GRADE analysis we did not downgrade the overall quality of the evidence for the primary endpoints for indirectness. Guideline panellists need to explore carefully the implications of this issue.</P>
<P>In women with metastatic cancer progressing while on trastuzumab it is important to test either the continuation or stopping of trastuzumab or to switch to other options: lapatinib, pertuzumab and TDM-1. The optimal therapeutic strategy for this growing group of patients is still a matter of debate.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>The authors gratefully acknowledge Su Golder and Carol Lefebvre for valuable suggestions about bibliographic searches; Deirdre Price, Jessica Thomas and Andrew Herxheimer for valuable suggestions about methodological issues in analysing adverse events; Davina Ghersi, Sharon Parker, Nancy Owens and Nicholas Wilcken for their helpful assistance during all the phases of the preparation of the protocol; Mario Kopljar for the informatics support provided for the selection of studies; and Melina Willson for her helpful assistance during all the phases of the preparation of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-05-07 18:30:37 +1000" MODIFIED_BY="sara ">
<P>SB: nothing to declare.</P>
<P>SM: nothing to declare.</P>
<P>VG: she acted as speaker for GlaxoSmithkline, and as consultant for Novartis and AstraZeneca. VG institution received a grant from Roche to support a trial in which she is Principal Investigator.</P>
<P>LT: nothing to declare.</P>
<P>VP: nothing to declare.</P>
<P>LM: nothing to declare.</P>
<P>RD: nothing to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-04-30 22:41:09 +1000" MODIFIED_BY="sara ">
<P>Study concept: RD, LM.<BR/>Study protocol: RD, LM.<BR/>Search strategy: LM, VP.<BR/>Selection of studies: SB, SM, LM, LT.<BR/>Acquisition of data: SB, SM, LT.<BR/>'Risk of bias' assessment: SB, SM, LM, LT.<BR/>Analysis of data: SB, RD, LM.<BR/>Drafting of the manuscript: SB, RD, LM.<BR/>Interpretation and critical revision of the manuscript for important intellectual content: SB, RD, VG, SM, LM, LT, VP.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Protocol</HEADING>
<P>Intervention group: trastuzumab alone or in combination with chemotherapy.</P>
<P>Comparator: the same chemotherapy alone or no trastuzumab.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Review</HEADING>
<P>Intervention group: trastuzumab alone or in combination with chemotherapy, hormonal therapy or targeted agents.</P>
<P>Comparator: the same regimen used in the intervention group without trastuzumab.</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-08-18 03:00:47 +1000" MODIFIED_BY="sara "/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-04-18 22:18:21 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-04-18 20:15:41 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-04-18 20:15:41 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Blackwell-2010" MODIFIED="2014-04-18 20:05:56 +1000" MODIFIED_BY="[Empty name]" NAME="Blackwell 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-10 11:28:18 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Aktan G, et al</AU>
<TI>Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2&#8211;positive metastatic breast cancer: final results from the EGF104900 Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>21</NO>
<PG>2585-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:05:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al</AU>
<TI>Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>7</NO>
<PG>1124-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:05:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, et al</AU>
<TI>A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [Abstract 1015]</TI>
<SO>American Society of Clinical Oncology</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:05:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, et al</AU>
<TI>Impact of lapatinib plus trastuzumab versus single agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>12</NO>
<PG>2582&#8211;90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gasparini-2006" MODIFIED="2014-04-18 20:06:12 +1000" MODIFIED_BY="[Empty name]" NAME="Gasparini 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-10 11:29:39 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gasparini G, Gion M, Crivellari D, Morabito A, Rocco S, Spada A, et al</AU>
<TI>Interim analysis of a randomized phase IIb study of weekly paclitaxel (PCT) with or without trastuzumab (T) as first-line therapy of patients (pts) with HER-2/neu positive metastatic breast cancer (MBC): Clinical and biological results [Abstract 138]</TI>
<SO>American Society of Clinical Oncology</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:06:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, et al</AU>
<TI>Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer</TI>
<SO>Breast Cancer Research and Treatment</SO>
<YR>2007</YR>
<VL>101</VL>
<NO>3</NO>
<PG>355-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huober-2012" MODIFIED="2014-04-18 20:06:24 +1000" MODIFIED_BY="[Empty name]" NAME="Huober 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-18 20:06:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, et al</AU>
<TI>Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial</TI>
<SO>The Breast</SO>
<YR>2012</YR>
<VL>21</VL>
<NO>1</NO>
<PG>27-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaufman-2009" MODIFIED="2014-04-18 20:06:38 +1000" MODIFIED_BY="[Empty name]" NAME="Kaufman 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-18 20:06:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al</AU>
<TI>Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>33</NO>
<PG>5529-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marty-2005" MODIFIED="2014-04-18 20:14:24 +1000" MODIFIED_BY="[Empty name]" NAME="Marty 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-10 11:32:19 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Extra J, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al</AU>
<TI>Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer [Abstract 555]</TI>
<SO>American Society of Clinical Oncology</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:14:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Extra JM, Cognetti F, Chan S, Maraninchi D, Snyder R, Lluch A, Tubiana-Hulin M, et al</AU>
<TI>Randomised phase II trial (M77001) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>2003</YR>
<VL>1</VL>
<PG>Abstract 672</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:06:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al</AU>
<TI>Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>19</NO>
<PG>4265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slamon-2001" MODIFIED="2014-04-18 20:15:41 +1000" MODIFIED_BY="[Empty name]" NAME="Slamon 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-04-18 20:14:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baselga J, Kerrigan M, Burchmore M, Ash M</AU>
<TI>Health-related quality of life (HRQL) in women with HER2-overexpressing metastatic breast cancer (MBC) in a phase III study of Herceptin (R) plus chemotherapy versus chemotherapy alone</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<PG>Abstract 1276</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-10 11:33:24 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P</AU>
<TI>Isolated central nervous system metastases in patients withHER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy</TI>
<SO>Annals of Oncology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>11</NO>
<PG>1772&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-10 11:33:36 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eiermann W, on behalf of the International Herceptin Study Group</AU>
<TI>Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data</TI>
<SO>Annals of Oncology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>1</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:15:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Osoba D, Burchmore M</AU>
<TI>Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin) [Abstract]</TI>
<SO>Seminars in Oncology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:11:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Osoba D, Slamon DJ, Burchmore M, Murphy M</AU>
<TI>Effects of treatment with Her2mab (trastuzumab/Herceptin&#8482;) plus chemotherapy (H+C) versus chemotherapy alone (C) on health-related quality of life (HRQL) in women with HER-2/neu-overexpressing metastatic breast cancer [Abstract 109]</TI>
<SO>American Society of Clinical Oncology</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-10 11:35:21 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osoba D, Slamon DJ, Burchmore M, Murphy M</AU>
<TI>Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>14</NO>
<PG>3106-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:07:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bayamonde A, et al</AU>
<TI>Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>11</NO>
<PG>783-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-10 11:35:53 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G</AU>
<TI>Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer</TI>
<SO>Clinical Breast Cancer</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>4</NO>
<PG>293-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-10 11:34:36 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, et al</AU>
<TI>Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>6</NO>
<PG>1063-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Minckwitz-2009" MODIFIED="2014-04-18 20:07:35 +1000" MODIFIED_BY="[Empty name]" NAME="von Minckwitz 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-10 11:38:02 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pirvulescu C, Uhlig M, von Minckwitz G</AU>
<TI>Trastuzumab improves the efficacy of chemotherapy in breast cancer treatment beyond progression</TI>
<SO>Breast Care</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>5</NO>
<PG>364-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-10 11:38:40 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, et al</AU>
<TI>Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>2011</YR>
<VL>47</VL>
<NO>15</NO>
<PG>2273-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-10 11:39:11 +1000" MODIFIED_BY="sara " PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, et al</AU>
<TI>Capecitabine vs capecitabine+trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05) [Abstract 1025]</TI>
<SO>American Society of Clinical Oncology</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-18 20:07:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al</AU>
<TI>Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>12</NO>
<PG>1999-2006</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-04-18 20:13:38 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Gelmon-2012" MODIFIED="2014-04-18 20:13:20 +1000" MODIFIED_BY="[Empty name]" NAME="Gelmon 2012" YEAR="2010">
<REFERENCE MODIFIED="2014-04-18 20:13:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelmon KA, Boyle F, Kaufman B, Huntsman D, Manikhas A, Di Leo A, et al</AU>
<TI>Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>30 Suppl</VL>
<PG>Abstract LBA 671</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papaldo-2006" MODIFIED="2014-04-18 20:13:38 +1000" MODIFIED_BY="[Empty name]" NAME="Papaldo 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-18 20:13:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papaldo P, Fabi A, Ferretti G, Mottolese M, Cianciulli AM, Di Cocco B, et al</AU>
<TI>A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>4</NO>
<PG>630-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16410363"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raff-2004" MODIFIED="2013-09-10 11:40:53 +1000" MODIFIED_BY="sara " NAME="Raff 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-10 11:40:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raff JP, Rajdev L, Malik U, Novik Y, Manalo JM, Negassa A, et al</AU>
<TI>Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer</TI>
<SO>Clinical Breast Cancer</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>6</NO>
<PG>420-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15023243"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-04-18 22:18:21 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-04-18 22:18:21 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Apolone-2005" MODIFIED="2013-08-05 23:43:54 +1000" MODIFIED_BY="sara " NAME="Apolone 2005" TYPE="JOURNAL_ARTICLE">
<AU>Apolone G, Joppi R, Bertele V, Garattini S</AU>
<TI>Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures</TI>
<SO>British Journal of Cancer</SO>
<YR>2005</YR>
<VL>93</VL>
<NO>5</NO>
<PG>504-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baselga-1996" MODIFIED="2013-08-05 23:40:43 +1000" MODIFIED_BY="sara " NAME="Baselga 1996" TYPE="JOURNAL_ARTICLE">
<AU>Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al</AU>
<TI>Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>3</NO>
<PG>737-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonifazi-2013" MODIFIED="2013-09-10 11:41:42 +1000" MODIFIED_BY="[Empty name]" NAME="Bonifazi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Bonifazi M, Franchi M, Rossi M, Moja L, Zambelli A, Zambon A, et al</AU>
<TI>Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study</TI>
<SO>The Oncologist</SO>
<YR>2013</YR>
<VL>18</VL>
<NO>7</NO>
<PG>795-801</PG>
<IDENTIFIERS MODIFIED="2013-08-18 02:10:49 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="23823908"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Burstein-2005" NAME="Burstein 2005" TYPE="JOURNAL_ARTICLE">
<AU>Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P</AU>
<TI>Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy</TI>
<SO>Annals of Oncology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>11</NO>
<PG>1772-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buzdar-2013" MODIFIED="2014-04-18 20:16:44 +1000" MODIFIED_BY="[Empty name]" NAME="Buzdar 2013" TYPE="JOURNAL_ARTICLE">
<AU>Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, et al; American College of Surgeons Oncology Group investigators</AU>
<TI>Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial</TI>
<SO>The Lancet Oncology</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>13</NO>
<PG>1317-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cobleigh-1999" MODIFIED="2013-08-05 23:40:53 +1000" MODIFIED_BY="sara " NAME="Cobleigh 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al</AU>
<TI>Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>9</NO>
<PG>2639-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coussens-1985" MODIFIED="2013-08-06 02:01:27 +1000" MODIFIED_BY="sara " NAME="Coussens 1985" TYPE="JOURNAL_ARTICLE">
<AU>Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al</AU>
<TI>Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene</TI>
<SO>Science</SO>
<YR>1985</YR>
<VL>230</VL>
<NO>4730</NO>
<PG>1132-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Amico-2011" MODIFIED="2014-04-18 22:18:21 +1000" MODIFIED_BY="[Empty name]" NAME="D'Amico 2011" TYPE="CONFERENCE_PROC">
<AU>D'Amico R, Bonafede E, Balduzzi S, Longo G, Guarneri V, Piacentini F, et al</AU>
<TI>Unplanned crossover in randomized controlled trials: consequences for efficacy and safety outcomes</TI>
<SO>Abstracts of the 19th Cochrane Colloquium; 2011 October 19-22; Madrid</SO>
<YR>2011</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2003" MODIFIED="2013-08-06 01:55:43 +1000" MODIFIED_BY="sara " NAME="Deeks 2003" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al</AU>
<TI>Evaluating non-randomised intervention studies</TI>
<SO>Health Technology Assessment</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>27</NO>
<PG>iii-x, 1-173</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-1998" MODIFIED="2013-08-05 23:43:04 +1000" MODIFIED_BY="sara " NAME="FDA 1998" TYPE="OTHER">
<TI>U.S. Food and Drug Administration. FDA Oncology Tools Approval Summary for Trastuzumab for HERCEPTIN</TI>
<SO>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (accessed 5 Aug 2013)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferlay-2010" MODIFIED="2013-09-10 11:43:05 +1000" MODIFIED_BY="sara " NAME="Ferlay 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM</AU>
<TI>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</TI>
<SO>International Journal of Cancer</SO>
<YR>2010</YR>
<VL>127</VL>
<NO>12</NO>
<PG>2893&#8211;917</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleeman-2011" MODIFIED="2013-09-10 11:25:21 +1000" MODIFIED_BY="[Empty name]" NAME="Fleeman 2011" TYPE="JOURNAL_ARTICLE">
<AU>Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, et al</AU>
<TI>Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2(HER2): a systematic review and economic analysis</TI>
<SO>Health Technology Assessment NIHR HTA programme</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>42</NO>
<PG>1-93</PG>
<IDENTIFIERS MODIFIED="2013-09-09 08:01:03 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-09 08:01:03 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.3310/hta15420"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gschwind-2004" MODIFIED="2013-09-10 11:43:44 +1000" MODIFIED_BY="sara " NAME="Gschwind 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gschwind A, Fischer OM, Ullrich A</AU>
<TI>The discovery of receptor tyrosine kinases: targets for cancer therapy</TI>
<SO>Nature Reviews Cancer</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>5</NO>
<PG>361&#8211;70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guarneri-2012" MODIFIED="2014-04-18 20:18:25 +1000" MODIFIED_BY="[Empty name]" NAME="Guarneri 2012" TYPE="JOURNAL_ARTICLE">
<AU>Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al</AU>
<TI>Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>16</NO>
<PG>1989-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2014-04-18 20:18:44 +1000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendation</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-2011" MODIFIED="2013-09-10 11:45:16 +1000" MODIFIED_BY="[Empty name]" NAME="Harris 2011" TYPE="JOURNAL_ARTICLE">
<AU>Harris CA, Ward L, Dobbins TA, Drew AK, Pearson S</AU>
<TI>The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis</TI>
<SO>Annals of Oncology</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>6</NO>
<PG>1308-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-04-18 20:19:28 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2010" MODIFIED="2013-09-10 11:46:25 +1000" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Karassa FB</AU>
<TI>The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>341</VL>
<PG>c4875</PG>
<IDENTIFIERS MODIFIED="2013-08-18 01:44:28 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20837576"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Joppi-2005" MODIFIED="2013-08-05 23:44:00 +1000" MODIFIED_BY="sara " NAME="Joppi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Joppi R, Bertele V, Garattini S</AU>
<TI>Disappointing biotech</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>331</VL>
<NO>7521</NO>
<PG>895-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennecke-2010" MODIFIED="2013-09-10 11:46:54 +1000" MODIFIED_BY="sara " NAME="Kennecke 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al</AU>
<TI>Metastatic behavior of breast cancer subtypes</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>20</NO>
<PG>3271-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liao-2011" MODIFIED="2013-09-10 11:47:04 +1000" MODIFIED_BY="[Empty name]" NAME="Liao 2011" TYPE="JOURNAL_ARTICLE">
<AU>Liao C, Yin F, Huang P, Cao Y, Gao F</AU>
<TI>A meta-analysis of randomised controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer</TI>
<SO>The Breast Journal</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>1</NO>
<PG>109-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mannocci-2010" MODIFIED="2013-09-10 11:47:48 +1000" MODIFIED_BY="[Empty name]" NAME="Mannocci 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mannocci A, De Feo E, de Waure C, Specchia ML, Gualano MR, Barone C, et al</AU>
<TI>Use of trastuzumab in HER2-positive metastatic breast cancer beyond progression: a systematic review of published studies</TI>
<SO>Tumori</SO>
<YR>2010</YR>
<VL>96</VL>
<NO>3</NO>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mauri-2008" MODIFIED="2013-08-18 01:44:09 +1000" MODIFIED_BY="[Empty name]" NAME="Mauri 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP</AU>
<TI>Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>24</NO>
<PG>1780-91</PG>
<IDENTIFIERS MODIFIED="2013-08-18 01:44:06 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19066278"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-2007" MODIFIED="2013-09-10 11:48:06 +1000" MODIFIED_BY="sara " NAME="Miller 2007" TYPE="JOURNAL_ARTICLE">
<AU>Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al</AU>
<TI>Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>26</NO>
<PG>2666-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moja-2012" MODIFIED="2014-04-18 20:20:30 +1000" MODIFIED_BY="[Empty name]" NAME="Moja 2012" TYPE="COCHRANE_REVIEW">
<AU>Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al</AU>
<TI>Trastuzumab containing regimens for early breast cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-08-19 17:28:12 +1000" MODIFIED_BY="Melina Luise Willson">
<IDENTIFIER MODIFIED="2013-08-19 17:28:12 +1000" MODIFIED_BY="Melina Luise Willson" TYPE="DOI" VALUE="10.1002/14651858.CD006243.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NICE-2002" MODIFIED="2014-04-18 20:22:10 +1000" MODIFIED_BY="[Empty name]" NAME="NICE 2002" TYPE="OTHER">
<AU>National Institute for Health and Care Excellence</AU>
<TI>Breast cancer - trastuzumab [TA 34]</TI>
<SO>London: National Institute for Health and Care Excellence (http://www.nice.org.uk/page.aspx?o=29274) (accessed 9 February 2006)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2013-08-06 02:16:59 +1000" MODIFIED_BY="sara " NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pegram-2004" MODIFIED="2013-08-06 01:16:14 +1000" MODIFIED_BY="sara " NAME="Pegram 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ</AU>
<TI>Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2004</YR>
<VL>96</VL>
<NO>10</NO>
<PG>739-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pestalozzi-2006" MODIFIED="2014-04-18 20:22:52 +1000" MODIFIED_BY="[Empty name]" NAME="Pestalozzi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al</AU>
<TI>Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<PG>935-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneeweiss-2013" MODIFIED="2014-04-18 20:23:17 +1000" MODIFIED_BY="[Empty name]" NAME="Schneeweiss 2013" TYPE="JOURNAL_ARTICLE">
<AU>Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al</AU>
<TI>Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)</TI>
<SO>Annals of Oncology</SO>
<YR>2013</YR>
<VL>9</VL>
<PG>2278-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seidman-2002" MODIFIED="2013-08-05 23:41:06 +1000" MODIFIED_BY="sara " NAME="Seidman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al</AU>
<TI>Cardiac dysfunction in the trastuzumab clinical trials experience</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>5</NO>
<PG>1215-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shadish-2002" MODIFIED="2014-04-18 20:23:52 +1000" MODIFIED_BY="[Empty name]" NAME="Shadish 2002" TYPE="BOOK_SECTION">
<AU>Shadish WR, Cook TD, Campbell DT</AU>
<TI>Statistical conclusion validity and internal validity</TI>
<SO>Experimental and Quasi-experimental Designs for Generalized Causal Inference</SO>
<YR>2002</YR>
<PB>Houghton Mifflin Company</PB>
<CY>Boston</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simes-2001" MODIFIED="2013-09-05 19:10:53 +1000" MODIFIED_BY="[Empty name]" NAME="Simes 2001" TYPE="JOURNAL_ARTICLE">
<AU>Simes RJ, Coates AS</AU>
<TI>Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?</TI>
<SO>Journal of the National Cancer Institute. Monographs</SO>
<YR>2001</YR>
<VL>30</VL>
<PG>146-52</PG>
<IDENTIFIERS MODIFIED="2013-08-18 01:51:03 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11773309"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Slamon-1987" NAME="Slamon 1987" TYPE="JOURNAL_ARTICLE">
<AU>Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL</AU>
<TI>Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</TI>
<SO>Science</SO>
<YR>1987</YR>
<VL>235</VL>
<NO>4785</NO>
<PG>177-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tabouret-2012" MODIFIED="2014-04-18 20:24:24 +1000" MODIFIED_BY="[Empty name]" NAME="Tabouret 2012" TYPE="JOURNAL_ARTICLE">
<AU>Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Gonçalves A</AU>
<TI>Recent trends in epidemiology of brain metastases: an overview</TI>
<SO>Anticancer Research</SO>
<YR>2012</YR>
<VL>32</VL>
<NO>11</NO>
<PG>4655-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vogel-2001" MODIFIED="2013-08-05 23:41:00 +1000" MODIFIED_BY="sara " NAME="Vogel 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al</AU>
<TI>First-line Herceptin monotherapy in metastatic breast cancer</TI>
<SO>Oncology</SO>
<YR>2001</YR>
<VL>61 Suppl 2</VL>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagner-2012" MODIFIED="2013-09-10 11:49:55 +1000" MODIFIED_BY="sara " NAME="Wagner 2012" TYPE="COCHRANE_REVIEW">
<AU>Wagner AD, Thomssen C, Haerting J, Unverzagt S</AU>
<TI>Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2013-09-05 21:01:54 +1000" MODIFIED_BY="sara ">
<IDENTIFIER MODIFIED="2013-09-05 21:01:54 +1000" MODIFIED_BY="sara " TYPE="DOI" VALUE="10.1002/14651858.CD008941.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-04-29 11:21:48 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-04-29 11:21:48 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blackwell-2010">
<CHAR_METHODS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual time: November 2005 to November 2006<BR/>Multi-centre, international<BR/>Baseline comparability: balanced</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>296 female enrolled</P>
<P>Age: trastuzumab arm: median 52, range from 26 to 81; control arm: median 51, range from 29 to 78</P>
<P>
<U>Diagnosis</U>: metastatic breast cancer progressed during prior trastuzumab-based therapy</P>
<P>
<U>Inclusion criteria</U>: women &#8805; 18 years of age with histologically or cytologically confirmed BC. Patients must have metastatic disease that progressed on their most recent treatment regimen, which must have contained trastuzumab. Tumours with ErbB2 gene amplification as measured by fluorescence in situ hybridisation or ErbB2 over-expression as measured by immunohistochemistry (3+). Patients must have received prior anthracycline- and taxane-based regimens in either the adjuvant or metastatic setting. Eligible patients had at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) or bone-only disease. ECOG performance status of &#8804; 2; adequate haematologic, renal and hepatic function; and a cardiac ejection fraction within the institutional normal range. Written informed consent</P>
<P>
<U>Exclusion criteria</U>: see inclusion criteria</P>
<P>HER2+: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>2-arm RCT</U>
</P>
<P>
<U>Trastuzumab arm</U> (randomised N = 148): oral lapatinib (1000 mg daily) in combination with intravenous trastuzumab (2 mg/kg weekly, after the initial 4 mg/kg loading dose)</P>
<P>
<U>Control arm</U> (randomised N = 148): oral lapatinib (1500 mg daily)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: progression-free survival</P>
<P>Secondary: ORR (confirmed complete response plus partial response), clinical benefit response rate (confirmed complete response plus partial response at any time, plus stable disease for &#8805; 24 weeks), OS, quality of life, safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Study ID: EGF104900</P>
<P>Median length of time on study: 12.8 months (range 0.4 to 31.3) for patients receiving lapatinib + trastuzumab; 8.7 months (range 0.8 to 29.2) for patients receiving lapatinib alone</P>
<P>1 patient randomly assigned to the combination group did not receive study treatment, and 2 patients randomly assigned to lapatinib monotherapy received lapatinib in combination with trastuzumab, accounting for small differences between the ITT and safety populations</P>
<P>Patients analysed for ORR: trastuzumab arm N = 146; control arm N = 145</P>
<P>Patients analysed for safety: trastuzumab arm N = 149; control arm N = 146</P>
<P>Patients with objective disease progression after receiving at least 4 weeks of study treatment with lapatinib monotherapy were permitted to cross over to combination therapy: 77 patients (52%) crossed over after progression</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-18 22:15:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gasparini-2006">
<CHAR_METHODS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual time: December 2000 to September 2004<BR/>Multi-centre, national (Italy)<BR/>Baseline comparability: balanced</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-18 22:15:53 +1000" MODIFIED_BY="[Empty name]">
<P>123 female enrolled</P>
<P>Age: trastuzumab arm: median 56, range from 32 to 72; control arm: median 54.3, range from 30 to 71</P>
<P>
<U>Diagnosis</U>: untreated metastatic breast cancer</P>
<P>
<U>Inclusion criteria</U>: women over-expressing HER2/<I>neu</I> by the Hercep Test assay (score 2+ or 3+), measurable disease, age &#8805; 18 years, performance status &#8804; 2 according to the ECOG scale, life expectancy &gt; 3 months and adequate organ function, defined as follows: LVEF &gt; 50% or within normal limits, AST and ALT levels &#8804; 2.5 times the normal value, total bilirubin &lt; 1.5 the normal value, serum creatinine levels &#8804; 1.5 mg/dl, neutrophils &#8805; 2000/mm<SUP>3</SUP>, platelets &#8805; 100.000 mm<SUP>3</SUP>, haemoglobin &gt; 10 g/dl. Patients may have received an anthracycline and/or taxane-containing regimen given as adjuvant chemotherapy and relapsed &gt; 12 months following the end of chemotherapy</P>
<P>
<U>Exclusion criteria</U>: patients were excluded if they had received previous chemotherapy for metastatic disease, brain, leptomeningeal or bone metastases as the only site of disease, a positive history for other types of cancer, with the exception of <I>in situ</I> cervix cancer radically resected and non melanoma skin cancer, prior history of myocardial infarction, unstable angina pectoris, cardiac insufficiency, uncontrolled arrhythmia or hypertension, peripheral neuropathy of grade &#8805; 2 or pregnancy</P>
<P>HER2+: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>2-arm RCT</U>
</P>
<P>
<U>Trastuzumab arm</U> (randomised N = 63): paclitaxel (80 mg/m<SUP>2</SUP> weekly) plus trastuzumab (first loading dose of 4 mg/kg, followed by weekly doses of 2 mg/kg until disease progression)</P>
<P>
<U>Control arm</U> (randomised N = 60): paclitaxel (80 mg/m<SUP>2</SUP> weekly until disease progression)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: ORR<BR/>Secondary: safety profile, TTP and duration of response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Median follow-up for efficacy: 16.6 for both arms</P>
<P>Trial stopped early for benefit. Interim analyses not planned in the RCT protocol<BR/>Stopping characteristics:<BR/>- Interim analyses: after the first 124 patients enrolled (sample size planned not reported)<BR/>- Outcome: ORR<BR/>- Details of stop: trialists interrupted the accrual but monitored follow-up of enrolled patients<BR/>- Monitoring methods/stopping boundaries: not planned - the decision was based on: 1. data from other trials suggesting that only the patients with strong HER2 over-expression (3+) gain benefit from trastuzumab; 2. trial results confirmed a statistically significant superior outcome for the patients HER2-3+; 3. the planned statistical difference of 15% for ORR was reached<BR/>- Role of monitoring committee: not described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-29 11:20:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huober-2012">
<CHAR_METHODS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual time: 2003 to 2007<BR/>Multi-centre, international<BR/>Baseline comparability: more patients in the control arm (71%) than in the trastuzumab arm (42%) had received adjuvant systemic treatment. Tamoxifen was exclusively used for adjuvant endocrine treatment (given in 65% and 31% of patients, respectively)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-29 11:20:20 +1000" MODIFIED_BY="[Empty name]">
<P>57 female enrolled</P>
<P>Age: trastuzumab arm: median 61.5, range from 39 to 87; control arm: median 61, range from 47 to 88</P>
<P>
<U>Diagnosis</U>: HER2 and hormone receptor-positive metastatic breast cancer or locally advanced breast cancer</P>
<P>
<U>Inclusion criteria</U>: postmenopausal women with newly diagnosed hormone receptor-positive MBC or LABC defined as ER and/or PgR &#8805; 10 fmol/mg cytosol protein, or &#8805; 10% of the tumour cells positive as assessed by immunohistochemical evaluation of the primary tumour. For the trastuzumab and control arms, the primary tumour had to reveal HER2 over-expression defined as 3+ staining by IHC or HER2 amplification (ratio &gt; 2) by FISH or an equivalent method. No prior treatment for metastatic or locally advanced breast cancer; LVEF &#8805; 50% at baseline; adequate hepatic, renal and bone marrow function; an ECOG performance status of 0 or 1. Furthermore, patients were required to have at least 1 measurable tumour lesion (patients with bone only disease were eligible)</P>
<P>
<U>Exclusion criteria</U>: clinical or radiological signs of CNS metastasis; inflammatory breast cancer; other concurrent or previous malignant disease; uncontrolled cardiac diseases; prior anti-HER2 therapy apart from trastuzumab in the adjuvant setting.</P>
<P>HER2+: 61.3% (57/93). We considered HER2+ women alone</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-29 11:20:24 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>2-arm RCT</U>
</P>
<P>
<U>Trastuzumab arm</U> (randomised N = 26): letrozole (2.5 mg once daily) plus trastuzumab (first loading dose of 4 mg/kg, followed by weekly doses of 2 mg/kg until disease progression) iv until progression of disease. As of May 2005 trastuzumab was allowed to be given as 3-weekly application with the typical dose of 6 mg/kg (after a loading dose of 8 mg/kg)</P>
<P>
<U>Control arm</U> (randomised N = 31): letrozole (2.5 mg once daily until disease progression)</P>
<P>In addition, in an amendment for German sites, a third arm (N = 35) was implemented where patients with HER2-negative and hormone receptor-positive tumours were assigned to receive letrozole alone as first-line treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: time to disease progression (interval between the date of randomisation/start of treatment and the earliest date of progression, or of death due to the underlying breast cancer, or of death from a cause thought to be connected to the underlying disease)</P>
<P>Secondary: TTF, ORR/CBR, duration of response/clinical benefit and OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Study ID: eLEcTRA</P>
<P>Median follow-up: not specified</P>
<P>Closed prematurely due to slow recruitment: the total number of patients to be recruited in the trastuzumab and the control arms was planned to be 300 (150 per arm)</P>
<P>Trastuzumab was admitted as second-line treatment in 31% and the 52% of the treatment and control arms respectively</P>
<P>ClinicalTrials identifier: NCT00171847</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaufman-2009">
<CHAR_METHODS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual time: 2001 to 2004<BR/>Multi-centre, international<BR/>Baseline comparability: balanced<BR/>Co-intervention: in the trastuzumab plus anastrozole arm, patients had almost twice the duration of exposure to anastrozole compared with patients receiving anastrozole alone (median, 189 days compared to 98 days, respectively)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>208 female enrolled</P>
<P>Age: trastuzumab arm: median 56, range from 31 to 85; control arm: median 54, range from 27 to 77</P>
<P>
<U>Diagnosis</U>: metastatic breast cancer<BR/>
<U>Inclusion criteria</U>: postmenopausal women over-expressing HER2/<I>neu</I> by the Hercep Test assay (score 2+ or 3+), and/or fluorescence in situ hybridisation positive with two-fold amplification, hormone receptor-positive (ER-positive and/or PgR-positive). Previous treatment with tamoxifen as adjuvant or hormonal therapy or anastrozole was permitted. Other requirements included a LVEF greater than 50%; adequate baseline hepatic, renal and bone marrow function; an ECOG performance status of 0 to 1; and measurable or evaluable disease</P>
<P>
<U>Exclusion criteria</U>: prior chemotherapy for MBC or adjuvant chemotherapy within 6 months, clinical or radiologic evidence of CNS metastases; history of another malignancy, CHF or uncontrolled cardiac disease (angina, arrhythmias, hypertension); uncontrolled serious intercurrent illness; and severe dyspnoea at rest. Patients with previous radiotherapy to indicator lesions were excluded from the response evaluation<BR/>HER2+: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>2-arm RCT</U>
</P>
<P>
<U>Trastuzumab arm</U> (randomised N = 104): anastrozole (1 mg/d orally) plus trastuzumab (first loading dose of 4 mg/kg, followed by weekly doses of 2 mg/kg) until disease progression</P>
<P>
<U>Control arm</U> (randomised N = 104): anastrozole (1 mg/d orally) until disease progression<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: progression-free survival<BR/>Secondary: clinical benefit rate, overall response rate, time to disease progression, time to treatment failure, duration of response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Median follow-up for efficacy: not reported</P>
<P>Upon documented disease progression, 58 of 103 patients (56.3%) crossed over from anastrozole<SUP> </SUP>alone to trastuzumab while 15 patients (14.6%) received trastuzumab after study withdrawal<BR/>Response data were reported for only 147 patients (70.6%; trastuzumab plus anastrozole, n = 74; anastrozole alone, n = 73).<BR/>Hormone receptor positivity was confirmed in the central laboratory for 150 patients (trastuzumab plus anastrozole, n = 77; anastrozole alone, n = 73). ER/PgR negativity was found centrally in 44 patients (trastuzumab plus anastrozole, n = 21; anastrozole alone, n = 23) and central confirmation was not possible in 13 patients (trastuzumab plus anastrozole, n = 5; anastrozole alone, n = 8)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marty-2005">
<CHAR_METHODS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual time: April 2000 to October 2002<BR/>Multi-centre, international<BR/>Baseline comparability: baseline patients characteristics were generally balanced between the 2 arms, although there were more patients with oestrogen receptor- or progesterone receptor-positive disease in the docetaxel alone arm compared with the combination arm (56% versus 41%) and more patients had received prior (neo)adjuvant anthracyclines in the combination arm (64% versus 55%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>188 female enrolled</P>
<P>Age: trastuzumab arm: median 53, range from 32 to 80; control arm: median 55; range from 24 to 79</P>
<P>
<U>Diagnosis</U>: metastatic breast cancer<BR/>
<U>Inclusion criteria</U>: women age 18 to 70 years with HER2 over-expression (IHC 3+) and/or gene amplification (FISH positive) who had not previously received chemotherapy for metastatic<SUP> </SUP>disease. Patients could have received prior (neo)adjuvant anthracyclines (maximum cumulative dose, 360 mg/m<SUP>2</SUP> doxorubicin or 750 mg/m<SUP>2</SUP> epirubicin). Baseline LVEF had to be more than 50%. Hormonal therapy had to be discontinued before the first dose of study drug. Previous radiotherapy was allowed only if treatment had ended at least 14 days before enrolment into the trial and the patient had fully recovered from all acute adverse effects. ECOG performance status of &#8804; 2, life expectancy &#8805; 12 weeks, and at least one bidimensionally measurable lesion (according to WHO criteria). Bone marrow, renal and hepatic function: haemoglobin &#8805; 10 g/dL and no blood transfusion within the previous 2 weeks; neutrophil count &#8805; 2.0 x 109 cells/L; platelet count &#8805; 100 x 109 cells/L; no evidence of myelodysplastic syndrome or abnormal bone marrow reserve; creatinine &#8804; 1.5 x upper limit of normal (ULN) or creatinine clearance &#8805; 60 mL/min; total bilirubin less than 1 x ULN; AST and/or ALT &#8804; 2.5 x ULN; and alkaline phosphatase &#8804; 5 x ULN (patients with AST and/or ALT &gt; 1.5 x ULN concomitantly with alkaline phosphatase &gt; 2.5 x ULN were ineligible for the study)</P>
<P>
<U>Exclusion criteria</U>: patients who had received prior chemotherapy for their metastatic disease or any prior taxanes or anti-HER therapy were excluded. Patients who had brain or leptomeningeal metastases, significant cardiac insufficiency (New York Heart Association III or IV), myocardial infarction within the previous 6 months, unstable angina pectoris, uncontrolled arrhythmia, or advanced pulmonary disease or severe dyspnoea at rest due to complications of advanced malignancy, or who required supplementary oxygen therapy, were ineligible for the trial</P>
<P>HER2+: group 1: 97%; group 2: 94%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>2-arm RCT</U>
</P>
<P>
<U>Trastuzumab arm</U> (randomised N = 94): docetaxel (100 mg/m<SUP>2</SUP> every 21 days for 6 cycles) plus trastuzumab (first loading dose of 4 mg/kg, followed by weekly doses of 2 mg/kg until disease progression)</P>
<P>
<U>Control arm</U> (randomised N = 94): docetaxel (100 mg/m<SUP>2</SUP> every 21 days for 6 cycles)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: ORR<BR/>Secondary: OS, duration of response, time to disease progression, time to treatment failure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Study ID: M77001 Study Group</P>
<P>Median follow-up for efficacy: 24 months; minimum, maximum not reported<BR/>Upon documented disease progression, 53 of 94 patients (57%) crossed over from docetaxel<SUP> </SUP>alone to trastuzumab</P>
<P>Patients analysed: trastuzumab arm N = 92; control arm N = 94</P>
<P>Patients analysed for cardiac safety: trastuzumab arm N = 86; control arm N = 76</P>
<P>OS: HR estimated using the ratio of the medians. HR variance estimated using number of deaths in the 2 groups. Time to progression: HR estimated using the ratio of the medians. HR variance estimated using the relationship between Chi<SUP>2</SUP> and the log of the HR</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Slamon-2001">
<CHAR_METHODS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual time: June 1995 to March 1997<BR/>Multi-centre, international<BR/>Baseline comparability: balanced</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>469 female enrolled</P>
<P>Age: trastuzumab + anthracycline arm: mean 54, range from 27 to 76; anthracycline control arm: mean 54, range from 25 to 75; trastuzumab + taxane arm: mean 51, range from 25 to 77; taxane control arm: mean 51, range from 26 to 73</P>
<P>
<U>Diagnosis</U>: progressive metastatic breast cancer<BR/>
<U>Inclusion criteria</U>: women over-expressing HER2 who had not previously received chemotherapy for metastatic disease. Only patients who had weak-to-moderate staining of the entire tumour cell membrane for HER2 (referred to as a score of 2+) or more than moderate staining (referred to as a score of 3+) in more than 10% of tumour cells on immunohistochemical analysis were eligible<BR/>
<U>Exclusion criteria</U>: patients were excluded if they had bilateral breast cancer, untreated brain metastases, osteoblastic bone metastases, pleural effusion or ascites as the only evidence of disease, a second type of primary cancer, or a Karnofsky score of less than 60, if they were pregnant or had received any type of investigational agent within 30 days before the study began</P>
<P>HER2+: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>4-arm RCT</U>
<BR/>
<U>Trastuzumab + anthracycline arm</U> (randomised N = 143): doxorubicin (or epirubicin) plus cyclophosphamide (60 mg/m<SUP>2</SUP> (75 mg/m<SUP>2</SUP>) and 600 mg/m<SUP>2</SUP> every 21 days for 6 cycles) plus trastuzumab (first loading dose of 4 mg/kg, followed by weekly doses of 2 mg/kg until disease progression)<BR/>
<U>Anthracycline control arm</U> (randomised N = 138): doxorubicin (or epirubicin) plus cyclophosphamide (60 mg/m<SUP>2</SUP> (75 mg/m<SUP>2</SUP>) and 600 mg/m<SUP>2</SUP> every 21 days for 6 cycles)<BR/>
<U>Trastuzumab + taxane arm</U> (randomised N = 92): paclitaxel (175 mg/m<SUP>2</SUP> every 21 days for 6 cycles) plus trastuzumab (first loading dose of 4 mg/kg, followed by weekly doses of 2 mg/kg until disease progression)<BR/>
<U>Taxane control arm</U> (randomised N = 96): paclitaxel (175 mg/m<SUP>2</SUP> every 21 days for 6 cycles)<BR/>
<BR/>
</P>
<P>Trastuzumab + anthracycline and anthracycline control arms: 100% patients naive to previous anthracycline chemotherapy<BR/>Trastuzumab + taxane and taxane control arm: 97% patients previously treated with adjuvant anthracycline chemotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: time to disease progression (disease progression was defined as an increase of more than 25% in the dimensions of any measurable lesion)<BR/>Secondary: OS, ORR, the<SUP> </SUP>duration of a response, the time to treatment failure (a composite<SUP> </SUP>of disease progression, death, discontinuation of treatment<SUP> </SUP>and the use of other types of antitumour therapy)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Study ID: HO648g</P>
<P>Median follow-up for efficacy: 30 months (30 min to 51 max)<BR/>Upon documented disease progression patients (66%) were entered into the extension study H0659g, a non-randomised, open-label study in which they could receive either trastuzumab alone or in combination with chemotherapy of choice</P>
<P>We found possible inconsistencies among different data reports (FDA Statistical Review - Trastuzumab Product Approval Information - Licensing Action 9/25/98, EMEA EPAR H-C-278 Scientific discussion for the approval of Herceptin 2004). For this systematic review we considered the NEJM publication as our primary data source</P>
<P>OS: HR estimated using the ratio of the medians. HR variance estimated using the relationship between Chi<SUP>2</SUP> and the log of the HR. Time to progression: HR estimated using the ratio of the medians. HR variance estimated using the relationship between Chi<SUP>2</SUP> and the log of the HR</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-von-Minckwitz-2009">
<CHAR_METHODS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Accrual time: September 2003 to June 2007<BR/>Multi-centre, international<BR/>Baseline comparability: 3 to 4 T stage at first diagnosis more frequent in the capecitabine + trastuzumab arm than in the capecitabine alone arm (respectively: 34% and 14%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>156 female enrolled</P>
<P>Age: capecitabine arm: median 59, range from 33 to 82; capecitabine + trastuzumab arm: median 52.5, range from 28 to 78</P>
<P>
<U>Diagnosis</U>: pathologically confirmed, HER2-positive, locally advanced or metastatic breast cancer</P>
<P>
<U>Inclusion criteria</U>: women with pathologically confirmed, HER2&#8211;positive, locally advanced or metastatic breast cancer. HER2 status was considered positive if over-expression was detected in either the primary or metastatic tumour tissue by local immunohistochemistry (grade 3+ staining intensity) or by fluorescence in situ hybridisation. Duration of previous trastuzumab treatment had to be 12 weeks or greater, and the time since the end of the last trastuzumab cycle had to be less than 6 weeks. Patients could have received up to 1 chemotherapy drug for metastatic disease. Karnofsky performance status of 60% or greater; a life expectancy of greater than 3 months; and adequate haematologic, renal, hepatic and cardiac function sonographically confirmed by a LVEF of 50% or greater. Written informed consent</P>
<P>
<U>Exclusion criteria</U>: see inclusion criteria</P>
<P>HER2+: 100%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>
<U>2-arm RCT</U>
</P>
<P>
<U>Trastuzumab arm</U> (randomised N = 78): capecitabine (2500 mg/m<SUP>2</SUP> (1250 mg/m<SUP>2</SUP> semi-daily) on days 1 through 14 followed by 1 week of rest) plus trastuzumab (6 mg/kg every 3 weeks until disease progression or unacceptable toxicity)</P>
<P>
<U>Control arm</U> (randomised N = 78): capecitabine (2500 mg/m<SUP>2</SUP> (1250 mg/m<SUP>2</SUP> semi-daily) on days 1 through 14 followed by 1 week of rest)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: time to progression (time period between random assignment and documented disease progression or disease-related death)</P>
<P>Secondary: response of tumour lesions; clinical benefit (complete response, partial response or disease stabilisation for greater than 24 weeks); duration of response (time period between first notification of a response and the date of documented progression, disease-related death or withdrawal); OS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<P>Study ID: GBG-26</P>
<P>Median follow-up: 20.7 months</P>
<P>As accrual was slowing down, the trial was closed in agreement with the IDMC on 1 July 2007</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALT: alanine aminotransferase<BR/>AST: aspartate aminotransferase<BR/>BC: breast cancer<BR/>CBR: clinical benefit rate<BR/>CHF: congestive heart failure<BR/>CNS: central nervous system<BR/>ECOG: Eastern Cooperative Oncology Group<BR/>ER: oestrogen receptor<BR/>FDA: (US) Food and Drug Administration<BR/>FISH: fluorescence in situ hybridisation<BR/>HER2: human epidermal growth factor receptor 2<BR/>HR: hazard ratio<BR/>IDMC: Independent Data Monitoring Committee<BR/>IHC: immunohistochemistry<BR/>ITT: intention-to-treat<BR/>iv: intravenous<BR/>LABC: locally advanced breast cancer<BR/>LVEF: left ventricular ejection fraction<BR/>MBC: metastatic breast cancer<BR/>NEJM: <I>New England Journal of Medicine</I>
<BR/>ORR: overall response rate<BR/>OS: overall survival<BR/>PFS: progression-free survival<BR/>PgR: progesterone receptor<BR/>RCT: randomised controlled trial<BR/>TTF: time to failure<BR/>TTP: time to progression<BR/>ULN: upper limit of normal<BR/>WHO: World Health Organization<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-04-18 19:59:53 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-08-19 01:06:08 +1000" MODIFIED_BY="sara " STUDY_ID="STD-Gelmon-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-19 01:06:08 +1000" MODIFIED_BY="sara ">
<P>Head-to-head comparison of trastuzumab and lapatinib</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-10 11:56:58 +1000" MODIFIED_BY="sara " STUDY_ID="STD-Papaldo-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-10 11:56:58 +1000" MODIFIED_BY="sara ">
<P>Not randomised, all HER2-positive patients were given trastuzumab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-10 11:57:02 +1000" MODIFIED_BY="sara " STUDY_ID="STD-Raff-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-10 11:57:02 +1000" MODIFIED_BY="sara ">
<P>Not randomised, all HER2-positive patients were given trastuzumab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>HER2: human epidermal growth factor receptor 2</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blackwell-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasparini-2006">
<DESCRIPTION>
<P>1:1 randomisation stratified according to visceral involvement, HER2/neu over-expression and centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huober-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaufman-2009">
<DESCRIPTION>
<P>Random assignment was conducted using a minimisation procedure, with stratification according to presence of liver metastases; measurable versus evaluable disease; time to relapse after adjuvant tamoxifen, if administered; and bisphosphonate therapy at enrolment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marty-2005">
<DESCRIPTION>
<P>Random assignment to treatment, block by country</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Slamon-2001">
<DESCRIPTION>
<P>Not reported<BR/>Stratification on the basis of history of adjuvant anthracycline treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-von-Minckwitz-2009">
<DESCRIPTION>
<P>Random assignment list was prepared before stratification (by pretreatment and participating centre); a block permutation method with a block size of 4 was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blackwell-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasparini-2006">
<DESCRIPTION>
<P>The patients were allocated by the independent monitoring agency to treatment group by randomisation code envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huober-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaufman-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marty-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Slamon-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-von-Minckwitz-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1" REF_IDS="CMP-001.01">
<NAME>Overall Survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blackwell-2010">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gasparini-2006">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huober-2012">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaufman-2009">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marty-2005">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Slamon-2001">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-von-Minckwitz-2009">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-10-24 23:32:35 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-001.05">
<NAME/>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-10-21 09:52:45 +1100" MODIFIED_BY="sara " NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.01">
<NAME>Overall Survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Blinding of outcome assessment (detection bias) (OS)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blackwell-2010">
<DESCRIPTION>
<P>Open-label, but our primary outcome (i.e. OS) is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasparini-2006">
<DESCRIPTION>
<P>Open-label, but our primary outcome (i.e. OS) is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huober-2012">
<DESCRIPTION>
<P>Open-label, but our primary outcome (i.e. OS) is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaufman-2009">
<DESCRIPTION>
<P>Open-label, but our primary outcome (i.e. OS) is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marty-2005">
<DESCRIPTION>
<P>Open-label, but our primary outcome (i.e. OS) is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slamon-2001">
<DESCRIPTION>
<P>Open-label (original double-blind design was abandoned due to ethical considerations), but our primary outcome (i.e. OS) is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-von-Minckwitz-2009">
<DESCRIPTION>
<P>Open-label, but our primary outcome (i.e. OS) is not likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Blinding of outcome assessment (detection bias) (outcomes other than OS)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blackwell-2010">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gasparini-2006">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huober-2012">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaufman-2009">
<DESCRIPTION>
<P>Open-label, but it is stated that "A reconciled data set, which integrated the tumor response/date of progression as determined by the investigator and a blinded Response Evaluation Committee, was used for the primary analyses. An independent oncologist reconciled cases where investigator and committee assessments differed."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marty-2005">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Slamon-2001">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-von-Minckwitz-2009">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blackwell-2010">
<DESCRIPTION>
<P>Although 26 patients (9%) had withdrawn consent or were lost to follow-up before death, only 8 patients (2.7%) were lost to follow-up before progression (PFS is the primary outcome of the study)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gasparini-2006">
<DESCRIPTION>
<P>124 patients enrolled: 123 patients assessable for efficacy and safety and 118 for ORR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huober-2012">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaufman-2009">
<DESCRIPTION>
<P>208 patients enrolled: 1 patient (trastuzumab plus anastrozole arm) withdrew<SUP> </SUP>before receiving the first dose. 207 patients assessable for efficacy and toxicity (although response data were reported for only 147 patients (70.6%))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marty-2005">
<DESCRIPTION>
<P>2 patients (both in the trastuzumab plus docetaxel arm) withdrew<SUP> </SUP>before receiving the first dose. 7 patients in the docetaxel alone arm withdrew at cycle 1 or 2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slamon-2001">
<DESCRIPTION>
<P>Enrolled 469 patients. 5 patients were never treated; 2 decline treatment; 1 died before treatment; 1 had disease progression at enrolment; 1 was enrolled inadvertently</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-von-Minckwitz-2009">
<DESCRIPTION>
<P>Enrolled 156 patients. 5 patients were never treated; 151 patients received at least 1 cycle of allocated treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blackwell-2010">
<DESCRIPTION>
<P>The protocol for the study is available (<A HREF="http://www.clinicaltrials.gov/ct2/show/NCT00320385">http://www.clinicaltrials.gov/ct2/show/NCT00320385</A>). All of the study pre-specified primary outcomes that are of interest in the review have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gasparini-2006">
<DESCRIPTION>
<P>Protocol not found</P>
<P>Results for OS not shown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huober-2012">
<DESCRIPTION>
<P>The protocol for the study is available (<A HREF="http://www.clinicaltrials.gov/ct2/show/NCT00171847">http://www.clinicaltrials.gov/ct2/show/NCT00171847</A>).</P>
<P>Results on OS not shown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaufman-2009">
<DESCRIPTION>
<P>Protocol not found</P>
<P>Results for primary and secondary outcomes are reported in published papers: it is likely that reporting bias has not occurred</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marty-2005">
<DESCRIPTION>
<P>The protocol for the study is available (<A HREF="http://www.roche-trials.com/studyResultGet.action?studyResultNumber=M77001">http://www.roche-trials.com/studyResultGet.action?studyResultNumber=M77001</A>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slamon-2001">
<DESCRIPTION>
<P>The protocol for the study is available (<A HREF="http://www.cancer.gov/clinicaltrials/search/view?cdrid=64329&amp;version=HealthProfessional&amp;protocolsearchid=6378103">http://www.cancer.gov/clinicaltrials/search/view?cdrid=64329&amp;version=HealthProfessional&amp;protocolsearchid=6378103</A>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-18 21:20:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-von-Minckwitz-2009">
<DESCRIPTION>
<P>The protocol is available (<A HREF="http://www.clinicaltrials.gov/ct2/show/NCT00320385">http://www.clinicaltrials.gov/ct2/show/NCT00320385</A>)</P>
<P>In the paper published in 2011, only updated results for OS are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-10-21 09:46:51 +1100" MODIFIED_BY="sara " NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-05-01 01:43:59 +1000" MODIFIED_BY="sara ">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-05-01 01:43:59 +1000" MODIFIED_BY="sara " NO="1" READONLY="YES">
<TITLE MODIFIED="2014-04-18 20:00:11 +1000" MODIFIED_BY="[Empty name]">Summary of findings for the main comparison</TITLE>
<TABLE COLS="7" ROWS="21">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Summary of findings for the main comparison. Overview: efficacy and safety outcomes for patient groups at different risks</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population:</B> patients with HER2-positive metastatic breast cancer<BR/>
<B>Settings:</B> metastatic breast cancer<BR/>
<B>Intervention:</B> trastuzumab<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Trastuzumab</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Overall survival</B>
<BR/>Follow-up: median 2 years</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>HR 0.82 </B>
<BR/>(0.71 to 0.94)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1309<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>700 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>627 per 1000</B>
<BR/>(575 to 678)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>High</B>
<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>800 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>733 per 1000</B>
<BR/>(681 to 780)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Progression-free survival</B>
</P>
<P>Follow-up: median 2 years</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>HR 0.61 </B>
<BR/>(0.54 to 0.70)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1489<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>700 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>520 per 1000</B>
<BR/>(478 to 569)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>High</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>800 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>625 per 1000</B>
<BR/>(581 to 676)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Congestive heart failure</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 3.49 </B>
<BR/>(1.88 to 6.47)<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>1459<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>
<B>moderate</B>
<SUP>3</SUP>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>35 per 1000</B>
<BR/>(19 to 65)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>70 per 1000</B>
<BR/>(38 to 129)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>High</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>175 per 1000</B>
<BR/>(94 to 323)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>HR:</B> hazard ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Moderate risk derived from <LINK REF="STD-Slamon-2001" TYPE="STUDY">Slamon 2001</LINK> first-line treatment. High risk: estimated from moderate risk increased by 10% absolute risk.<BR/>
<SUP>2</SUP>
<LINK REF="STD-Gasparini-2006" TYPE="STUDY">Gasparini 2006</LINK>, <LINK REF="STD-Huober-2012" TYPE="STUDY">Huober 2012</LINK> and <LINK REF="STD-von-Minckwitz-2009" TYPE="STUDY">von Minckwitz 2009</LINK> did not report the overall survival data stratified by arm.<BR/>
<SUP>3</SUP>All the studies were open-label.<BR/>
<SUP>4</SUP>Confidence interval 90%.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-08-19 00:40:30 +1000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-04-30 22:28:26 +1000" MODIFIED_BY="sara ">
<COMPARISON ID="CMP-001" MODIFIED="2014-04-30 22:24:40 +1000" MODIFIED_BY="sara " NO="1">
<NAME>Efficacy of trastuzumab</NAME>
<IV_OUTCOME CHI2="1.0594588888085077" CI_END="0.9364594681808294" CI_START="0.7111897304929136" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.8160884491236604" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.0285110150066751" LOG_CI_START="-0.14801452316053712" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08826276908360609" MODIFIED="2014-04-18 20:25:48 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9006500018007287" P_Q="1.0" P_Z="0.0037894591475477885" Q="0.0" RANDOM="YES" SCALE="2.36" SHOW_PARTICIPANTS="NO" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.895176070595593">
<NAME>Overall survival - all studies</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Without trastuzumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0537899660482348" CI_START="0.500377153922258" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.02275405900178207" LOG_CI_START="-0.3007025274198632" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2013-08-05 20:22:48 +1000" MODIFIED_BY="sara " ORDER="130" SE="0.19" STUDY_ID="STD-Marty-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.649895024911995"/>
<IV_DATA CI_END="1.340166040647158" CI_START="0.6617989188032768" EFFECT_SIZE="0.9417645335842487" ESTIMABLE="YES" ESTIMATE="-0.06" LOG_CI_END="0.12715860886447894" LOG_CI_START="-0.17927394669286917" LOG_EFFECT_SIZE="-0.026057668914195104" MODIFIED="2013-08-06 00:15:19 +1000" MODIFIED_BY="sara " ORDER="132" SE="0.18" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.208679333312443"/>
<IV_DATA CI_END="1.1886206500442813" CI_START="0.5869629860839449" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="0.07504327103608872" LOG_CI_START="-0.23138928452125937" LOG_EFFECT_SIZE="-0.07817300674258534" MODIFIED="2013-08-02 00:32:33 +1000" MODIFIED_BY="sara " ORDER="129" SE="0.18" STUDY_ID="STD-Kaufman-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.208679333312443"/>
<IV_DATA CI_END="1.142014167720915" CI_START="0.5639478382027663" EFFECT_SIZE="0.8025187979624785" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="0.0576714917599587" LOG_CI_START="-0.2487610637973895" LOG_EFFECT_SIZE="-0.0955447860187154" MODIFIED="2013-08-06 00:15:19 +1000" MODIFIED_BY="sara " ORDER="128" SE="0.18" STUDY_ID="STD-Blackwell-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.208679333312443"/>
<IV_DATA CI_END="0.9956057215186785" CI_START="0.6468789874979225" EFFECT_SIZE="0.8025187979624785" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="-0.0019126162650812632" LOG_CI_START="-0.18917695577234953" LOG_EFFECT_SIZE="-0.0955447860187154" MODIFIED="2013-08-02 00:36:54 +1000" MODIFIED_BY="sara " ORDER="131" SE="0.11" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="40.72406697515067"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.049225055548712" CI_END="0.9504580569339509" CI_START="0.7049426677452275" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.8185465400543604" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.022067043495071718" LOG_CI_START="-0.15184620229138646" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08695662289322909" MODIFIED="2014-04-18 20:25:54 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7893433035798227" P_Q="1.0" P_Z="0.008627045823114904" Q="0.0" RANDOM="YES" SCALE="2.33" SHOW_PARTICIPANTS="NO" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.6264902726862145">
<NAME>Overall survival - excluding Blackwell</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0537899660482348" CI_START="0.500377153922258" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.02275405900178207" LOG_CI_START="-0.3007025274198632" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2013-08-05 20:20:09 +1000" MODIFIED_BY="sara " ORDER="130" SE="0.19" STUDY_ID="STD-Marty-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.098221984971048"/>
<IV_DATA CI_END="1.340166040647158" CI_START="0.6617989188032768" EFFECT_SIZE="0.9417645335842487" ESTIMABLE="YES" ESTIMATE="-0.06" LOG_CI_END="0.12715860886447894" LOG_CI_START="-0.17927394669286917" LOG_EFFECT_SIZE="-0.026057668914195104" MODIFIED="2013-08-05 20:20:33 +1000" MODIFIED_BY="sara " ORDER="132" SE="0.18" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.936599186958485"/>
<IV_DATA CI_END="1.1886206500442813" CI_START="0.5869629860839449" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="0.07504327103608872" LOG_CI_START="-0.23138928452125937" LOG_EFFECT_SIZE="-0.07817300674258534" MODIFIED="2013-08-05 20:20:14 +1000" MODIFIED_BY="sara " ORDER="129" SE="0.18" STUDY_ID="STD-Kaufman-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.936599186958485"/>
<IV_DATA CI_END="0.9956057215186785" CI_START="0.6468789874979225" EFFECT_SIZE="0.8025187979624785" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="-0.0019126162650812632" LOG_CI_START="-0.18917695577234953" LOG_EFFECT_SIZE="-0.0955447860187154" MODIFIED="2013-08-05 20:20:27 +1000" MODIFIED_BY="sara " ORDER="131" SE="0.11" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="48.028579641111975"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.4173827069553434" CI_END="0.9300687538901592" CI_START="0.6986235538224368" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.8060818433273066" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.03148494571335294" LOG_CI_START="-0.15575677638134983" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.09362086104735134" MODIFIED="2014-04-18 20:26:15 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9810291529381665" P_Q="0.9972795058141352" P_Z="0.0031460094585942424" Q="0.04757138620062633" RANDOM="YES" SCALE="2.31" SHOW_PARTICIPANTS="NO" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.9530991032820086">
<NAME>Overall survival - stratified by type of regimen</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.369811320754717" CI_END="0.9857454880947838" CI_START="0.6473126081848937" DF="1" EFFECT_SIZE="0.7988025306076124" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.006235202081290276" LOG_CI_START="-0.1888859338258839" LOG_EFFECT_SIZE="-0.09756056795358709" MODIFIED="2013-08-02 00:39:39 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="0.5431074086259803" P_Z="0.036279607034340786" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="46.291639163216686" Z="2.093779725642552">
<NAME>Taxane-containing regimen</NAME>
<IV_DATA CI_END="1.0537899660482348" CI_START="0.500377153922258" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.02275405900178207" LOG_CI_START="-0.3007025274198632" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2013-08-02 00:39:39 +1000" MODIFIED_BY="sara " ORDER="133" SE="0.19" STUDY_ID="STD-Marty-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.760918902987962"/>
<IV_DATA CI_END="1.0776635499675942" CI_START="0.6473971640703728" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="0.03248319387534593" LOG_CI_START="-0.18882920736051662" LOG_EFFECT_SIZE="-0.07817300674258534" MODIFIED="2013-08-02 00:39:39 +1000" MODIFIED_BY="sara " ORDER="134" SE="0.13" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="31.530720260228723"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.0981140820202397" CI_START="0.5864931810165702" DF="0" EFFECT_SIZE="0.8025187979624785" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.04064746089566154" LOG_CI_START="-0.2317370329330924" LOG_EFFECT_SIZE="-0.0955447860187154" MODIFIED="2013-08-02 00:40:22 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="1.0" P_Z="0.16913144470846297" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.81520204679162" Z="1.375">
<NAME>Anthracycline-containing regimen</NAME>
<IV_DATA CI_END="1.0981140820202397" CI_START="0.5864931810165702" EFFECT_SIZE="0.8025187979624785" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="0.04064746089566154" LOG_CI_START="-0.2317370329330924" LOG_EFFECT_SIZE="-0.0955447860187154" MODIFIED="2013-08-02 00:40:22 +1000" MODIFIED_BY="sara " ORDER="135" SE="0.16" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.81520204679162"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.1886206500442813" CI_START="0.5869629860839449" DF="0" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.07504327103608872" LOG_CI_START="-0.23138928452125937" LOG_EFFECT_SIZE="-0.07817300674258534" MODIFIED="2014-04-18 20:26:15 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.446579394995847" Z="1.0">
<NAME>Aromatase inhibitor-containing regimen</NAME>
<IV_DATA CI_END="1.1886206500442813" CI_START="0.5869629860839449" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="0.07504327103608872" LOG_CI_START="-0.23138928452125937" LOG_EFFECT_SIZE="-0.07817300674258534" MODIFIED="2013-08-02 00:41:06 +1000" MODIFIED_BY="sara " ORDER="136" SE="0.18" STUDY_ID="STD-Kaufman-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.446579394995847"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.142014167720915" CI_START="0.5639478382027663" DF="0" EFFECT_SIZE="0.8025187979624785" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.0576714917599587" LOG_CI_START="-0.2487610637973895" LOG_EFFECT_SIZE="-0.0955447860187154" MODIFIED="2013-08-02 00:41:31 +1000" MODIFIED_BY="sara " NO="4" P_CHI2="1.0" P_Z="0.2216236253554823" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.446579394995847" Z="1.2222222222222223">
<NAME>Other</NAME>
<IV_DATA CI_END="1.142014167720915" CI_START="0.5639478382027663" EFFECT_SIZE="0.8025187979624785" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="0.0576714917599587" LOG_CI_START="-0.2487610637973895" LOG_EFFECT_SIZE="-0.0955447860187154" MODIFIED="2013-08-02 00:41:31 +1000" MODIFIED_BY="sara " ORDER="137" SE="0.18" STUDY_ID="STD-Blackwell-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.446579394995847"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.0594588888085075" CI_END="0.9364594681808294" CI_START="0.7111897304929136" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.8160884491236604" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.0285110150066751" LOG_CI_START="-0.14801452316053712" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.08826276908360609" MODIFIED="2014-04-18 20:26:31 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9006500018007288" P_Q="0.5514629028873934" P_Z="0.0037894591475477885" Q="0.35470334158022643" RANDOM="YES" SCALE="2.23" SHOW_PARTICIPANTS="NO" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.895176070595593">
<NAME>Overall survival - stratified by treatment line</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.3096938188332191" CI_END="0.9361890514672716" CI_START="0.6731344616142242" DF="2" EFFECT_SIZE="0.793839475667816" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.028636442160886528" LOG_CI_START="-0.17189817484842673" LOG_EFFECT_SIZE="-0.10026730850465665" MODIFIED="2014-04-18 20:26:31 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8565463133885883" P_Z="0.006078538162455337" STUDIES="3" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="69.58264133337511" Z="2.7435144027541916">
<NAME>First-line</NAME>
<IV_DATA CI_END="1.0537899660482348" CI_START="0.500377153922258" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.02275405900178207" LOG_CI_START="-0.3007025274198632" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2013-08-02 00:42:46 +1000" MODIFIED_BY="sara " ORDER="139" SE="0.19" STUDY_ID="STD-Marty-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.649895024911995"/>
<IV_DATA CI_END="1.1886206500442813" CI_START="0.5869629860839449" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="0.07504327103608872" LOG_CI_START="-0.23138928452125937" LOG_EFFECT_SIZE="-0.07817300674258534" MODIFIED="2013-08-02 00:42:41 +1000" MODIFIED_BY="sara " ORDER="138" SE="0.18" STUDY_ID="STD-Kaufman-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.208679333312443"/>
<IV_DATA CI_END="0.9956057215186785" CI_START="0.6468789874979225" EFFECT_SIZE="0.8025187979624785" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="-0.0019126162650812632" LOG_CI_START="-0.18917695577234953" LOG_EFFECT_SIZE="-0.0955447860187154" MODIFIED="2013-08-02 00:42:46 +1000" MODIFIED_BY="sara " ORDER="140" SE="0.11" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="40.72406697515067"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.39506172839506176" CI_END="1.115678442391736" CI_START="0.6774207627741858" DF="1" EFFECT_SIZE="0.8693582353988059" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.0475390415390069" LOG_CI_START="-0.16914149647191745" LOG_EFFECT_SIZE="-0.060801227466455235" MODIFIED="2013-08-06 00:15:05 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="0.529651062999335" P_Z="0.2713565909016875" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="30.417358666624885" Z="1.0999438818457408">
<NAME>Beyond progression</NAME>
<IV_DATA CI_END="1.142014167720915" CI_START="0.5639478382027663" EFFECT_SIZE="0.8025187979624785" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="0.0576714917599587" LOG_CI_START="-0.2487610637973895" LOG_EFFECT_SIZE="-0.0955447860187154" MODIFIED="2013-08-06 00:15:05 +1000" MODIFIED_BY="sara " ORDER="141" SE="0.18" STUDY_ID="STD-Blackwell-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.208679333312443">
<FOOTNOTE>Lapatinib-containing regimen</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.340166040647158" CI_START="0.6617989188032768" EFFECT_SIZE="0.9417645335842487" ESTIMABLE="YES" ESTIMATE="-0.06" LOG_CI_END="0.12715860886447894" LOG_CI_START="-0.17927394669286917" LOG_EFFECT_SIZE="-0.026057668914195104" MODIFIED="2013-08-02 00:43:21 +1000" MODIFIED_BY="sara " ORDER="142" SE="0.18" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.208679333312443"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.852303145334605" CI_END="0.6979596054731483" CI_START="0.541545301076177" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.6147981332803198" ESTIMABLE="YES" I2="12.43819964262521" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.15616971151402584" LOG_CI_START="-0.2663652081346813" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.21126745982435352" MODIFIED="2014-04-18 20:26:45 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3347226160477954" P_Q="1.0" P_Z="5.677660381704562E-14" Q="0.0" RANDOM="YES" SCALE="3.14" SHOW_PARTICIPANTS="NO" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0036971125835862733" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000003" Z="7.515309156170721">
<NAME>Progression-free survival - all studies</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2799078906316406" CI_START="0.35106351590306684" EFFECT_SIZE="0.6703200460356393" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.10717871649960178" LOG_CI_START="-0.45461430202220315" LOG_EFFECT_SIZE="-0.17371779276130073" MODIFIED="2013-08-02 00:44:48 +1000" MODIFIED_BY="sara " ORDER="145" SE="0.33" STUDY_ID="STD-Huober-2012" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.721136860292597"/>
<IV_DATA CI_END="1.1613587269287575" CI_START="0.4191230880463613" EFFECT_SIZE="0.697676326071031" ESTIMABLE="YES" ESTIMATE="-0.36" LOG_CI_END="0.06496638775069193" LOG_CI_START="-0.37765841472103323" LOG_EFFECT_SIZE="-0.1563460134851707" MODIFIED="2013-08-02 00:44:48 +1000" MODIFIED_BY="sara " ORDER="144" SE="0.26" STUDY_ID="STD-Gasparini-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.8766652787809575"/>
<IV_DATA CI_END="0.9731602799347948" CI_START="0.4805646476254092" EFFECT_SIZE="0.6838614092123558" ESTIMABLE="YES" ESTIMATE="-0.38" LOG_CI_END="-0.011815625344561625" LOG_CI_START="-0.31824818090190976" LOG_EFFECT_SIZE="-0.1650319031232357" MODIFIED="2013-08-02 00:44:48 +1000" MODIFIED_BY="sara " ORDER="149" SE="0.18" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.607279253349951"/>
<IV_DATA CI_END="0.7241722137418863" CI_START="0.37483327592691823" EFFECT_SIZE="0.5210027286033344" ESTIMABLE="YES" ESTIMATE="-0.652" LOG_CI_END="-0.1401581429408244" LOG_CI_START="-0.42616186146101603" LOG_EFFECT_SIZE="-0.2831600022009202" MODIFIED="2013-10-11 00:50:09 +1100" MODIFIED_BY="sara " ORDER="147" SE="0.168" STUDY_ID="STD-Marty-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.125772634025958"/>
<IV_DATA CI_END="0.8470416581878022" CI_START="0.4704834021234837" EFFECT_SIZE="0.631283645506926" ESTIMABLE="YES" ESTIMATE="-0.46" LOG_CI_END="-0.07209523019326747" LOG_CI_START="-0.3274556931577242" LOG_EFFECT_SIZE="-0.19977546167549584" MODIFIED="2013-08-02 00:44:48 +1000" MODIFIED_BY="sara " ORDER="146" SE="0.15" STUDY_ID="STD-Kaufman-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.99371933301592"/>
<IV_DATA CI_END="0.9372508449414927" CI_START="0.5855546986765168" EFFECT_SIZE="0.7408182206817179" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="-0.02814415938519282" LOG_CI_START="-0.23243252975675824" LOG_EFFECT_SIZE="-0.13028834457097555" MODIFIED="2013-10-11 00:49:54 +1100" MODIFIED_BY="sara " ORDER="143" SE="0.12" STUDY_ID="STD-Blackwell-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.152271615821935"/>
<IV_DATA CI_END="0.634826235956017" CI_START="0.41246825312126445" EFFECT_SIZE="0.5117085777865424" ESTIMABLE="YES" ESTIMATE="-0.67" LOG_CI_END="-0.19734513312154459" LOG_CI_START="-0.38460947262881295" LOG_EFFECT_SIZE="-0.29097730287517876" MODIFIED="2013-10-11 00:50:10 +1100" MODIFIED_BY="sara " ORDER="148" SE="0.11" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="26.523155024712697"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.551272952914996" CI_END="0.6586899841466013" CI_START="0.5049054782220609" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.5766941836412272" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.18131894026720582" LOG_CI_START="-0.29678991718586706" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.23905442872653646" MODIFIED="2014-04-18 20:26:54 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6156441265491301" P_Q="1.0" P_Z="4.847755219879093E-16" Q="0.0" RANDOM="YES" SCALE="3.14" SHOW_PARTICIPANTS="NO" SORT_BY="WEIGHT" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="8.11525256218887">
<NAME>Progression-free survival - excluding Blackwell</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2799078906316406" CI_START="0.35106351590306684" EFFECT_SIZE="0.6703200460356393" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.10717871649960178" LOG_CI_START="-0.45461430202220315" LOG_EFFECT_SIZE="-0.17371779276130073" MODIFIED="2013-09-06 22:18:59 +1000" MODIFIED_BY="sara " ORDER="145" SE="0.33" STUDY_ID="STD-Huober-2012" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.224672078989379"/>
<IV_DATA CI_END="1.1613587269287575" CI_START="0.4191230880463613" EFFECT_SIZE="0.697676326071031" ESTIMABLE="YES" ESTIMATE="-0.36" LOG_CI_END="0.06496638775069193" LOG_CI_START="-0.37765841472103323" LOG_EFFECT_SIZE="-0.1563460134851707" MODIFIED="2013-09-06 22:18:59 +1000" MODIFIED_BY="sara " ORDER="144" SE="0.26" STUDY_ID="STD-Gasparini-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.805721736715138"/>
<IV_DATA CI_END="0.9731602799347948" CI_START="0.4805646476254092" EFFECT_SIZE="0.6838614092123558" ESTIMABLE="YES" ESTIMATE="-0.38" LOG_CI_END="-0.011815625344561625" LOG_CI_START="-0.31824818090190976" LOG_EFFECT_SIZE="-0.1650319031232357" MODIFIED="2013-09-06 22:18:59 +1000" MODIFIED_BY="sara " ORDER="149" SE="0.18" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.19959226549208"/>
<IV_DATA CI_END="0.7241722137418863" CI_START="0.37483327592691823" EFFECT_SIZE="0.5210027286033344" ESTIMABLE="YES" ESTIMATE="-0.652" LOG_CI_END="-0.1401581429408244" LOG_CI_START="-0.42616186146101603" LOG_EFFECT_SIZE="-0.2831600022009202" MODIFIED="2013-09-06 22:18:59 +1000" MODIFIED_BY="sara " ORDER="147" SE="0.168" STUDY_ID="STD-Marty-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.300552345590397"/>
<IV_DATA CI_END="0.8470416581878022" CI_START="0.4704834021234837" EFFECT_SIZE="0.631283645506926" ESTIMABLE="YES" ESTIMATE="-0.46" LOG_CI_END="-0.07209523019326747" LOG_CI_START="-0.3274556931577242" LOG_EFFECT_SIZE="-0.19977546167549584" MODIFIED="2013-09-06 22:18:59 +1000" MODIFIED_BY="sara " ORDER="146" SE="0.15" STUDY_ID="STD-Kaufman-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.447412862308596"/>
<IV_DATA CI_END="0.634826235956017" CI_START="0.41246825312126445" EFFECT_SIZE="0.5117085777865424" ESTIMABLE="YES" ESTIMATE="-0.67" LOG_CI_END="-0.19734513312154459" LOG_CI_START="-0.38460947262881295" LOG_EFFECT_SIZE="-0.29097730287517876" MODIFIED="2013-09-06 22:18:59 +1000" MODIFIED_BY="sara " ORDER="148" SE="0.11" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="38.022048710904414"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="9.55726714054235" CI_END="0.7668448515463735" CI_START="0.5928721137046984" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="0.6742706637692789" ESTIMABLE="YES" I2="26.75730523105617" I2_Q="60.81014248498298" ID="CMP-001.07" LOG_CI_END="-0.11529249385156214" LOG_CI_START="-0.22703897662246528" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.17116573523701378" MODIFIED="2014-04-18 20:31:22 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.21508122295278254" P_Q="0.05370583060104639" P_Z="1.9218087928838326E-9" Q="7.655041865999234" RANDOM="YES" SCALE="3.99" SHOW_PARTICIPANTS="NO" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.00869284815934797" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="6.004281622709261">
<NAME>Progression-free survival - stratified by type of regimen</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.7380758775170073" CI_END="0.6782896866357324" CI_START="0.4186175907038723" DF="2" EFFECT_SIZE="0.5328639548878633" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.16858478631289747" LOG_CI_START="-0.37818252615234466" LOG_EFFECT_SIZE="-0.27338365623262106" MODIFIED="2013-10-11 00:51:02 +1100" MODIFIED_BY="sara " NO="1" P_CHI2="0.41935515776359755" P_Z="3.173147466760857E-7" STUDIES="3" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.286755859507117" Z="5.112861623300505">
<NAME>Taxane-containing regimen</NAME>
<IV_DATA CI_END="1.1613587269287575" CI_START="0.4191230880463613" EFFECT_SIZE="0.697676326071031" ESTIMABLE="YES" ESTIMATE="-0.36" LOG_CI_END="0.06496638775069193" LOG_CI_START="-0.37765841472103323" LOG_EFFECT_SIZE="-0.1563460134851707" MODIFIED="2013-08-02 00:55:45 +1000" MODIFIED_BY="sara " ORDER="150" SE="0.26" STUDY_ID="STD-Gasparini-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.647537208331805"/>
<IV_DATA CI_END="0.713131762218402" CI_START="0.265560943012427" EFFECT_SIZE="0.4351780592663567" ESTIMABLE="YES" ESTIMATE="-0.832" LOG_CI_END="-0.1468302200533618" LOG_CI_START="-0.5758357978336491" LOG_EFFECT_SIZE="-0.3613330089435055" MODIFIED="2013-10-11 00:51:02 +1100" MODIFIED_BY="sara " ORDER="152" SE="0.252" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.967943334015727"/>
<IV_DATA CI_END="0.7241722137418863" CI_START="0.37483327592691823" EFFECT_SIZE="0.5210027286033344" ESTIMABLE="YES" ESTIMATE="-0.652" LOG_CI_END="-0.1401581429408244" LOG_CI_START="-0.42616186146101603" LOG_EFFECT_SIZE="-0.2831600022009202" MODIFIED="2013-10-11 00:51:02 +1100" MODIFIED_BY="sara " ORDER="151" SE="0.168" STUDY_ID="STD-Marty-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.671275317159587"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.3695501826753677E-31" CI_END="0.9057402614713361" CI_START="0.6750305709489074" DF="0" EFFECT_SIZE="0.7819222249254772" ESTIMABLE="YES" I2="100.0" ID="CMP-001.07.02" LOG_CI_END="-0.04299632680708575" LOG_CI_START="-0.17067655828931413" LOG_EFFECT_SIZE="-0.10683644254819996" MODIFIED="2013-10-11 00:51:03 +1100" MODIFIED_BY="sara " NO="2" P_CHI2="0.0" P_Z="0.001038070866442222" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="30.09297863158425" Z="3.2800000000000002">
<NAME>Anthracycline-containing regimen</NAME>
<IV_DATA CI_END="0.9057402614713361" CI_START="0.6750305709489074" EFFECT_SIZE="0.7819222249254772" ESTIMABLE="YES" ESTIMATE="-0.246" LOG_CI_END="-0.04299632680708575" LOG_CI_START="-0.17067655828931413" LOG_EFFECT_SIZE="-0.10683644254819996" MODIFIED="2013-10-11 00:51:03 +1100" MODIFIED_BY="sara " ORDER="153" SE="0.075" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="30.09297863158425"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.027397260273972594" CI_END="0.8335319867413014" CI_START="0.4880346587212503" DF="1" EFFECT_SIZE="0.637802868198738" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="-0.07907772949081461" LOG_CI_START="-0.31154933464298706" LOG_EFFECT_SIZE="-0.1953135320669008" MODIFIED="2014-04-18 20:31:22 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8685338079114926" P_Z="9.899415856030338E-4" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.4770516815208" Z="3.2933698573109993">
<NAME>Aromatase inhibitor-containing regimen</NAME>
<IV_DATA CI_END="1.2799078906316406" CI_START="0.35106351590306684" EFFECT_SIZE="0.6703200460356393" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.10717871649960178" LOG_CI_START="-0.45461430202220315" LOG_EFFECT_SIZE="-0.17371779276130073" MODIFIED="2013-10-09 21:50:55 +1100" MODIFIED_BY="sara " ORDER="154" SE="0.33" STUDY_ID="STD-Huober-2012" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.6640553014386263"/>
<IV_DATA CI_END="0.8470416581878022" CI_START="0.4704834021234837" EFFECT_SIZE="0.631283645506926" ESTIMABLE="YES" ESTIMATE="-0.46" LOG_CI_END="-0.07209523019326747" LOG_CI_START="-0.3274556931577242" LOG_EFFECT_SIZE="-0.19977546167549584" MODIFIED="2013-10-09 21:51:30 +1100" MODIFIED_BY="sara " ORDER="155" SE="0.15" STUDY_ID="STD-Kaufman-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.812996380082174"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.13675213675213682" CI_END="0.87904362577253" CI_START="0.5943362645594851" DF="1" EFFECT_SIZE="0.7228053022263128" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="-0.05598957093063357" LOG_CI_START="-0.22596776962809298" LOG_EFFECT_SIZE="-0.14097867027936328" MODIFIED="2013-10-09 23:10:10 +1100" MODIFIED_BY="sara " NO="4" P_CHI2="0.7115315210227402" P_Z="0.001149353645060529" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="29.143213827387825" Z="3.251159483431204">
<NAME>Other</NAME>
<IV_DATA CI_END="0.9731602799347948" CI_START="0.4805646476254092" EFFECT_SIZE="0.6838614092123558" ESTIMABLE="YES" ESTIMATE="-0.38" LOG_CI_END="-0.011815625344561625" LOG_CI_START="-0.31824818090190976" LOG_EFFECT_SIZE="-0.1650319031232357" MODIFIED="2013-08-02 01:00:23 +1000" MODIFIED_BY="sara " ORDER="157" SE="0.18" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.48519920154308"/>
<IV_DATA CI_END="0.9372508449414927" CI_START="0.5855546986765168" EFFECT_SIZE="0.7408182206817179" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="-0.02814415938519282" LOG_CI_START="-0.23243252975675824" LOG_EFFECT_SIZE="-0.13028834457097555" MODIFIED="2013-08-02 01:03:23 +1000" MODIFIED_BY="sara " ORDER="156" SE="0.12" STUDY_ID="STD-Blackwell-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="18.658014625844746"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.852303145334605" CI_END="0.6979596054731483" CI_START="0.541545301076177" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.6147981332803198" ESTIMABLE="YES" I2="12.43819964262521" I2_Q="76.24307268970027" ID="CMP-001.08" LOG_CI_END="-0.15616971151402584" LOG_CI_START="-0.2663652081346813" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.21126745982435352" MODIFIED="2014-04-18 20:32:17 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3347226160477954" P_Q="0.040203100413157444" P_Z="5.677660381704562E-14" Q="4.209298563482383" RANDOM="YES" SCALE="3.1" SHOW_PARTICIPANTS="NO" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.003697112583586272" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="7.515309156170721">
<NAME>Progression-free survival - stratified by treatment line</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.5062524451000847" CI_END="0.6471803409873504" CI_START="0.4856965487553555" DF="4" EFFECT_SIZE="0.5606543124242158" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-0.18897468350083033" LOG_CI_START="-0.31363498250973104" LOG_EFFECT_SIZE="-0.2513048330052807" MODIFIED="2014-04-18 20:32:17 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.643516642346881" P_Z="2.739134078483564E-15" STUDIES="5" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="65.24044913082813" Z="7.90224996646342">
<NAME>First-line</NAME>
<IV_DATA CI_END="1.2799078906316406" CI_START="0.35106351590306684" EFFECT_SIZE="0.6703200460356393" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.10717871649960178" LOG_CI_START="-0.45461430202220315" LOG_EFFECT_SIZE="-0.17371779276130073" MODIFIED="2013-08-02 01:01:47 +1000" MODIFIED_BY="sara " ORDER="159" SE="0.33" STUDY_ID="STD-Huober-2012" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.7211368602925967"/>
<IV_DATA CI_END="1.1613587269287575" CI_START="0.4191230880463613" EFFECT_SIZE="0.697676326071031" ESTIMABLE="YES" ESTIMATE="-0.36" LOG_CI_END="0.06496638775069193" LOG_CI_START="-0.37765841472103323" LOG_EFFECT_SIZE="-0.1563460134851707" MODIFIED="2013-08-02 01:01:47 +1000" MODIFIED_BY="sara " ORDER="158" SE="0.26" STUDY_ID="STD-Gasparini-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.876665278780957"/>
<IV_DATA CI_END="0.7241722137418863" CI_START="0.37483327592691823" EFFECT_SIZE="0.5210027286033344" ESTIMABLE="YES" ESTIMATE="-0.652" LOG_CI_END="-0.1401581429408244" LOG_CI_START="-0.42616186146101603" LOG_EFFECT_SIZE="-0.2831600022009202" MODIFIED="2013-08-02 01:01:47 +1000" MODIFIED_BY="sara " ORDER="161" SE="0.168" STUDY_ID="STD-Marty-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.125772634025957"/>
<IV_DATA CI_END="0.8470416581878022" CI_START="0.4704834021234837" EFFECT_SIZE="0.631283645506926" ESTIMABLE="YES" ESTIMATE="-0.46" LOG_CI_END="-0.07209523019326747" LOG_CI_START="-0.3274556931577242" LOG_EFFECT_SIZE="-0.19977546167549584" MODIFIED="2013-08-02 01:01:47 +1000" MODIFIED_BY="sara " ORDER="160" SE="0.15" STUDY_ID="STD-Kaufman-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.993719333015918"/>
<IV_DATA CI_END="0.634826235956017" CI_START="0.41246825312126445" EFFECT_SIZE="0.5117085777865424" ESTIMABLE="YES" ESTIMATE="-0.67" LOG_CI_END="-0.19734513312154459" LOG_CI_START="-0.38460947262881295" LOG_EFFECT_SIZE="-0.29097730287517876" MODIFIED="2013-08-02 01:01:47 +1000" MODIFIED_BY="sara " ORDER="162" SE="0.11" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="26.523155024712693"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.13675213675213682" CI_END="0.87904362577253" CI_START="0.5943362645594851" DF="1" EFFECT_SIZE="0.7228053022263128" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-0.05598957093063357" LOG_CI_START="-0.22596776962809298" LOG_EFFECT_SIZE="-0.14097867027936328" MODIFIED="2013-08-06 00:05:43 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="0.7115315210227402" P_Z="0.001149353645060529" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="34.75955086917188" Z="3.251159483431204">
<NAME>Beyond progression</NAME>
<IV_DATA CI_END="0.9731602799347948" CI_START="0.4805646476254092" EFFECT_SIZE="0.6838614092123558" ESTIMABLE="YES" ESTIMATE="-0.38" LOG_CI_END="-0.011815625344561625" LOG_CI_START="-0.31824818090190976" LOG_EFFECT_SIZE="-0.1650319031232357" MODIFIED="2013-08-02 01:02:43 +1000" MODIFIED_BY="sara " ORDER="164" SE="0.18" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.607279253349951"/>
<IV_DATA CI_END="0.9372508449414927" CI_START="0.5855546986765168" EFFECT_SIZE="0.7408182206817179" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="-0.02814415938519282" LOG_CI_START="-0.23243252975675824" LOG_EFFECT_SIZE="-0.13028834457097555" MODIFIED="2013-08-06 00:05:43 +1000" MODIFIED_BY="sara " ORDER="163" SE="0.12" STUDY_ID="STD-Blackwell-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.15227161582193">
<FOOTNOTE>Lapatinib-containing regimen</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="4.5008919056049415" CI_END="1.8213063613346852" CI_START="1.3783341721348725" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.584414338408429" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="178" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.2603830044694173" LOG_CI_START="0.13935452346401964" LOG_EFFECT_SIZE="0.19986876396671843" METHOD="IV" MODIFIED="2014-04-30 22:24:15 +1000" MODIFIED_BY="sara " NO="9" P_CHI2="0.609220414680415" P_Q="1.0" P_Z="9.579359276131975E-11" Q="0.0" RANDOM="YES" SCALE="8.69" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="710" TOTAL_2="709" WEIGHT="100.0" Z="6.473444527356077">
<NAME>Overall response rate - all studies</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trastuzumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.346645346541633" CI_START="0.6859754269791748" EFFECT_SIZE="2.0865384615384617" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8025442304167856" LOG_CI_START="-0.16369144131728733" LOG_EFFECT_SIZE="0.3194263945497492" MODIFIED="2013-08-02 01:07:08 +1000" MODIFIED_BY="sara " ORDER="167" O_E="0.0" SE="0.5675716165203079" STUDY_ID="STD-Huober-2012" TOTAL_1="26" TOTAL_2="31" VAR="0.32213753987947535" WEIGHT="1.5689497399979166"/>
<DICH_DATA CI_END="7.722183725221662" CI_START="1.1341869869759769" EFFECT_SIZE="2.9594594594594597" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8877401300905114" LOG_CI_START="0.05468466012777306" LOG_EFFECT_SIZE="0.4712123951091422" MODIFIED="2013-08-02 01:07:08 +1000" MODIFIED_BY="sara " ORDER="168" O_E="0.0" SE="0.4893409067471948" STUDY_ID="STD-Kaufman-2009" TOTAL_1="74" TOTAL_2="73" VAR="0.23945452301616682" WEIGHT="2.1107039577755144"/>
<DICH_DATA CI_END="3.206044366293804" CI_START="0.6922186292981094" EFFECT_SIZE="1.4897260273972603" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.5059695279692371" LOG_CI_START="-0.15975671695679905" LOG_EFFECT_SIZE="0.17310640550621906" MODIFIED="2013-10-10 21:05:13 +1100" MODIFIED_BY="sara " ORDER="165" O_E="0.0" SE="0.39105089166761353" STUDY_ID="STD-Blackwell-2010" TOTAL_1="146" TOTAL_2="145" VAR="0.15292079987403562" WEIGHT="3.3050939430986204"/>
<DICH_DATA CI_END="2.7621461994220686" CI_START="1.1444024634989072" EFFECT_SIZE="1.777922077922078" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.4412466619044102" LOG_CI_START="0.058578784018606035" LOG_EFFECT_SIZE="0.24991272296150813" MODIFIED="2013-08-02 01:07:08 +1000" MODIFIED_BY="sara " ORDER="171" O_E="0.0" SE="0.2247810057066667" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="0.050526500526500526" WEIGHT="10.003020279870483"/>
<DICH_DATA CI_END="2.476215574619411" CI_START="1.2911232418213898" EFFECT_SIZE="1.7880434782608696" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="32" LOG_CI_END="0.3937884508457443" LOG_CI_START="0.11096769903513147" LOG_EFFECT_SIZE="0.25237807494043785" MODIFIED="2013-08-02 01:07:08 +1000" MODIFIED_BY="sara " ORDER="169" O_E="0.0" SE="0.16613030959885414" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="0.027599279767411125" WEIGHT="18.312710103191243"/>
<DICH_DATA CI_END="1.7223341527986564" CI_START="1.0088653836200463" EFFECT_SIZE="1.3181818181818181" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="33" LOG_CI_END="0.2361174134580004" LOG_CI_START="0.0038332206954992975" LOG_EFFECT_SIZE="0.11997531707674983" MODIFIED="2013-08-02 01:07:08 +1000" MODIFIED_BY="sara " ORDER="166" O_E="0.0" SE="0.1364448846539915" STUDY_ID="STD-Gasparini-2006" TOTAL_1="60" TOTAL_2="58" VAR="0.01861720654824104" WEIGHT="27.14787570991543"/>
<DICH_DATA CI_END="1.9931943397277156" CI_START="1.2648729942293997" EFFECT_SIZE="1.5878090856814262" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="74" LOG_CI_END="0.299549645191519" LOG_CI_START="0.10204692023559263" LOG_EFFECT_SIZE="0.2007982827135558" MODIFIED="2013-08-02 01:07:08 +1000" MODIFIED_BY="sara " ORDER="170" O_E="0.0" SE="0.11601407829336709" STUDY_ID="STD-Slamon-2001" TOTAL_1="235" TOTAL_2="234" VAR="0.01345926636225951" WEIGHT="37.5516462661508"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.30964161547515" CI_END="1.909535370728264" CI_START="1.3493901867956029" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6052128490015969" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="178" I2="24.80913563456512" I2_Q="22.315681238371443" ID="CMP-001.10" LOG_CI_END="0.28092770731254935" LOG_CI_START="0.13013754750001089" LOG_EFFECT_SIZE="0.20553262740628017" METHOD="IV" MODIFIED="2014-04-30 22:24:29 +1000" MODIFIED_BY="sara " NO="10" P_CHI2="0.2311829268654343" P_Q="0.27678108296403103" P_Z="9.141651130439834E-8" Q="3.8617832373678764" RANDOM="YES" SCALE="8.69" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.014588987707940572" TOTALS="YES" TOTAL_1="710" TOTAL_2="709" WEIGHT="100.0" Z="5.343008427937252">
<NAME>Overall response rate - stratified by type of regimen</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.298752999759854" CI_END="2.383545776248454" CI_START="1.2263022730750055" DF="2" EFFECT_SIZE="1.7096630087218379" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="81" I2="62.25527024772352" ID="CMP-001.10.01" LOG_CI_END="0.37722349701456165" LOG_CI_START="0.08859753327213765" LOG_EFFECT_SIZE="0.2329105151433496" MODIFIED="2013-09-05 18:45:32 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="0.07069542161803832" P_Z="0.0015602504291770077" STUDIES="3" TAU2="0.05270648630953144" TOTAL_1="244" TOTAL_2="248" WEIGHT="51.7769587400537" Z="3.1632373982059576">
<NAME>Taxane-containing regimen</NAME>
<DICH_DATA CI_END="4.124241441307099" CI_START="1.4891894727849952" EFFECT_SIZE="2.4782608695652173" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="16" LOG_CI_END="0.6153440818195436" LOG_CI_START="0.1729499574902534" LOG_EFFECT_SIZE="0.3941470196548985" MODIFIED="2013-09-05 18:45:32 +1000" MODIFIED_BY="sara " ORDER="174" O_E="0.0" SE="0.2598644985172585" STUDY_ID="STD-Slamon-2001" TOTAL_1="92" TOTAL_2="96" VAR="0.06752955758962624" WEIGHT="9.553883905438488"/>
<DICH_DATA CI_END="2.476215574619411" CI_START="1.2911232418213898" EFFECT_SIZE="1.7880434782608696" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="32" LOG_CI_END="0.3937884508457443" LOG_CI_START="0.11096769903513147" LOG_EFFECT_SIZE="0.25237807494043785" MODIFIED="2013-08-02 01:14:20 +1000" MODIFIED_BY="sara " ORDER="173" O_E="0.0" SE="0.16613030959885414" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="0.027599279767411125" WEIGHT="18.596427281940777"/>
<DICH_DATA CI_END="1.7223341527986564" CI_START="1.0088653836200463" EFFECT_SIZE="1.3181818181818181" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="33" LOG_CI_END="0.2361174134580004" LOG_CI_START="0.0038332206954992975" LOG_EFFECT_SIZE="0.11997531707674983" MODIFIED="2013-08-02 01:14:20 +1000" MODIFIED_BY="sara " ORDER="172" O_E="0.0" SE="0.1364448846539915" STUDY_ID="STD-Gasparini-2006" TOTAL_1="60" TOTAL_2="58" VAR="0.01861720654824104" WEIGHT="23.626647552674434"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6989695737222343" CI_START="1.0428563343989534" DF="0" EFFECT_SIZE="1.3310827103930551" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="58" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.23018560130408974" LOG_CI_START="0.018224483426272177" LOG_EFFECT_SIZE="0.12420504236518098" MODIFIED="2013-08-02 01:19:02 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="1.0" P_Z="0.021618734288200443" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="138" WEIGHT="26.07262922202096" Z="2.2970006213531384">
<NAME>Anthracycline-containing regimen</NAME>
<DICH_DATA CI_END="1.6989695737222343" CI_START="1.0428563343989534" EFFECT_SIZE="1.3310827103930551" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="58" LOG_CI_END="0.23018560130408974" LOG_CI_START="0.018224483426272177" LOG_EFFECT_SIZE="0.12420504236518098" MODIFIED="2013-08-02 01:19:02 +1000" MODIFIED_BY="sara " ORDER="175" O_E="0.0" SE="0.12450700986588518" STUDY_ID="STD-Slamon-2001" TOTAL_1="143" TOTAL_2="138" VAR="0.015501995505743632" WEIGHT="26.07262922202096"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2175073072387591" CI_END="5.271815774701517" CI_START="1.233178566809812" DF="1" EFFECT_SIZE="2.549723557865004" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="9" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.7219602252907155" LOG_CI_START="0.09102596788943736" LOG_EFFECT_SIZE="0.4064930965900763" MODIFIED="2014-04-18 20:34:11 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6409458401732585" P_Z="0.011553420281981249" STUDIES="2" TAU2="0.0" TOTAL_1="100" TOTAL_2="104" WEIGHT="5.418190004953397" Z="2.52549871855824">
<NAME>Aromatase inhibitor-containing regimen</NAME>
<DICH_DATA CI_END="6.346645346541633" CI_START="0.6859754269791748" EFFECT_SIZE="2.0865384615384617" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8025442304167856" LOG_CI_START="-0.16369144131728733" LOG_EFFECT_SIZE="0.3194263945497492" MODIFIED="2013-08-02 01:19:52 +1000" MODIFIED_BY="sara " ORDER="176" O_E="0.0" SE="0.5675716165203079" STUDY_ID="STD-Huober-2012" TOTAL_1="26" TOTAL_2="31" VAR="0.32213753987947535" WEIGHT="2.3299353747909617"/>
<DICH_DATA CI_END="7.722183725221662" CI_START="1.1341869869759769" EFFECT_SIZE="2.9594594594594597" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8877401300905114" LOG_CI_START="0.05468466012777306" LOG_EFFECT_SIZE="0.4712123951091422" MODIFIED="2013-08-02 01:19:48 +1000" MODIFIED_BY="sara " ORDER="177" O_E="0.0" SE="0.4893409067471948" STUDY_ID="STD-Kaufman-2009" TOTAL_1="74" TOTAL_2="73" VAR="0.23945452301616682" WEIGHT="3.0882546301624356"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.15373520522034934" CI_END="2.49298555049178" CI_START="1.161330179744652" DF="1" EFFECT_SIZE="1.7015226585189631" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="30" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="0.3967197613116867" LOG_CI_START="0.06495571229217839" LOG_EFFECT_SIZE="0.2308377368019326" MODIFIED="2013-10-10 21:05:53 +1100" MODIFIED_BY="sara " NO="4" P_CHI2="0.694991289384948" P_Z="0.006382741951357655" STUDIES="2" TAU2="0.0" TOTAL_1="223" TOTAL_2="219" WEIGHT="16.73222203297194" Z="2.7274422996803986">
<NAME>Other</NAME>
<DICH_DATA CI_END="3.206044366293804" CI_START="0.6922186292981094" EFFECT_SIZE="1.4897260273972603" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.5059695279692371" LOG_CI_START="-0.15975671695679905" LOG_EFFECT_SIZE="0.17310640550621906" MODIFIED="2013-10-10 21:05:53 +1100" MODIFIED_BY="sara " ORDER="178" O_E="0.0" SE="0.39105089166761353" STUDY_ID="STD-Blackwell-2010" TOTAL_1="146" TOTAL_2="145" VAR="0.15292079987403562" WEIGHT="4.683613176170379"/>
<DICH_DATA CI_END="2.7621461994220686" CI_START="1.1444024634989072" EFFECT_SIZE="1.777922077922078" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.4412466619044102" LOG_CI_START="0.058578784018606035" LOG_EFFECT_SIZE="0.24991272296150813" MODIFIED="2013-08-02 01:20:29 +1000" MODIFIED_BY="sara " ORDER="179" O_E="0.0" SE="0.2247810057066667" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="0.050526500526500526" WEIGHT="12.048608856801563"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.500891905604942" CI_END="1.8213063613346852" CI_START="1.3783341721348723" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.584414338408429" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="178" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.2603830044694173" LOG_CI_START="0.13935452346401955" LOG_EFFECT_SIZE="0.19986876396671843" METHOD="IV" MODIFIED="2014-04-30 22:24:40 +1000" MODIFIED_BY="sara " NO="11" P_CHI2="0.6092204146804149" P_Q="0.7043058368442605" P_Z="9.579359276132113E-11" Q="0.14403139063213813" RANDOM="YES" SCALE="8.88" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="710" TOTAL_2="709" WEIGHT="99.99999999999997" Z="6.473444527356075">
<NAME>Overall response rate - stratified by treatment line</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.192712117534511" CI_END="1.837044604029156" CI_START="1.3431596582391678" DF="4" EFFECT_SIZE="1.5708100466058614" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="148" I2="4.596359400125806" ID="CMP-001.11.01" LOG_CI_END="0.26411970124242273" LOG_CI_START="0.1281276393038857" LOG_EFFECT_SIZE="0.19612367027315425" MODIFIED="2014-04-18 20:34:45 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3805529442522926" P_Z="1.5748560878564873E-8" STUDIES="5" TAU2="0.0016799975218099803" TOTAL_1="487" TOTAL_2="490" WEIGHT="86.69188577703088" Z="5.653202470375402">
<NAME>First-line</NAME>
<DICH_DATA CI_END="6.346645346541633" CI_START="0.6859754269791748" EFFECT_SIZE="2.0865384615384617" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.8025442304167856" LOG_CI_START="-0.16369144131728733" LOG_EFFECT_SIZE="0.3194263945497492" MODIFIED="2013-08-02 01:33:20 +1000" MODIFIED_BY="sara " ORDER="181" O_E="0.0" SE="0.5675716165203079" STUDY_ID="STD-Huober-2012" TOTAL_1="26" TOTAL_2="31" VAR="0.32213753987947535" WEIGHT="1.5689497399979164"/>
<DICH_DATA CI_END="7.722183725221662" CI_START="1.1341869869759769" EFFECT_SIZE="2.9594594594594597" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8877401300905114" LOG_CI_START="0.05468466012777306" LOG_EFFECT_SIZE="0.4712123951091422" MODIFIED="2013-08-02 01:33:13 +1000" MODIFIED_BY="sara " ORDER="182" O_E="0.0" SE="0.4893409067471948" STUDY_ID="STD-Kaufman-2009" TOTAL_1="74" TOTAL_2="73" VAR="0.23945452301616682" WEIGHT="2.110703957775514"/>
<DICH_DATA CI_END="2.476215574619411" CI_START="1.2911232418213898" EFFECT_SIZE="1.7880434782608696" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="32" LOG_CI_END="0.3937884508457443" LOG_CI_START="0.11096769903513147" LOG_EFFECT_SIZE="0.25237807494043785" MODIFIED="2013-08-02 01:33:13 +1000" MODIFIED_BY="sara " ORDER="183" O_E="0.0" SE="0.16613030959885414" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="0.027599279767411125" WEIGHT="18.31271010319124"/>
<DICH_DATA CI_END="1.7223341527986564" CI_START="1.0088653836200463" EFFECT_SIZE="1.3181818181818181" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="33" LOG_CI_END="0.2361174134580004" LOG_CI_START="0.0038332206954992975" LOG_EFFECT_SIZE="0.11997531707674983" MODIFIED="2013-08-02 01:33:20 +1000" MODIFIED_BY="sara " ORDER="180" O_E="0.0" SE="0.1364448846539915" STUDY_ID="STD-Gasparini-2006" TOTAL_1="60" TOTAL_2="58" VAR="0.01861720654824104" WEIGHT="27.14787570991542"/>
<DICH_DATA CI_END="1.9931943397277156" CI_START="1.2648729942293997" EFFECT_SIZE="1.5878090856814262" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="74" LOG_CI_END="0.299549645191519" LOG_CI_START="0.10204692023559263" LOG_EFFECT_SIZE="0.2007982827135558" MODIFIED="2013-08-02 01:33:25 +1000" MODIFIED_BY="sara " ORDER="184" O_E="0.0" SE="0.11601407829336709" STUDY_ID="STD-Slamon-2001" TOTAL_1="235" TOTAL_2="234" VAR="0.01345926636225951" WEIGHT="37.55164626615079"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.15373520522034934" CI_END="2.49298555049178" CI_START="1.161330179744652" DF="1" EFFECT_SIZE="1.7015226585189631" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="30" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.3967197613116867" LOG_CI_START="0.06495571229217839" LOG_EFFECT_SIZE="0.2308377368019326" MODIFIED="2013-10-10 21:05:57 +1100" MODIFIED_BY="sara " NO="2" P_CHI2="0.694991289384948" P_Z="0.006382741951357655" STUDIES="2" TAU2="0.0" TOTAL_1="223" TOTAL_2="219" WEIGHT="13.308114222969103" Z="2.7274422996803986">
<NAME>Beyond progression</NAME>
<DICH_DATA CI_END="3.206044366293804" CI_START="0.6922186292981094" EFFECT_SIZE="1.4897260273972603" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.5059695279692371" LOG_CI_START="-0.15975671695679905" LOG_EFFECT_SIZE="0.17310640550621906" MODIFIED="2013-10-10 21:05:57 +1100" MODIFIED_BY="sara " ORDER="185" O_E="0.0" SE="0.39105089166761353" STUDY_ID="STD-Blackwell-2010" TOTAL_1="146" TOTAL_2="145" VAR="0.15292079987403562" WEIGHT="3.30509394309862"/>
<DICH_DATA CI_END="2.7621461994220686" CI_START="1.1444024634989072" EFFECT_SIZE="1.777922077922078" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.4412466619044102" LOG_CI_START="0.058578784018606035" LOG_EFFECT_SIZE="0.24991272296150813" MODIFIED="2013-08-02 01:34:33 +1000" MODIFIED_BY="sara " ORDER="186" O_E="0.0" SE="0.2247810057066667" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="0.050526500526500526" WEIGHT="10.003020279870482"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-04-30 22:25:45 +1000" MODIFIED_BY="sara " NO="2">
<NAME>Cardiac toxicity of trastuzumab</NAME>
<DICH_OUTCOME CHI2="3.3424581784653937" CI_END="6.472431914935962" CI_START="1.8836619881066847" CI_STUDY="90" CI_TOTAL="90" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4916864075648935" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.8110674906830961" LOG_CI_START="0.27500297389730854" LOG_EFFECT_SIZE="0.5430352322902023" METHOD="IV" MODIFIED="2014-04-30 22:24:56 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="0.647347967994062" P_Q="1.0" P_Z="8.607412090828519E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="738" TOTAL_2="721" WEIGHT="100.0" Z="3.332484965618064">
<NAME>Congestive heart failure - all studies</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-10 00:18:54 +1100" MODIFIED_BY="sara " ORDER="189" O_E="0.0" SE="0.0" STUDY_ID="STD-Huober-2012" TOTAL_1="26" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="42.847706109239226" CI_START="0.20172841873876146" EFFECT_SIZE="2.94" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6319275765330583" LOG_CI_START="-0.6952329157087439" LOG_EFFECT_SIZE="0.46834733041215726" MODIFIED="2013-08-02 01:36:35 +1000" MODIFIED_BY="sara " ORDER="187" O_E="0.0" SE="1.6288637999880666" STUDY_ID="STD-Blackwell-2010" TOTAL_1="149" TOTAL_2="146" VAR="2.6531972789115645" WEIGHT="5.306173568303338"/>
<DICH_DATA CI_END="55.84062836774095" CI_START="0.35069748959585667" EFFECT_SIZE="4.425287356321839" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7469502967051307" LOG_CI_START="-0.4550673429253665" LOG_EFFECT_SIZE="0.6459414768898821" MODIFIED="2013-08-02 01:36:35 +1000" MODIFIED_BY="sara " ORDER="191" O_E="0.0" SE="1.5412717911320584" STUDY_ID="STD-Marty-2005" TOTAL_1="86" TOTAL_2="76" VAR="2.3755187341394235" WEIGHT="5.926421488717504"/>
<DICH_DATA CI_END="99.04111612047018" CI_START="0.7561410471520277" EFFECT_SIZE="8.653846153846153" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9958155258827277" LOG_CI_START="-0.12139718560163859" LOG_EFFECT_SIZE="0.9372091701405445" MODIFIED="2013-08-02 01:36:35 +1000" MODIFIED_BY="sara " ORDER="193" O_E="0.0" SE="1.4819137545985517" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.1960683760683763" WEIGHT="6.410695325461279"/>
<DICH_DATA CI_END="9.567608681388363" CI_START="0.09480210872571242" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9808034042081828" LOG_CI_START="-1.0231820023480591" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2013-08-02 01:36:35 +1000" MODIFIED_BY="sara " ORDER="188" O_E="0.0" SE="1.4026618685414949" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="1.9674603174603176" WEIGHT="7.1555828333187375"/>
<DICH_DATA CI_END="5.147675906188107" CI_START="0.1980528210980603" EFFECT_SIZE="1.0097087378640777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7116111962383987" LOG_CI_START="-0.7032189670511825" LOG_EFFECT_SIZE="0.004196114593608148" MODIFIED="2013-08-02 01:36:35 +1000" MODIFIED_BY="sara " ORDER="190" O_E="0.0" SE="0.9902908045218525" STUDY_ID="STD-Kaufman-2009" TOTAL_1="103" TOTAL_2="104" VAR="0.9806758775205378" WEIGHT="14.355737298697905"/>
<DICH_DATA CI_END="10.841711944637101" CI_START="2.2277482010354097" EFFECT_SIZE="4.914529914529915" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" LOG_CI_END="1.0350978642509314" LOG_CI_START="0.34786610163600634" LOG_EFFECT_SIZE="0.6914819829434689" MODIFIED="2014-02-08 02:11:24 +1100" MODIFIED_BY="sara " ORDER="192" O_E="0.0" SE="0.4810183672579865" STUDY_ID="STD-Slamon-2001" TOTAL_1="234" TOTAL_2="230" VAR="0.2313786696395392" WEIGHT="60.84538948550124"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7055431374204715" CI_END="6.269032983959021" CI_START="1.8145492940995962" CI_STUDY="90" CI_TOTAL="90" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="3.372753974978004" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.7972005548467288" LOG_CI_START="0.25876877075352495" LOG_EFFECT_SIZE="0.5279846628001269" METHOD="IV" MODIFIED="2014-04-30 22:25:06 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="0.7164522776440383" P_Q="0.40432199175935146" P_Z="0.0012558709855765725" Q="2.918755511144325" RANDOM="YES" SCALE="143.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="738" TOTAL_2="721" WEIGHT="100.0" Z="3.2258774954905216">
<NAME>Congestive heart failure - stratified by type of regimen</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5464370457037339" CI_END="7.262505301335102" CI_START="0.5414638121537229" DF="2" EFFECT_SIZE="1.9830239046081934" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.8610864624159075" LOG_CI_START="-0.26643056342854277" LOG_EFFECT_SIZE="0.2973279494936823" MODIFIED="2013-08-02 01:39:30 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="0.760926507396011" P_Z="0.38566768740511137" STUDIES="3" TAU2="0.0" TOTAL_1="240" TOTAL_2="231" WEIGHT="22.804216755596634" Z="0.8675007914003731">
<NAME>Taxane-containing regimen</NAME>
<DICH_DATA CI_END="9.567608681388363" CI_START="0.09480210872571242" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9808034042081828" LOG_CI_START="-1.0231820023480591" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2013-08-02 01:39:30 +1000" MODIFIED_BY="sara " ORDER="194" O_E="0.0" SE="1.4026618685414949" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="1.9674603174603176" WEIGHT="7.2189206539722885"/>
<DICH_DATA CI_END="55.84062836774095" CI_START="0.35069748959585667" EFFECT_SIZE="4.425287356321839" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7469502967051307" LOG_CI_START="-0.4550673429253665" LOG_EFFECT_SIZE="0.6459414768898821" MODIFIED="2013-08-02 01:39:30 +1000" MODIFIED_BY="sara " ORDER="195" O_E="0.0" SE="1.5412717911320584" STUDY_ID="STD-Marty-2005" TOTAL_1="86" TOTAL_2="76" VAR="2.3755187341394235" WEIGHT="5.978879356946199"/>
<DICH_DATA CI_END="15.428102712724753" CI_START="0.2825607897498568" EFFECT_SIZE="2.087912087912088" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.188312521522828" LOG_CI_START="-0.5488881042593573" LOG_EFFECT_SIZE="0.3197122086317354" MODIFIED="2013-08-02 01:39:30 +1000" MODIFIED_BY="sara " ORDER="196" O_E="0.0" SE="1.2159295510931196" STUDY_ID="STD-Slamon-2001" TOTAL_1="91" TOTAL_2="95" VAR="1.4784846732215153" WEIGHT="9.606416744678148"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.94319672309058" CI_START="2.2766150336546094" DF="0" EFFECT_SIZE="5.428321678321678" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="1.1120415520467537" LOG_CI_START="0.3572895993923959" LOG_EFFECT_SIZE="0.7346655757195748" MODIFIED="2014-02-08 02:16:33 +1100" MODIFIED_BY="sara " NO="2" P_CHI2="1.0" P_Z="0.0013640236735901674" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="135" WEIGHT="50.89239472526585" Z="3.20215756333958">
<NAME>Anthracycline-containing regimen</NAME>
<DICH_DATA CI_END="12.94319672309058" CI_START="2.2766150336546094" EFFECT_SIZE="5.428321678321678" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" LOG_CI_END="1.1120415520467537" LOG_CI_START="0.3572895993923959" LOG_EFFECT_SIZE="0.7346655757195748" MODIFIED="2014-02-08 02:16:13 +1100" MODIFIED_BY="sara " ORDER="197" O_E="0.0" SE="0.52827819041595" STUDY_ID="STD-Slamon-2001" TOTAL_1="143" TOTAL_2="135" VAR="0.2790778464691508" WEIGHT="50.89239472526585"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.147675906188107" CI_START="0.1980528210980603" DF="0" EFFECT_SIZE="1.0097087378640777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.7116111962383987" LOG_CI_START="-0.7032189670511825" LOG_EFFECT_SIZE="0.004196114593608148" MODIFIED="2014-04-18 20:35:51 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9922154510529907" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="135" WEIGHT="14.482807466922443" Z="0.00975664003706669">
<NAME>Aromatase inhibitor-containing regimen</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-10 00:19:22 +1100" MODIFIED_BY="sara " ORDER="198" O_E="0.0" SE="0.0" STUDY_ID="STD-Huober-2012" TOTAL_1="26" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.147675906188107" CI_START="0.1980528210980603" EFFECT_SIZE="1.0097087378640777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7116111962383987" LOG_CI_START="-0.7032189670511825" LOG_EFFECT_SIZE="0.004196114593608148" MODIFIED="2013-08-02 01:40:41 +1000" MODIFIED_BY="sara " ORDER="199" O_E="0.0" SE="0.9902908045218525" STUDY_ID="STD-Kaufman-2009" TOTAL_1="103" TOTAL_2="104" VAR="0.9806758775205378" WEIGHT="14.482807466922443"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24035058057241296" CI_END="32.204213295397224" CI_START="0.8746661358138774" DF="1" EFFECT_SIZE="5.307347246978567" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="1.507912694405111" LOG_CI_START="-0.058157687598174336" LOG_EFFECT_SIZE="0.7248775034034683" MODIFIED="2013-08-02 01:41:05 +1000" MODIFIED_BY="sara " NO="4" P_CHI2="0.6239530488899504" P_Z="0.1278370687584651" STUDIES="2" TAU2="0.0" TOTAL_1="226" TOTAL_2="220" WEIGHT="11.820581052215061" Z="1.5226868527371487">
<NAME>Other</NAME>
<DICH_DATA CI_END="42.847706109239226" CI_START="0.20172841873876146" EFFECT_SIZE="2.94" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6319275765330583" LOG_CI_START="-0.6952329157087439" LOG_EFFECT_SIZE="0.46834733041215726" MODIFIED="2013-08-02 01:41:05 +1000" MODIFIED_BY="sara " ORDER="200" O_E="0.0" SE="1.6288637999880666" STUDY_ID="STD-Blackwell-2010" TOTAL_1="149" TOTAL_2="146" VAR="2.6531972789115645" WEIGHT="5.353141296530996"/>
<DICH_DATA CI_END="99.04111612047018" CI_START="0.7561410471520277" EFFECT_SIZE="8.653846153846153" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9958155258827277" LOG_CI_START="-0.12139718560163859" LOG_EFFECT_SIZE="0.9372091701405445" MODIFIED="2013-08-02 01:41:05 +1000" MODIFIED_BY="sara " ORDER="201" O_E="0.0" SE="1.4819137545985517" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.1960683760683763" WEIGHT="6.467439755684066"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3424581784653937" CI_END="6.472431914935962" CI_START="1.8836619881066847" CI_STUDY="90" CI_TOTAL="90" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4916864075648935" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.8110674906830961" LOG_CI_START="0.27500297389730854" LOG_EFFECT_SIZE="0.5430352322902023" METHOD="IV" MODIFIED="2014-04-30 22:25:19 +1000" MODIFIED_BY="sara " NO="3" P_CHI2="0.647347967994062" P_Q="0.6843470222284185" P_Z="8.607412090828519E-4" Q="0.1652737642529526" RANDOM="YES" SCALE="117.67" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="738" TOTAL_2="721" WEIGHT="100.0" Z="3.332484965618064">
<NAME>Congestive heart failure - stratified by treatment line</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9368338336400286" CI_END="6.370390826699994" CI_START="1.712523169708379" DF="3" EFFECT_SIZE="3.3029444274497646" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="8" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.804166077338875" LOG_CI_START="0.23363645602339775" LOG_EFFECT_SIZE="0.5189012666811363" MODIFIED="2014-04-18 20:36:07 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.40146719758292193" P_Z="0.0027714252418715155" STUDIES="5" TAU2="0.0" TOTAL_1="512" TOTAL_2="501" WEIGHT="88.28313110623539" Z="2.9920151334551797">
<NAME>First-line</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-10 00:19:52 +1100" MODIFIED_BY="sara " ORDER="203" O_E="0.0" SE="0.0" STUDY_ID="STD-Huober-2012" TOTAL_1="26" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="55.84062836774095" CI_START="0.35069748959585667" EFFECT_SIZE="4.425287356321839" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7469502967051307" LOG_CI_START="-0.4550673429253665" LOG_EFFECT_SIZE="0.6459414768898821" MODIFIED="2013-08-02 01:43:39 +1000" MODIFIED_BY="sara " ORDER="205" O_E="0.0" SE="1.5412717911320584" STUDY_ID="STD-Marty-2005" TOTAL_1="86" TOTAL_2="76" VAR="2.3755187341394235" WEIGHT="5.926421488717504"/>
<DICH_DATA CI_END="9.567608681388363" CI_START="0.09480210872571242" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9808034042081828" LOG_CI_START="-1.0231820023480591" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2013-08-02 01:43:39 +1000" MODIFIED_BY="sara " ORDER="202" O_E="0.0" SE="1.4026618685414949" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="1.9674603174603176" WEIGHT="7.1555828333187375"/>
<DICH_DATA CI_END="5.147675906188107" CI_START="0.1980528210980603" EFFECT_SIZE="1.0097087378640777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7116111962383987" LOG_CI_START="-0.7032189670511825" LOG_EFFECT_SIZE="0.004196114593608148" MODIFIED="2013-08-02 01:43:39 +1000" MODIFIED_BY="sara " ORDER="204" O_E="0.0" SE="0.9902908045218525" STUDY_ID="STD-Kaufman-2009" TOTAL_1="103" TOTAL_2="104" VAR="0.9806758775205378" WEIGHT="14.355737298697905"/>
<DICH_DATA CI_END="10.841711944637101" CI_START="2.2277482010354097" EFFECT_SIZE="4.914529914529915" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" LOG_CI_END="1.0350978642509314" LOG_CI_START="0.34786610163600634" LOG_EFFECT_SIZE="0.6914819829434689" MODIFIED="2013-08-02 01:43:39 +1000" MODIFIED_BY="sara " ORDER="206" O_E="0.0" SE="0.4810183672579865" STUDY_ID="STD-Slamon-2001" TOTAL_1="234" TOTAL_2="230" VAR="0.2313786696395392" WEIGHT="60.84538948550124"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24035058057241296" CI_END="32.204213295397224" CI_START="0.8746661358138774" DF="1" EFFECT_SIZE="5.307347246978567" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="1.507912694405111" LOG_CI_START="-0.058157687598174336" LOG_EFFECT_SIZE="0.7248775034034683" MODIFIED="2013-08-02 01:43:57 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="0.6239530488899504" P_Z="0.1278370687584651" STUDIES="2" TAU2="0.0" TOTAL_1="226" TOTAL_2="220" WEIGHT="11.716868893764616" Z="1.5226868527371487">
<NAME>Beyond progression</NAME>
<DICH_DATA CI_END="42.847706109239226" CI_START="0.20172841873876146" EFFECT_SIZE="2.94" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6319275765330583" LOG_CI_START="-0.6952329157087439" LOG_EFFECT_SIZE="0.46834733041215726" MODIFIED="2013-08-02 01:43:57 +1000" MODIFIED_BY="sara " ORDER="207" O_E="0.0" SE="1.6288637999880666" STUDY_ID="STD-Blackwell-2010" TOTAL_1="149" TOTAL_2="146" VAR="2.6531972789115645" WEIGHT="5.306173568303338"/>
<DICH_DATA CI_END="99.04111612047018" CI_START="0.7561410471520277" EFFECT_SIZE="8.653846153846153" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9958155258827277" LOG_CI_START="-0.12139718560163859" LOG_EFFECT_SIZE="0.9372091701405445" MODIFIED="2013-08-02 01:43:57 +1000" MODIFIED_BY="sara " ORDER="208" O_E="0.0" SE="1.4819137545985517" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.1960683760683763" WEIGHT="6.410695325461279"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18096871461638694" CI_END="4.738749090606398" CI_START="1.4843376517360793" CI_STUDY="90" CI_TOTAL="90" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6521507682100545" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.6756637140908538" LOG_CI_START="0.1715327039119569" LOG_EFFECT_SIZE="0.4235982090014053" METHOD="IV" MODIFIED="2014-04-30 22:25:27 +1000" MODIFIED_BY="sara " NO="4" P_CHI2="0.9806015045869212" P_Q="1.0" P_Z="0.005706423012831734" Q="0.0" RANDOM="YES" SCALE="80.24" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="478" TOTAL_2="460" WEIGHT="100.0" Z="2.764190404390545">
<NAME>Left ventricular ejection fraction (LVEF) decline - all studies</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-02 01:46:54 +1000" MODIFIED_BY="sara " ORDER="210" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="44.01629937689665" CI_START="0.2084207249027359" EFFECT_SIZE="3.0288461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.643613526909932" LOG_CI_START="-0.6810590979282914" LOG_EFFECT_SIZE="0.4812772144908201" MODIFIED="2013-08-02 01:46:54 +1000" MODIFIED_BY="sara " ORDER="211" O_E="0.0" SE="1.627122451608198" STUDY_ID="STD-Kaufman-2009" TOTAL_1="103" TOTAL_2="104" VAR="2.6475274725274724" WEIGHT="4.702872691985725"/>
<DICH_DATA CI_END="41.771819756886615" CI_START="0.19920142252811338" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6208833953790638" LOG_CI_START="-0.7007075645372995" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2013-08-02 01:46:54 +1000" MODIFIED_BY="sara " ORDER="213" O_E="0.0" SE="1.6249654828681195" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.6405128205128205" WEIGHT="4.715366104305942"/>
<DICH_DATA CI_END="9.481395391970116" CI_START="1.1251706820168326" EFFECT_SIZE="3.266219239373602" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.9768722578482693" LOG_CI_START="0.051218407456731986" LOG_EFFECT_SIZE="0.5140453326525006" MODIFIED="2013-08-02 01:46:54 +1000" MODIFIED_BY="sara " ORDER="209" O_E="0.0" SE="0.6478986100223298" STUDY_ID="STD-Blackwell-2010" TOTAL_1="149" TOTAL_2="146" VAR="0.419772608868867" WEIGHT="29.66126037947608"/>
<DICH_DATA CI_END="4.957140097690991" CI_START="1.1203057205699767" EFFECT_SIZE="2.356589147286822" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.6952311930214191" LOG_CI_START="0.049336553597590566" LOG_EFFECT_SIZE="0.3722838733095048" MODIFIED="2013-08-02 01:46:54 +1000" MODIFIED_BY="sara " ORDER="212" O_E="0.0" SE="0.4520850196070208" STUDY_ID="STD-Marty-2005" TOTAL_1="86" TOTAL_2="76" VAR="0.2043808649530804" WEIGHT="60.92050082423226"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18096871461638694" CI_END="4.738749090606397" CI_START="1.4843376517360793" CI_STUDY="90" CI_TOTAL="90" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6521507682100545" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.6756637140908537" LOG_CI_START="0.1715327039119569" LOG_EFFECT_SIZE="0.4235982090014053" METHOD="IV" MODIFIED="2014-04-30 22:25:36 +1000" MODIFIED_BY="sara " NO="5" P_CHI2="0.9806015045869212" P_Q="0.915795372159888" P_Z="0.005706423012831734" Q="0.17592475327541865" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="478" TOTAL_2="460" WEIGHT="100.0" Z="2.764190404390545">
<NAME>LVEF decline - stratified by type of regimen</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.957140097690991" CI_START="1.1203057205699767" DF="0" EFFECT_SIZE="2.356589147286822" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.6952311930214191" LOG_CI_START="0.049336553597590566" LOG_EFFECT_SIZE="0.3722838733095048" MODIFIED="2013-08-02 01:48:22 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="1.0" P_Z="0.05794188311219736" STUDIES="2" TAU2="0.0" TOTAL_1="149" TOTAL_2="136" WEIGHT="60.92050082423226" Z="1.896137363254576">
<NAME>Taxane-containing regimen</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-02 01:48:22 +1000" MODIFIED_BY="sara " ORDER="214" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.957140097690991" CI_START="1.1203057205699767" EFFECT_SIZE="2.356589147286822" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.6952311930214191" LOG_CI_START="0.049336553597590566" LOG_EFFECT_SIZE="0.3722838733095048" MODIFIED="2013-08-02 01:48:22 +1000" MODIFIED_BY="sara " ORDER="215" O_E="0.0" SE="0.4520850196070208" STUDY_ID="STD-Marty-2005" TOTAL_1="86" TOTAL_2="76" VAR="0.2043808649530804" WEIGHT="60.92050082423226"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="44.01629937689665" CI_START="0.2084207249027359" DF="0" EFFECT_SIZE="3.0288461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="1.643613526909932" LOG_CI_START="-0.6810590979282914" LOG_EFFECT_SIZE="0.4812772144908201" MODIFIED="2014-04-18 20:36:28 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4958281941784126" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="104" WEIGHT="4.702872691985725" Z="0.6810684337795029">
<NAME>Aromatase inhibitor-containing regimen</NAME>
<DICH_DATA CI_END="44.01629937689665" CI_START="0.2084207249027359" EFFECT_SIZE="3.0288461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.643613526909932" LOG_CI_START="-0.6810590979282914" LOG_EFFECT_SIZE="0.4812772144908201" MODIFIED="2013-08-02 01:48:54 +1000" MODIFIED_BY="sara " ORDER="216" O_E="0.0" SE="1.627122451608198" STUDY_ID="STD-Kaufman-2009" TOTAL_1="103" TOTAL_2="104" VAR="2.6475274725274724" WEIGHT="4.702872691985725"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005043961340968187" CI_END="8.640886724319303" CI_START="1.1932457971420387" DF="1" EFFECT_SIZE="3.211028148019641" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="0.9365583118907903" LOG_CI_START="0.0767299133661799" LOG_EFFECT_SIZE="0.5066441126284851" MODIFIED="2013-08-02 01:49:40 +1000" MODIFIED_BY="sara " NO="3" P_CHI2="0.9433811604029188" P_Z="0.05257168358466257" STUDIES="2" TAU2="0.0" TOTAL_1="226" TOTAL_2="220" WEIGHT="34.37662648378202" Z="1.93842261469972">
<NAME>Other</NAME>
<DICH_DATA CI_END="41.771819756886615" CI_START="0.19920142252811338" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6208833953790638" LOG_CI_START="-0.7007075645372995" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2013-08-02 01:49:34 +1000" MODIFIED_BY="sara " ORDER="218" O_E="0.0" SE="1.6249654828681195" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.6405128205128205" WEIGHT="4.715366104305942"/>
<DICH_DATA CI_END="9.481395391970116" CI_START="1.1251706820168326" EFFECT_SIZE="3.266219239373602" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.9768722578482693" LOG_CI_START="0.051218407456731986" LOG_EFFECT_SIZE="0.5140453326525006" MODIFIED="2013-08-02 01:49:40 +1000" MODIFIED_BY="sara " ORDER="217" O_E="0.0" SE="0.6478986100223298" STUDY_ID="STD-Blackwell-2010" TOTAL_1="149" TOTAL_2="146" VAR="0.419772608868867" WEIGHT="29.66126037947608"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18096871461638694" CI_END="4.738749090606397" CI_START="1.4843376517360793" CI_STUDY="90" CI_TOTAL="90" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6521507682100545" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.6756637140908537" LOG_CI_START="0.1715327039119569" LOG_EFFECT_SIZE="0.4235982090014053" METHOD="IV" MODIFIED="2014-04-30 22:25:45 +1000" MODIFIED_BY="sara " NO="6" P_CHI2="0.9806015045869212" P_Q="0.6948927253419657" P_Z="0.005706423012831734" Q="0.15383983753549932" RANDOM="YES" SCALE="78.3" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="478" TOTAL_2="460" WEIGHT="99.99999999999997" Z="2.764190404390545">
<NAME>LVEF decline - stratified by treatment line</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.022084915739919248" CI_END="4.911963240948009" CI_START="1.1720187687426495" DF="1" EFFECT_SIZE="2.3993568116820474" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.6912551080693543" LOG_CI_START="0.06893456654222385" LOG_EFFECT_SIZE="0.3800948373057891" MODIFIED="2014-04-18 20:36:36 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8818614372766836" P_Z="0.04451008329713878" STUDIES="3" TAU2="0.0" TOTAL_1="252" TOTAL_2="240" WEIGHT="65.62337351621797" Z="2.0092551346409353">
<NAME>First-line</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-02 01:50:45 +1000" MODIFIED_BY="sara " ORDER="219" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="44.01629937689665" CI_START="0.2084207249027359" EFFECT_SIZE="3.0288461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.643613526909932" LOG_CI_START="-0.6810590979282914" LOG_EFFECT_SIZE="0.4812772144908201" MODIFIED="2013-08-02 01:50:45 +1000" MODIFIED_BY="sara " ORDER="220" O_E="0.0" SE="1.627122451608198" STUDY_ID="STD-Kaufman-2009" TOTAL_1="103" TOTAL_2="104" VAR="2.6475274725274724" WEIGHT="4.702872691985723"/>
<DICH_DATA CI_END="4.957140097690991" CI_START="1.1203057205699767" EFFECT_SIZE="2.356589147286822" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.6952311930214191" LOG_CI_START="0.049336553597590566" LOG_EFFECT_SIZE="0.3722838733095048" MODIFIED="2013-08-02 01:50:45 +1000" MODIFIED_BY="sara " ORDER="221" O_E="0.0" SE="0.4520850196070208" STUDY_ID="STD-Marty-2005" TOTAL_1="86" TOTAL_2="76" VAR="0.2043808649530804" WEIGHT="60.92050082423224"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005043961340968187" CI_END="8.640886724319303" CI_START="1.1932457971420387" DF="1" EFFECT_SIZE="3.211028148019641" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.9365583118907903" LOG_CI_START="0.0767299133661799" LOG_EFFECT_SIZE="0.5066441126284851" MODIFIED="2013-08-02 01:51:11 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="0.9433811604029188" P_Z="0.05257168358466257" STUDIES="2" TAU2="0.0" TOTAL_1="226" TOTAL_2="220" WEIGHT="34.37662648378201" Z="1.93842261469972">
<NAME>Beyond progression</NAME>
<DICH_DATA CI_END="9.481395391970116" CI_START="1.1251706820168326" EFFECT_SIZE="3.266219239373602" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.9768722578482693" LOG_CI_START="0.051218407456731986" LOG_EFFECT_SIZE="0.5140453326525006" MODIFIED="2013-08-02 01:51:11 +1000" MODIFIED_BY="sara " ORDER="222" O_E="0.0" SE="0.6478986100223298" STUDY_ID="STD-Blackwell-2010" TOTAL_1="149" TOTAL_2="146" VAR="0.419772608868867" WEIGHT="29.661260379476072"/>
<DICH_DATA CI_END="41.771819756886615" CI_START="0.19920142252811338" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6208833953790638" LOG_CI_START="-0.7007075645372995" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2013-08-02 01:51:11 +1000" MODIFIED_BY="sara " ORDER="223" O_E="0.0" SE="1.6249654828681195" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.6405128205128205" WEIGHT="4.715366104305941"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-04-30 22:28:26 +1000" MODIFIED_BY="sara " NO="3">
<NAME>Other toxicities</NAME>
<DICH_OUTCOME CHI2="0.7354045051060675" CI_END="2.2119343081687033" CI_START="0.8629462069366232" CI_STUDY="90" CI_TOTAL="90" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.381586161347589" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.34477222479202696" LOG_CI_START="-0.06401627584762697" LOG_EFFECT_SIZE="0.14037797447220002" METHOD="IV" MODIFIED="2014-04-30 22:25:58 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="0.6923234193158874" P_Q="1.0" P_Z="0.2586087887059706" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="228" WEIGHT="100.00000000000001" Z="1.1296854979697106">
<NAME>Neutropenic fever - all studies</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="60.611887942291055" CI_START="0.38134277136278394" EFFECT_SIZE="4.8076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7825578116481808" LOG_CI_START="-0.418684481573704" LOG_EFFECT_SIZE="0.6819366650372384" MODIFIED="2013-08-02 19:23:32 +1000" MODIFIED_BY="sara " ORDER="226" O_E="0.0" SE="1.5407290981370327" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.373846153846154" WEIGHT="3.4487494478543903"/>
<DICH_DATA CI_END="9.567608681388363" CI_START="0.09480210872571242" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9808034042081828" LOG_CI_START="-1.0231820023480591" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2013-08-02 19:23:23 +1000" MODIFIED_BY="sara " ORDER="224" O_E="0.0" SE="1.4026618685414949" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="1.9674603174603176" WEIGHT="4.161100754975361"/>
<DICH_DATA CI_END="2.188188157550451" CI_START="0.8218527512726486" EFFECT_SIZE="1.341032608695652" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.34008466330696313" LOG_CI_START="-0.08520598664268741" LOG_EFFECT_SIZE="0.12743933833213786" MODIFIED="2013-08-02 19:23:28 +1000" MODIFIED_BY="sara " ORDER="225" O_E="0.0" SE="0.29767630831041275" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="0.08861118452931589" WEIGHT="92.39014979717025"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7354045051060674" CI_END="2.2119343081687033" CI_START="0.8629462069366232" CI_STUDY="90" CI_TOTAL="90" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.381586161347589" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.34477222479202696" LOG_CI_START="-0.06401627584762697" LOG_EFFECT_SIZE="0.14037797447220002" METHOD="IV" MODIFIED="2014-04-30 22:26:08 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="0.6923234193158876" P_Q="0.4101244969944373" P_Z="0.2586087887059706" Q="0.6784408095927772" RANDOM="YES" SCALE="115.78" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="228" WEIGHT="100.00000000000001" Z="1.1296854979697106">
<NAME>Neutropenic fever - stratified by type of regimen</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.056963695513290225" CI_END="2.1332732133380685" CI_START="0.8185047474899675" DF="1" EFFECT_SIZE="1.3213985972485318" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.32904648013136273" LOG_CI_START="-0.08697879725055373" LOG_EFFECT_SIZE="0.12103384144040454" MODIFIED="2013-09-06 22:31:07 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="0.8113609525335542" P_Z="0.33853121588565116" STUDIES="2" TAU2="0.0" TOTAL_1="155" TOTAL_2="154" WEIGHT="96.55125055214562" Z="0.9570714276303847">
<NAME>Taxane-containing regimen</NAME>
<DICH_DATA CI_END="9.567608681388363" CI_START="0.09480210872571242" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9808034042081828" LOG_CI_START="-1.0231820023480591" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2013-09-06 22:31:07 +1000" MODIFIED_BY="sara " ORDER="227" O_E="0.0" SE="1.4026618685414949" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="1.9674603174603176" WEIGHT="4.161100754975361"/>
<DICH_DATA CI_END="2.188188157550451" CI_START="0.8218527512726486" EFFECT_SIZE="1.341032608695652" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.34008466330696313" LOG_CI_START="-0.08520598664268741" LOG_EFFECT_SIZE="0.12743933833213786" MODIFIED="2013-08-02 19:27:45 +1000" MODIFIED_BY="sara " ORDER="228" O_E="0.0" SE="0.29767630831041275" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="0.08861118452931589" WEIGHT="92.39014979717025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="60.611887942291055" CI_START="0.38134277136278394" DF="0" EFFECT_SIZE="4.807692307692307" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="1.7825578116481808" LOG_CI_START="-0.418684481573704" LOG_EFFECT_SIZE="0.6819366650372384" MODIFIED="2013-08-02 19:28:16 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="1.0" P_Z="0.3081369685991786" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="74" WEIGHT="3.4487494478543903" Z="1.0191390564242875">
<NAME>Other</NAME>
<DICH_DATA CI_END="60.611887942291055" CI_START="0.38134277136278394" EFFECT_SIZE="4.8076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7825578116481808" LOG_CI_START="-0.418684481573704" LOG_EFFECT_SIZE="0.6819366650372384" MODIFIED="2013-08-02 19:28:16 +1000" MODIFIED_BY="sara " ORDER="229" O_E="0.0" SE="1.5407290981370327" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.373846153846154" WEIGHT="3.4487494478543903"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7354045051060674" CI_END="2.2119343081687033" CI_START="0.8629462069366232" CI_STUDY="90" CI_TOTAL="90" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.381586161347589" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.34477222479202696" LOG_CI_START="-0.06401627584762697" LOG_EFFECT_SIZE="0.14037797447220002" METHOD="IV" MODIFIED="2014-04-30 22:27:33 +1000" MODIFIED_BY="sara " NO="3" P_CHI2="0.6923234193158876" P_Q="0.4101244969944373" P_Z="0.2586087887059706" Q="0.6784408095927772" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="228" WEIGHT="100.00000000000001" Z="1.1296854979697106">
<NAME>Neutropenic fever - stratified by treatment line</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.056963695513290225" CI_END="2.1332732133380685" CI_START="0.8185047474899675" DF="1" EFFECT_SIZE="1.3213985972485318" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.32904648013136273" LOG_CI_START="-0.08697879725055373" LOG_EFFECT_SIZE="0.12103384144040454" MODIFIED="2014-04-18 20:37:12 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8113609525335542" P_Z="0.33853121588565116" STUDIES="2" TAU2="0.0" TOTAL_1="155" TOTAL_2="154" WEIGHT="96.55125055214562" Z="0.9570714276303847">
<NAME>First-line</NAME>
<DICH_DATA CI_END="9.567608681388363" CI_START="0.09480210872571242" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9808034042081828" LOG_CI_START="-1.0231820023480591" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2013-10-10 00:25:01 +1100" MODIFIED_BY="sara " ORDER="227" O_E="0.0" SE="1.4026618685414949" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="1.9674603174603176" WEIGHT="4.161100754975361"/>
<DICH_DATA CI_END="2.188188157550451" CI_START="0.8218527512726486" EFFECT_SIZE="1.341032608695652" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.34008466330696313" LOG_CI_START="-0.08520598664268741" LOG_EFFECT_SIZE="0.12743933833213786" MODIFIED="2013-08-02 19:29:18 +1000" MODIFIED_BY="sara " ORDER="228" O_E="0.0" SE="0.29767630831041275" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="0.08861118452931589" WEIGHT="92.39014979717025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="60.611887942291055" CI_START="0.38134277136278394" DF="0" EFFECT_SIZE="4.807692307692307" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="1.7825578116481808" LOG_CI_START="-0.418684481573704" LOG_EFFECT_SIZE="0.6819366650372384" MODIFIED="2013-08-02 19:29:53 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="1.0" P_Z="0.3081369685991786" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="74" WEIGHT="3.4487494478543903" Z="1.0191390564242875">
<NAME>Beyond progression</NAME>
<DICH_DATA CI_END="60.611887942291055" CI_START="0.38134277136278394" EFFECT_SIZE="4.8076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7825578116481808" LOG_CI_START="-0.418684481573704" LOG_EFFECT_SIZE="0.6819366650372384" MODIFIED="2013-08-02 19:29:18 +1000" MODIFIED_BY="sara " ORDER="229" O_E="0.0" SE="1.5407290981370327" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.373846153846154" WEIGHT="3.4487494478543903"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2265251939877255" CI_END="2.3457051785116074" CI_START="0.3720873337235475" CI_STUDY="90" CI_TOTAL="90" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9342415028106502" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.37027342662368234" LOG_CI_START="-0.4293551136054395" LOG_EFFECT_SIZE="-0.029540843490878554" METHOD="IV" MODIFIED="2014-04-30 22:27:43 +1000" MODIFIED_BY="sara " NO="4" P_CHI2="0.5415813111091452" P_Q="1.0" P_Z="0.9032694014479149" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="466" TOTAL_2="458" WEIGHT="100.0" Z="0.12153233936661276">
<NAME>Anaemia - all studies</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-02 19:30:54 +1000" MODIFIED_BY="sara " ORDER="233" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.4244755176916426" CI_START="0.015253710854511368" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.38461780297614323" LOG_CI_START="-1.8166244902457414" LOG_EFFECT_SIZE="-0.7160033436347991" MODIFIED="2013-08-02 19:31:02 +1000" MODIFIED_BY="sara " ORDER="236" O_E="0.0" SE="1.5407290981370327" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.373846153846154" WEIGHT="13.195956525071717"/>
<DICH_DATA CI_END="10.330895245666067" CI_START="0.10105134413201758" EFFECT_SIZE="1.0217391304347827" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0141379578609642" LOG_CI_START="-0.9954579053526772" LOG_EFFECT_SIZE="0.009340026254143432" MODIFIED="2013-08-02 19:31:15 +1000" MODIFIED_BY="sara " ORDER="234" O_E="0.0" SE="1.40658883008158" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="1.9784921369102682" WEIGHT="15.832850714424278"/>
<DICH_DATA CI_END="3.664464532468988" CI_START="0.4119395219070423" EFFECT_SIZE="1.2286324786324787" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.564010522610494" LOG_CI_START="-0.385166539379481" LOG_EFFECT_SIZE="0.08942199161550649" MODIFIED="2013-08-02 19:31:15 +1000" MODIFIED_BY="sara " ORDER="235" O_E="0.0" SE="0.6643633566351619" STUDY_ID="STD-Slamon-2001" TOTAL_1="234" TOTAL_2="230" VAR="0.44137866963953926" WEIGHT="70.971192760504"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2184736733299224" CI_END="2.316978435246979" CI_START="0.3672639854526628" CI_STUDY="90" CI_TOTAL="90" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.922465573523847" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.36492199171107015" LOG_CI_START="-0.435021657241528" LOG_EFFECT_SIZE="-0.03504983276522895" METHOD="IV" MODIFIED="2014-04-30 22:27:51 +1000" MODIFIED_BY="sara " NO="5" P_CHI2="0.748577129141949" P_Q="0.543797762063944" P_Z="0.8853901051496265" Q="1.2183567328267835" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="466" TOTAL_2="458" WEIGHT="100.0" Z="0.1441397644031939">
<NAME>Anaemia - stratified by type of regimen</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1694050313910947E-4" CI_END="5.302856678556438" CI_START="0.20114644775447327" DF="1" EFFECT_SIZE="1.0327878697209376" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.7245098895071715" LOG_CI_START="-0.6964876326639491" LOG_EFFECT_SIZE="0.01401112842161129" MODIFIED="2013-08-02 19:33:30 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="0.9913719217382987" P_Z="0.974123772791353" STUDIES="3" TAU2="0.0" TOTAL_1="246" TOTAL_2="249" WEIGHT="31.690723056588965" Z="0.032436728484590324">
<NAME>Taxane-containing regimen</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-02 19:33:30 +1000" MODIFIED_BY="sara " ORDER="237" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.330895245666067" CI_START="0.10105134413201758" EFFECT_SIZE="1.0217391304347827" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0141379578609642" LOG_CI_START="-0.9954579053526772" LOG_EFFECT_SIZE="0.009340026254143432" MODIFIED="2013-08-02 19:33:12 +1000" MODIFIED_BY="sara " ORDER="238" O_E="0.0" SE="1.40658883008158" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="1.9784921369102682" WEIGHT="15.845331640617022"/>
<DICH_DATA CI_END="10.555486370614371" CI_START="0.10324907668360911" EFFECT_SIZE="1.043956043956044" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0234782493165766" LOG_CI_START="-0.986113823381068" LOG_EFFECT_SIZE="0.018682212967754193" MODIFIED="2013-08-02 19:33:12 +1000" MODIFIED_BY="sara " ORDER="239" O_E="0.0" SE="1.4065861769623342" STUDY_ID="STD-Slamon-2001" TOTAL_1="91" TOTAL_2="95" VAR="1.9784846732215153" WEIGHT="15.845391415971944"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.352657277822872" CI_START="0.3640143147796911" DF="0" EFFECT_SIZE="1.2587412587412588" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.6387544727604264" LOG_CI_START="-0.438881537483938" LOG_EFFECT_SIZE="0.09993646763824426" MODIFIED="2013-08-02 19:34:45 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="1.0" P_Z="0.7603076770976971" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="135" WEIGHT="55.10291813751178" Z="0.3050767786095225">
<NAME>Anthracycline-containing regimen</NAME>
<DICH_DATA CI_END="4.352657277822872" CI_START="0.3640143147796911" EFFECT_SIZE="1.2587412587412588" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6387544727604264" LOG_CI_START="-0.438881537483938" LOG_EFFECT_SIZE="0.09993646763824426" MODIFIED="2013-08-02 19:34:45 +1000" MODIFIED_BY="sara " ORDER="240" O_E="0.0" SE="0.7542764207721987" STUDY_ID="STD-Slamon-2001" TOTAL_1="143" TOTAL_2="135" VAR="0.5689329189329189" WEIGHT="55.10291813751178"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4244755176916426" CI_START="0.015253710854511368" DF="0" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="0.38461780297614323" LOG_CI_START="-1.8166244902457414" LOG_EFFECT_SIZE="-0.7160033436347991" MODIFIED="2013-08-02 19:35:11 +1000" MODIFIED_BY="sara " NO="3" P_CHI2="1.0" P_Z="0.28459639461871966" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="74" WEIGHT="13.206358805899264" Z="1.0700509437907362">
<NAME>Other</NAME>
<DICH_DATA CI_END="2.4244755176916426" CI_START="0.015253710854511368" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.38461780297614323" LOG_CI_START="-1.8166244902457414" LOG_EFFECT_SIZE="-0.7160033436347991" MODIFIED="2013-08-02 19:35:11 +1000" MODIFIED_BY="sara " ORDER="241" O_E="0.0" SE="1.5407290981370327" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.373846153846154" WEIGHT="13.206358805899264"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2265251939877255" CI_END="2.345705178511608" CI_START="0.37208733372354746" CI_STUDY="90" CI_TOTAL="90" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9342415028106502" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="17.524014732293452" ID="CMP-003.06" LOG_CI_END="0.3702734266236824" LOG_CI_START="-0.42935511360543954" LOG_EFFECT_SIZE="-0.029540843490878554" METHOD="IV" MODIFIED="2014-04-30 22:28:00 +1000" MODIFIED_BY="sara " NO="6" P_CHI2="0.5415813111091452" P_Q="0.2708427454752963" P_Z="0.9032694014479149" Q="1.2124741483889248" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="466" TOTAL_2="458" WEIGHT="100.00000000000001" Z="0.12153233936661276">
<NAME>Anaemia - stratified by treatment line</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.014051045598800705" CI_END="3.191131308865308" CI_START="0.44226827648960787" DF="1" EFFECT_SIZE="1.1879966936081456" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.5039446749369585" LOG_CI_START="-0.3543142110704063" LOG_EFFECT_SIZE="0.07481523193327609" MODIFIED="2014-04-18 20:37:24 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9056420981494618" P_Z="0.7742908350889997" STUDIES="3" TAU2="0.0" TOTAL_1="389" TOTAL_2="384" WEIGHT="86.80404347492829" Z="0.2867668662753789">
<NAME>First-line</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-02 19:36:27 +1000" MODIFIED_BY="sara " ORDER="242" O_E="0.0" SE="0.0" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.330895245666067" CI_START="0.10105134413201758" EFFECT_SIZE="1.0217391304347827" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0141379578609642" LOG_CI_START="-0.9954579053526772" LOG_EFFECT_SIZE="0.009340026254143432" MODIFIED="2013-08-02 19:36:39 +1000" MODIFIED_BY="sara " ORDER="243" O_E="0.0" SE="1.40658883008158" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="1.9784921369102682" WEIGHT="15.83285071442428"/>
<DICH_DATA CI_END="3.664464532468988" CI_START="0.4119395219070423" EFFECT_SIZE="1.2286324786324787" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.564010522610494" LOG_CI_START="-0.385166539379481" LOG_EFFECT_SIZE="0.08942199161550649" MODIFIED="2013-08-02 19:36:34 +1000" MODIFIED_BY="sara " ORDER="244" O_E="0.0" SE="0.6643633566351619" STUDY_ID="STD-Slamon-2001" TOTAL_1="234" TOTAL_2="230" VAR="0.44137866963953926" WEIGHT="70.97119276050401"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4244755176916426" CI_START="0.015253710854511368" DF="0" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.38461780297614323" LOG_CI_START="-1.8166244902457414" LOG_EFFECT_SIZE="-0.7160033436347991" MODIFIED="2013-08-02 19:37:08 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="1.0" P_Z="0.28459639461871966" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="74" WEIGHT="13.195956525071718" Z="1.0700509437907362">
<NAME>Beyond progression</NAME>
<DICH_DATA CI_END="2.4244755176916426" CI_START="0.015253710854511368" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.38461780297614323" LOG_CI_START="-1.8166244902457414" LOG_EFFECT_SIZE="-0.7160033436347991" MODIFIED="2013-08-02 19:37:08 +1000" MODIFIED_BY="sara " ORDER="245" O_E="0.0" SE="1.5407290981370327" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="2.373846153846154" WEIGHT="13.195956525071718"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2563014288210862" CI_END="2.0844360503060626" CI_START="1.0205515203463513" CI_STUDY="90" CI_TOTAL="90" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4585178710610975" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.31898857567952676" LOG_CI_START="0.008834934027434451" LOG_EFFECT_SIZE="0.16391175485348067" METHOD="IV" MODIFIED="2014-04-30 22:28:08 +1000" MODIFIED_BY="sara " NO="7" P_CHI2="0.8797207880660458" P_Q="1.0" P_Z="0.08211163494878562" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="228" WEIGHT="99.99999999999999" Z="1.7385631394465972">
<NAME>Neutropenia - all studies</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.372573612627014" CI_START="0.3755107140127401" EFFECT_SIZE="1.2813852813852813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6407371295946488" LOG_CI_START="-0.42537766726106024" LOG_EFFECT_SIZE="0.10767973116679425" MODIFIED="2013-08-02 19:38:35 +1000" MODIFIED_BY="sara " ORDER="249" O_E="0.0" SE="0.7462123068087304" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="0.5568328068328068" WEIGHT="8.463418713861605"/>
<DICH_DATA CI_END="4.987461955388515" CI_START="0.7274477372027542" EFFECT_SIZE="1.9047619047619047" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.6978795958872154" LOG_CI_START="-0.1381982026991292" LOG_EFFECT_SIZE="0.2798406965940431" MODIFIED="2013-08-02 19:38:46 +1000" MODIFIED_BY="sara " ORDER="246" O_E="0.0" SE="0.5852010914722541" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.34246031746031746" WEIGHT="13.761329291493592"/>
<DICH_DATA CI_END="2.115252276977366" CI_START="0.9411856296961124" EFFECT_SIZE="1.4109730848861284" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.32536217122188815" LOG_CI_START="-0.026324712383527706" LOG_EFFECT_SIZE="0.1495187294191802" MODIFIED="2013-08-02 19:38:40 +1000" MODIFIED_BY="sara " ORDER="247" O_E="0.0" SE="0.24615837005880084" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="0.06059394315000553" WEIGHT="77.77525199464479"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2563014288210862" CI_END="2.0844360503060626" CI_START="1.0205515203463513" CI_STUDY="90" CI_TOTAL="90" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4585178710610975" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.31898857567952676" LOG_CI_START="0.008834934027434451" LOG_EFFECT_SIZE="0.16391175485348067" METHOD="IV" MODIFIED="2014-04-30 22:28:17 +1000" MODIFIED_BY="sara " NO="8" P_CHI2="0.8797207880660458" P_Q="0.8560856705144424" P_Z="0.08211163494878562" Q="0.03289116837319064" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="228" WEIGHT="99.99999999999999" Z="1.7385631394465972">
<NAME>Neutropenia - stratified by type of regimen</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.22341026044789558" CI_END="2.1438699784997297" CI_START="1.0163035134381058" DF="1" EFFECT_SIZE="1.476083531343586" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="25" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.33119844271271626" LOG_CI_START="0.0070234269701441405" LOG_EFFECT_SIZE="0.16911093484143017" MODIFIED="2013-08-02 19:41:28 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="0.6364536848388029" P_Z="0.0861388163785791" STUDIES="2" TAU2="0.0" TOTAL_1="155" TOTAL_2="154" WEIGHT="91.53658128613839" Z="1.7161269130744492">
<NAME>Taxane-containing regimen</NAME>
<DICH_DATA CI_END="4.987461955388515" CI_START="0.7274477372027542" EFFECT_SIZE="1.9047619047619047" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.6978795958872154" LOG_CI_START="-0.1381982026991292" LOG_EFFECT_SIZE="0.2798406965940431" MODIFIED="2013-08-02 19:39:59 +1000" MODIFIED_BY="sara " ORDER="250" O_E="0.0" SE="0.5852010914722541" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.34246031746031746" WEIGHT="13.761329291493592"/>
<DICH_DATA CI_END="2.115252276977366" CI_START="0.9411856296961124" EFFECT_SIZE="1.4109730848861284" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.32536217122188815" LOG_CI_START="-0.026324712383527706" LOG_EFFECT_SIZE="0.1495187294191802" MODIFIED="2013-08-02 19:39:59 +1000" MODIFIED_BY="sara " ORDER="251" O_E="0.0" SE="0.24615837005880084" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="0.06059394315000553" WEIGHT="77.77525199464479"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.372573612627014" CI_START="0.3755107140127401" DF="0" EFFECT_SIZE="1.2813852813852813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="0.6407371295946488" LOG_CI_START="-0.42537766726106024" LOG_EFFECT_SIZE="0.10767973116679425" MODIFIED="2013-08-02 19:40:22 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="1.0" P_Z="0.7396876369712708" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="74" WEIGHT="8.463418713861605" Z="0.33226702580478795">
<NAME>Other</NAME>
<DICH_DATA CI_END="4.372573612627014" CI_START="0.3755107140127401" EFFECT_SIZE="1.2813852813852813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6407371295946488" LOG_CI_START="-0.42537766726106024" LOG_EFFECT_SIZE="0.10767973116679425" MODIFIED="2013-08-02 19:40:22 +1000" MODIFIED_BY="sara " ORDER="252" O_E="0.0" SE="0.7462123068087304" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="0.5568328068328068" WEIGHT="8.463418713861605"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2563014288210862" CI_END="2.0844360503060626" CI_START="1.0205515203463513" CI_STUDY="90" CI_TOTAL="90" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4585178710610975" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.31898857567952676" LOG_CI_START="0.008834934027434451" LOG_EFFECT_SIZE="0.16391175485348067" METHOD="IV" MODIFIED="2014-04-30 22:28:26 +1000" MODIFIED_BY="sara " NO="9" P_CHI2="0.8797207880660458" P_Q="0.8560856705144424" P_Z="0.08211163494878562" Q="0.03289116837319064" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="228" WEIGHT="99.99999999999999" Z="1.7385631394465972">
<NAME>Neutropenia - stratified by treatment line</NAME>
<GROUP_LABEL_1>Trastuzumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Less with trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More with trastuzumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.22341026044789558" CI_END="2.1438699784997297" CI_START="1.0163035134381058" DF="1" EFFECT_SIZE="1.476083531343586" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="25" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.33119844271271626" LOG_CI_START="0.0070234269701441405" LOG_EFFECT_SIZE="0.16911093484143017" MODIFIED="2014-04-18 20:37:35 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6364536848388029" P_Z="0.0861388163785791" STUDIES="2" TAU2="0.0" TOTAL_1="155" TOTAL_2="154" WEIGHT="91.53658128613839" Z="1.7161269130744492">
<NAME>First-line</NAME>
<DICH_DATA CI_END="4.987461955388515" CI_START="0.7274477372027542" EFFECT_SIZE="1.9047619047619047" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.6978795958872154" LOG_CI_START="-0.1381982026991292" LOG_EFFECT_SIZE="0.2798406965940431" MODIFIED="2013-08-02 19:40:41 +1000" MODIFIED_BY="sara " ORDER="250" O_E="0.0" SE="0.5852010914722541" STUDY_ID="STD-Gasparini-2006" TOTAL_1="63" TOTAL_2="60" VAR="0.34246031746031746" WEIGHT="13.761329291493592"/>
<DICH_DATA CI_END="2.115252276977366" CI_START="0.9411856296961124" EFFECT_SIZE="1.4109730848861284" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.32536217122188815" LOG_CI_START="-0.026324712383527706" LOG_EFFECT_SIZE="0.1495187294191802" MODIFIED="2013-08-02 19:40:41 +1000" MODIFIED_BY="sara " ORDER="251" O_E="0.0" SE="0.24615837005880084" STUDY_ID="STD-Marty-2005" TOTAL_1="92" TOTAL_2="94" VAR="0.06059394315000553" WEIGHT="77.77525199464479"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.372573612627014" CI_START="0.3755107140127401" DF="0" EFFECT_SIZE="1.2813852813852813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="0.6407371295946488" LOG_CI_START="-0.42537766726106024" LOG_EFFECT_SIZE="0.10767973116679425" MODIFIED="2013-08-02 19:41:40 +1000" MODIFIED_BY="sara " NO="2" P_CHI2="1.0" P_Z="0.7396876369712708" STUDIES="1" TAU2="0.0" TOTAL_1="77" TOTAL_2="74" WEIGHT="8.463418713861605" Z="0.33226702580478795">
<NAME>Beyond progression</NAME>
<DICH_DATA CI_END="4.372573612627014" CI_START="0.3755107140127401" EFFECT_SIZE="1.2813852813852813" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6407371295946488" LOG_CI_START="-0.42537766726106024" LOG_EFFECT_SIZE="0.10767973116679425" MODIFIED="2013-08-02 19:40:41 +1000" MODIFIED_BY="sara " ORDER="252" O_E="0.0" SE="0.7462123068087304" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="77" TOTAL_2="74" VAR="0.5568328068328068" WEIGHT="8.463418713861605"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-04-18 20:38:27 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Sensitivity analysis: progression-free survival - by allocation concealment</NAME>
<IV_OUTCOME CHI2="6.852303145334606" CI_END="0.6979596054731483" CI_START="0.541545301076177" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.6147981332803198" ESTIMABLE="YES" I2="12.438199642625221" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.15616971151402584" LOG_CI_START="-0.2663652081346813" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.21126745982435352" MODIFIED="2014-04-18 20:38:27 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3347226160477953" P_Q="0.6228781101825053" P_Z="5.677660381704562E-14" Q="0.24184310921623575" RANDOM="YES" SCALE="3.55" SHOW_PARTICIPANTS="NO" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.003697112583586277" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="7.515309156170721">
<NAME>Progression-free survival - by allocation concealment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours trastuzumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="1.1613587269287575" CI_START="0.4191230880463613" DF="0" EFFECT_SIZE="0.697676326071031" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.06496638775069193" LOG_CI_START="-0.37765841472103323" LOG_EFFECT_SIZE="-0.1563460134851707" MODIFIED="2013-08-06 20:35:43 +1000" MODIFIED_BY="sara " NO="1" P_CHI2="1.0" P_Z="0.16617010468792645" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.8766652787809575" Z="1.3846153846153846">
<NAME>Adequate</NAME>
<IV_DATA CI_END="1.1613587269287575" CI_START="0.4191230880463613" EFFECT_SIZE="0.697676326071031" ESTIMABLE="YES" ESTIMATE="-0.36" LOG_CI_END="0.06496638775069193" LOG_CI_START="-0.37765841472103323" LOG_EFFECT_SIZE="-0.1563460134851707" MODIFIED="2013-08-06 20:35:43 +1000" MODIFIED_BY="sara " ORDER="411" SE="0.26" STUDY_ID="STD-Gasparini-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.8766652787809575"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="6.589506057898933" CI_END="0.703795081506263" CI_START="0.5304016323618289" DF="5" EFFECT_SIZE="0.6109779538405198" ESTIMABLE="YES" I2="24.121778535943065" ID="CMP-004.01.02" LOG_CI_END="-0.1525537725706669" LOG_CI_START="-0.27539514801835896" LOG_EFFECT_SIZE="-0.21397446029451292" MODIFIED="2014-04-18 20:38:27 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25300229971953625" P_Z="8.608919827596815E-12" STUDIES="6" TAU2="0.0074455712411535995" TOTAL_1="0" TOTAL_2="0" WEIGHT="94.12333472121904" Z="6.828028980629923">
<NAME>Unclear/inadequate</NAME>
<IV_DATA CI_END="1.2799078906316406" CI_START="0.35106351590306684" EFFECT_SIZE="0.6703200460356393" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.10717871649960178" LOG_CI_START="-0.45461430202220315" LOG_EFFECT_SIZE="-0.17371779276130073" MODIFIED="2013-08-06 20:35:58 +1000" MODIFIED_BY="sara " ORDER="413" SE="0.33" STUDY_ID="STD-Huober-2012" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.721136860292597"/>
<IV_DATA CI_END="0.9731602799347948" CI_START="0.4805646476254092" EFFECT_SIZE="0.6838614092123558" ESTIMABLE="YES" ESTIMATE="-0.38" LOG_CI_END="-0.011815625344561625" LOG_CI_START="-0.31824818090190976" LOG_EFFECT_SIZE="-0.1650319031232357" MODIFIED="2013-08-06 20:35:58 +1000" MODIFIED_BY="sara " ORDER="417" SE="0.18" STUDY_ID="STD-von-Minckwitz-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.607279253349951"/>
<IV_DATA CI_END="0.7241722137418863" CI_START="0.37483327592691823" EFFECT_SIZE="0.5210027286033344" ESTIMABLE="YES" ESTIMATE="-0.652" LOG_CI_END="-0.1401581429408244" LOG_CI_START="-0.42616186146101603" LOG_EFFECT_SIZE="-0.2831600022009202" MODIFIED="2013-08-06 20:35:58 +1000" MODIFIED_BY="sara " ORDER="415" SE="0.168" STUDY_ID="STD-Marty-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.125772634025958"/>
<IV_DATA CI_END="0.8470416581878022" CI_START="0.4704834021234837" EFFECT_SIZE="0.631283645506926" ESTIMABLE="YES" ESTIMATE="-0.46" LOG_CI_END="-0.07209523019326747" LOG_CI_START="-0.3274556931577242" LOG_EFFECT_SIZE="-0.19977546167549584" MODIFIED="2013-08-06 20:35:58 +1000" MODIFIED_BY="sara " ORDER="414" SE="0.15" STUDY_ID="STD-Kaufman-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.993719333015918"/>
<IV_DATA CI_END="0.9372508449414927" CI_START="0.5855546986765168" EFFECT_SIZE="0.7408182206817179" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="-0.02814415938519282" LOG_CI_START="-0.23243252975675824" LOG_EFFECT_SIZE="-0.13028834457097555" MODIFIED="2013-08-06 20:35:58 +1000" MODIFIED_BY="sara " ORDER="412" SE="0.12" STUDY_ID="STD-Blackwell-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.15227161582193"/>
<IV_DATA CI_END="0.634826235956017" CI_START="0.41246825312126445" EFFECT_SIZE="0.5117085777865424" ESTIMABLE="YES" ESTIMATE="-0.67" LOG_CI_END="-0.19734513312154459" LOG_CI_START="-0.38460947262881295" LOG_EFFECT_SIZE="-0.29097730287517876" MODIFIED="2013-08-06 20:35:58 +1000" MODIFIED_BY="sara " ORDER="416" SE="0.11" STUDY_ID="STD-Slamon-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="26.523155024712686"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-04-30 22:24:57 +1000" MODIFIED_BY="sara ">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-04-18 20:38:49 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUIAAARyCAYAAADS7/yWAAB1IUlEQVR42uydD4RVTfz/Hx6PJEkk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-04-18 21:20:05 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVMAAAKJCAIAAACJZF33AAAdeklEQVR42u3dP48lR/XG8ZGQEMEG
DvwKeA0boRURRLwnHG5gCYd+F4iXgDCExhEZAtYIb+BgDRl/rP7Nsj+h8ey9PXXvrVN9TtXn0QgN
17Nneqrr2+ec7up67u6IaE1tRLSSkE+EfCJCPhEhn4iQT0TIJyLkExHyiQj5RIR8okPn/cJrWJFP
K874lg+RTzTPdL/6vyKfiJBPVLba1+cjn5ar9s99j3wi5COfCPnIJ0I+8omqzfjv3uRbdxxMCCLk
ExHyiSYt+Fee/Min5Wb8k58gn2hy7JeFH/mEfOQTIR/5RPp85BPNNend20c+EfKJCPlEhHwiQj4R
IZ+o3Lxf+A4/8mlF7A0C8gn5yCcCP/KJFmny9flEhHwiQj7RxAU/8onmn/QPv/GWLtGK5G925iBC
PvKJloBftU9EyCci5BNNOO891TMVaMEm37XPQBDykU8EfuQTTdze6/OJCPlEK5X6cj6Rah/5RGvk
fNU+ESGfiJBPRMgn0ucjnwj8yCcqMOk91UM+EfKJCPlEUxf8m123idaZ9Oe+QT4R8pFPhHzkE03T
59tvn4iQT0TIJ5q72tfnEy0x6Q0C8gn5yCcCP/KJpm/v9flEhHyilUp9OZ9ItY98ojVyvmqfiJBP
tEbZj3yiFat9fT4R8pFPhHzkE+nzkU9EyCci5BMR8okI+USEfKKj5v1DAJBPtBb2j75BPhHykU+E
fOQTzTHvl8Ue+URLX/uQT4R8okXm/X9nvmqfaJVJf+4b5BMhH/lEyEc+0TR9vtW7RIR8IkI+0dzV
vj6faIlJbxCQT53zJ/KRT0vMnpYPwY98WqJmTj6p9PnIJ9csOZ/oBpD0+cinFbEvxJU5j3xajvy7
U0I+0fw5n5BPfeYQ7JFPVGTee1fPVKAFO5SdT5BPdFn+rLiAD/lEV1JUaDdL5COfOpNfCH59PvJp
OfIJ+dQTfnMJ+UQ1Wn3VPtFy2C8LP/LpJn5C18DHhUU+8invvGz5MNU1BflEPXPy4vkZ+ZR4DlXe
gVO1T5SCokfv//WapXfnhXyig8k/98itY5PvxCGftiBQ05JPyKeMlfOAnK/aRz6VKSKCJqqnekTp
CoqH/3fk3QrkE61VZSCfaPKCwho+5FN2Pg0I8ilvTx73yN0sRT5l7JA77slzLkL+twCRT8jPS76C
AvmEfOQTpamcQ+FEPvJprQuKPh/5RC6syKdOxXP3d/X6dvt2+0E+pe6Z4/bhi97hD/mE/LzduD4f
+YQifT4RIZ+IkE/UVO2bTsinJSaQQUA+IT+wmigRGfkE/lvnZcuHeSIjn5Zu8uPe1bv9QmMNH/KJ
XLKRT7n7iIg+f9k6H/kUVfB3h7NvNR4XGfm0YlreYvbPQD7yKTv5JfhEPvIpNUWPDLa6z/tlsUc+
dYbfXEI+ESGf6OrZGbDM1ltGyKekFA17aqDPJ7qeotDbB31/l3v7yM+eP5GPfOQvcSZaPlwTfqt3
kb9czZz8BLlbhnxyzSLk0wJVaNC2HFvkm/8RkZFPfbAvlFHNH+TTcuTLn8inRXP+sMtKicjIp+vP
h1J/i3TsC/UCRD4tV6ogH/m0aEHe/b2aIDjjIiOf+oBkEPo+1QuKjHzqkIhWfoeMkL86+Vudm3we
6SGf1iLf3TLkU2f4iz7VM52QTwtdqpCPfFpyDsWvtLMPH/LnzJy1njZFH9vI1YFyPtHFVyvkI5+W
rvND1/CBH/l65iVq/rhrijV8yM9O0crbbxLykQ9+Qv4y8Fdcuhv67G3lrgr5S7T3lsFv3s9HPiEf
+cinvAXLFuN7iXzkU97MHPF+oT4f+bQi+YR8Qj4hf4GeudYyvr4HzF0L+YvmTyLkI99odB4f9/aR
D/6k1b5dt5G/dJO/8g6cXtFFPq1IPiGfysBfxQOLuxbyJ++ZD+lQOj6BG9NH6PNJ5bziHYQSK46R
b64nPdruR15r3f7JUGn5Qv4q5Jvr1a+DyNfn5+LTe2/6fJKLQq6DW8C9/bjIJWof5FP2a1b3twAr
Rkb+zLN8jGtFuZ38kY98mn9GIh/5evIVZ+TJbrzQblwPA+rz6bKJGHF7vzv53nubYcoZiJw5f8Fc
NLICGjPyyCc6uJoYUKdUqYCQnzfRVTkvw/bbLxQ5YqUA8heq9vPnInvvFh0N5K/V2cZl5lCnja3I
Gj7kU5/MnH9GirwTXLVPM1ehrlaFcww2loLf6l3kIz9ptb/ZyrLUGr5y7j3IX6UmH8an6STn0/Hk
R+cikwf5tGLOjzjCmdbwIZ+mmjdj0n65/fYLvRGAfNeU/lk0OUXeBUL+cn1Eof687n77JQYZ+RkT
cqH8WbT3KeT/i3zK2zN7qlc12RgI1USvaiI65i2/sfQe5MhfAtSt7M45Hceh5cM8kZFPt1JUfdus
Bfv8cnc9kI/8/t2EU5m/AnKqkE+xl8Kcdz2QP3NFR9M0Pvp8ypKLXK0Gk993hwVny4zsHHnxNbZx
Dzv6doLIz9vqF93BOvMbdQNWN1TZ4xj5SbEvl4sGZOYFu3HkIz9pLtLnj5we/W0RDev0Ob/uXK/l
gWVnDjr+uj7HdbB0ZO/qUa78GVSq8NWL+1196xTkF8hvEevAavnVVIG/kD8a8jPW+fsfLkJ+xWdv
Wx3HIeQvUZMXzfmEfErd58N+MPyqfVriarWld9HmrkWLJqL89a0OBfnLkRl9Twv55+Kk9UdDPvW8
fZD5HZXQyHbdps4TKG0uGj8a+SPbmYOyzJtyuYjGXK1MgsnJH5CLyu0UXvF+SveqDfmrwB99wEGr
d8u9qzdsYiB/5iY/v9PjyPvkaquOvwj5i5YSFZ+QleMzLh94qkcHk78Nef+3Cvye6lFGiqr7Sa3c
5yNfZl53NCpGlvNpWvLLrYqxbgL5K3bjW/C2OfbkUe1TuvxZ4h2VnSyaP/LI0eClS4eRv4WtFCh9
yR62IoOXLh2W870XcEh7cmPjhvxEM4YTzs4Fq8RO4SOvKcgndUqu3mfktRv5c9aKnudvNffkyf/m
IvIznYaCvtHIH1ZNIH+hnG9AghAKilyoj0A+LVdNDCtVMi9qcqqy49Q9ckT+VLaUqweRn7ezXXwN
31bqqV60J2pQv4P8jORvq+4wX3Q0oj1R9fnITxR5q/yuQaHRiOorUZcQ/sV35vDsDfm07nWw1lO9
uCugan+JhF8ye3iqJ+dTQvirPGemxnGW86e7DNd0pwwdkKBqv4QvkF23KSP5GxftIb2PlTyUjiIu
2uciW71LWerbQs25d/VC4Uf+KjX5BDc+8kcuVFshf3Lyx6wn91Tv5Em0ho+OzBjR68mDOltCvvp2
xfp2K7gDZyHnUuRT3s62UOTofUqs5KFVOts53llOW00gP3W1b+/dzbt6yF9nrtP7RUSV1Q1VvFKQ
vwT5dvI/pE7xVI8Og98OuXN0KMhfq8kv8UbdGJBqPdXLv88X8mk5iiquQXCHj7oVFMvy6d4+8vPy
uVV4hR75R8Gv2p+2bA6a64WOeSv1VG/AGr6+8ZG/BPnR8HutOCgzh1eXqJs+53uqV7EbR/5yfX45
P4yIuT5sPVwVl8GO94CQT3k724ffxD0vXPNtaOQvB+rmqUHlp3rIXyiLmuvIR/788O+c7JxzPbQb
f/grgkCqMv+t3l0C+76NaFGPHQq/jhiIucnf4u880eC5gfyZW/0SdJk/J8/gFvDUAPmU9FJlB7G4
rorTBvWZOsakEPn6fFqoIC/nol3IJQn5yE9aTczhot0xZsuHyKdB8A9bY7t5P9/z/BW68a3IbtB2
5qg90yCXKi3bmSOuch4c2R0+mpP8reZK2Ir3U5CP/MknJfKRv26fH70RRcV7WrXeMkI+uVolvTdR
6GrV/Q1u5FNniio6Ule5puw0hsifB6Qqu0HHzf5yiI73REW+/DnP1Uqfj3zkF9glKqimKFrtD7ta
qfZng3/xFSbVu/FiM81ALFJNRKwLBj/yqQb5W7+3Rwc7yRWtyRNWbcjP3janJZ9aSom0zziRv0Rx
u1ldj3zkr0n+mMMu+kZdfvI3O3CCf9ksV8v3MvmbF8hP3eSndWJF/iSTDXWLlBKF9s9APvIpNfnD
iqAqkfteUIKeniI/6VzfiuxmSUWrCeSryXPlIuSPiYx8NXkNkJLX5KFX2Ih3opCP/FWyXMWaPO4I
kZ+0zy9x56nonh9zREY+TTUjh10HS9TkcUONfOTnJX+CcQ66VOnzZy71C7096g5C1cmGuqUSSPKr
VegOX9H3JrhrkVo6b+Vc8U/gpWv290lHhrfQGbSSZ60+v0SWsxsX8mndyjl6b88SkUdeu5FPR5Iz
ct3h4lvx6vMXqvZD72kjvxb5IZMNdQkzc7ld8QsZYFV88x/5CxXkTo0zqNo3b5bIRc7gmMjmQepW
f/Fril23kU+rzMjSkbc671kjH/kir+hWjvykJ3gr5VcTlDyRHz7TIJcqM9fajSvu7TfP3pCPfDI9
etaDyF+F/IprhChubiA/dfGcv2em0MyMfEpHvvX5I6s25FOWaiLutdyKkcf0a1bvLtHO1b2xv2bk
rdQ9WuQnxb5KN67mj66tgo4Z+cinYtMD+cif8w5C3cih6w45bUwOfzns4+Z6ocgD3LVU+9RnaiJ/
QOTs8wEYWkTkr5gJsIF8fX7fyMkvKMgHP/UfZM/zKWmT76SXI9+7emshakyQv1m3ryCnWtfutNcU
5K9CvlJCNYH85eAfvLZs5Zd2qly7kb9Enx+9z/ROaloksjV8lLHaH78qJmLnj/yRo0FFPvKz9PnI
P6QkRD74k/afcbtuV4ycsARAfuom36mpfuGOWxos59PTc9E1pTr5+nwqUKosHrlE74b8Aj1z8lxU
7pZHdPvdt8IKqtqQP3mtGP2cGfm1c4yBmL5LHHnY4M8/N5C/BPkjm/y0e04OiBxxByGoakP+En3+
5v3fg67daSObBGvNyCqL1ZCvz6f+5G/91sBGVM4VIw9O+97Vm7PIX9nvbb5TGXRB0edPWy527/Mf
nnJDXb3PR/7M86bAIrCYmrxc5AHny84cyF+uTikauUBXgrqciTT/XOex82RNgXyasJoQeXxW2Nzb
pwxznbvWyDNo790lqv0SfNKAcUb+WpmZ1FbIR/7qdUr+yIW6KuSvAn/pxap1I7u3T9ckoor3yVcm
f6tzPwX5+k/w18sH3s+n43O+nTkKF5jYSHuBX60Knekiq9qnyyaN/TPUVjvX7s0avrnJz580Njtz
DOyq+s4N5E9Ofjl358n6tbRzwyTIC7/zQsin7MnNzhy1qgnk45NiBzz1cTpheWbMyRqPatXkZeab
c5Znxjy8/xx61vterYIW2xSKHEf+w4NU7c9MfugEiniC1X0r+HKR4+APOmbkJ835QcAPMIpfmfy4
NQjIR/5NKQj5Y662cj7J+chHPl1SJcZtO5n8mEXeP3Hu8NFNZ904mAMmARHyiQj5RIR8IkI+ESGf
nh5oorFC/vHkiyxynsjIR77IyCfki4x8Mm9ERj6ZNyIjn8xIkZFPt5/db7998803L1+/fvHllx/8
5S93r149++qr52/efPTtt1+njfzvN29evXz5xYsXv/3gg1/f3X327Nnnz5//+aOP/vX1rZHf/PvN
y1cvX3zx4oPffnD367tnnz17/vnzj/780df/yjsaccccERn5Kcj/xz8+/fLLD+8n4vtf9xP073//
JGHkv3366e8+/PAe+Pe/7i8Ef/3k+sif/u3TD3/34d2p0PdT/5O/ZhyNuGMOioz848m/Tzgn5+LD
r/ufSRX5PrGfZP7h1/3PXBH5PpXdPRX6/mdSjUbcMcdFRv7B5N9noSen47uvcxlpfOT7bP8k9u++
zmX+c5Hv89tdW+hzuW78aMQdc1zkQeSfW0546e/tuBnTyVDndrw/OUQnP9kZzJOf3/ecD4vP3/zm
7sc/vvvBD95+/exnd7///eNy9D//eX145Pve/lyRf7Ls/+fr1sj33ey5svZkofv6n8ePRtwxx0Ue
Sn47fkeRf/KStLMF2s7OlucuK+9/+M03Lx/OuR/+8G3YX/3q7pe/fPvNj37UVIsOjvzq5ctG7Hdq
/pORX756eXdJ6JNV7uDRiDvmuMi5yN/Jty3sneP23I/t/8n75J/cyvI68l+/fnGy4PzjH98e9ve/
//jzr756fnjkL168uIj8z5+3Rn7xxYsT//6dToV+/vnxoxF3zHGRE5G/D+e5b/bJb4x5BflP/t92
8t89WHr09Yc/3P3kJ29Pyi9+8fg/vXr17PDI7x7gtX999qw18rtHVu1z/dlnx49G3DHHRU7a5z9Z
kJ+D/NF/vZr8xk2Ou5B/MhH99KdvR+nnPz99/+nwyO/Pug+/e37f/4HGyKdn+W7ow0cj7pjjIiet
9vfJP3ntOEf+Tswk5J/MRd/73tsD/tOfTkzHG3N+l8jT5PwuoyHnB1b7T/7DJ3N+e5/fznNon3/u
6/Y+//bIM/X5t4+GPr8P+fv5ueWWe+O9+kY4o8l/dM/53dc7ta8zGRx5gnv7HUfDvf1b+/yT9k+N
N/B3aGy/t79zkMOe5+/PyFue53eMPMHz/I6j4Xk+XVb4/E/W8D2UNXxjIiP/ePI36/a/K+v2x0RG
/vHkb///DtkH598h+zhh5PvMf+4+//3nX358feT7XHf6zvZ/y9qPv8w4GnHHHBQZ+SnI386/N36y
50wS+dz7+Sd7+4sin3sj/WQ3m2Q04o45IjLys5AvssgjIyMf+SIjn5AvMvLJvBEZ+WTeiIx8MiNF
Rj61nAMiXrpyvsgiy/nIF1lk5CNfZJGRj3yRRUY+8kUWGfnIF1lk5Ncmv5YT6zvx0q07zshPQX45
J9aNl27xcUb+8eRX3NHFnjzVxxn5B5NfcRc3+/BVH+dt8N67earrG710L3Ld3fmNFXdu5aVbfZwH
kX+LbfZRV4p2C5CWzb93Pqy4Wzsv3erjPIL8J70rWjLn//bhb//J7ZQPT/s16Eby23N+RYcWXrrV
x/kY8q/Lse2GXJf69vQl/9Jqv6IrGy/d6uM8mvydNrjd9Kr9n1+doq9z9dn3At0mcmLlpVt9nBNV
+/sXiH1DrnPIjSf/ij5fzj8w5yf30p0n51+NSsS9t1u8dDuSr88/ts/P7KVbu89vTKG39Pkdc36j
l657+7x03du/6Xn+jn9u+739Xjn/Ii9dz/N56XqeP/RJe11Zw3fsMVvDh/x0f4V1+2OO2br9YuTP
ocmcWDdeusXHGflZKpdaTqz/60V56RYdZ+SX71lEFhn5yBdZZOQjX2SRkY98kUVGPvJFRj7ykS8y
8inoHBDx0pXzRRZZzke+yCIjH/kii4x85IssMvKRL7LIyEe+yCIjvzb5cR6vcZF56Y45Zl6605If
5/EaF5mX7phj5qU7Lflxe8XERbYnz5hjtifPtOTH7Q8XF9k+fGOOef59+Pa3ux52m+SiHXV3du9t
P7w4j9e4yLx0xxzzEnvvZiD/ol30T14g9o9ksMdrXGReumOOeYb99m8h/0lrrUf/9VLL3f3j2TfP
vOgaNNjjNS4yL90xx1zeYyeC/I6Wu1eQ3zKmjR/GebzGRealO+aYa/vqXdpg9zLJvMXrvsXMc2t2
5tv/PM7jNS4yL90xx1zbS3dwzj+X3neuJseSH+fxGheZl66cX4P8S4ej8b7djZH3+8/bPV7jIvPS
1ecPJf9Gy93tcgvtS8lvLyXO3XPu6PEaF5mXrnv7g57qdbHcbXnq1u6le/JCsL8F0mCP17jIvHTH
HDMv3UlkDV9LZGv4xowz8o8nf7Nu/7uybn/MOCP/ePK3SI/XuMi8dMccMy/dmcnfIj1e4yLz0h1z
zLx0ZyZfZJFHRkY+8kVGPiFfZOSTeSMy8sm8ERn5ZEaKjHxqOQdEvHTlfJFFlvORL7LIyEe+yCIj
H/kii4x85IssMvKRL7LIyK9NfkX32IpeuhUjR5xB5Kcgv6J7bEUv3YqRg84g8o8nv+IuNBX35KkY
Oe4MIv9g8ivuPFdxH76KkePO4FDye9lmht4OafTSvch1d+ePregeW3Hv3YqR487gweQf4pPdGLyX
z8eTB1/RPbbifvsVI8edwSPJv2hL/Icb6T/ceP+RtUa7he6Tf+8w8iu6x1b02KkYOe4MHkZ+i4PV
/ofnmL/ChOdY8iu6x1b01asYOe4MHkN+F+QaTS8vhbMxePtV6clzUNE9tqKXbsXIcWfwAPLPwX+p
eXYL+Y0xe5G//wduE7nHyvnVz2CWPv+6vNrrzlz7bcgbC/tp3GP1+dXPYJZ7+0927LeQf1HOb/TS
rXhvf3Ev3Qnu7Xc8g4me5++45d5Y7bfDeZGXbrnn+Yt76U7wPL/jGRxN/uKyhu/Y0bCGD/m5yN+s
2x81GtbtIz8X+VtN99iKXroVIwedQeSnIH+r6R5b0Uu3YuSIM4j8LOSLLPLIyMhHvsjIJ+SLjHwy
b0RGPpk3IiOfzEiRkU8t54CIl66cL7LIcj7yRRYZ+cgXWWTkI19kkZGPfJFFRj7yRRYZ+bXJj3O8
5aU7ZjRqufQiPwX5cY63vHTHjEY5l17kH09+3L4r9uQZMxoVd/tB/sHkx+21Zh++MaNRcYe/YuTf
4sbb8pO9vHTbd92O80vlpTtmNCru6luS/JP7anch//at9RuNwx4qzi+Vl+6Y0ai4k/9s5O+b5+7b
9Z4br+suB+3kx/ml8tIdMxoV3XuqVvvv/+/WbJ4bSv4VThtxfqm8dMeMRkXHvqnIv5TbOC/d7RJ3
rTi/VF66Y0ajokvvbORfZMgb4aV7xYdxfqm8dMeMhpyftNq/lPzBXrpxfqm8dMeMhj5/6FO9/W+u
vgk/3ks3zi+Vl+6Y0XBv/2Dytwbz3P378Id46cb5pfLSHTManudX0iF/rzV8LZGt4RsTeUXyj/pj
rdtvjGzd/pjI1u2nuOLEOd7y0h0zGuVcepGfpdaIc7zlpTtmNGq59CK/fJchssjIR77IIiMf+SKL
jHzkiywy8pEvMvKRj3yRkU9B54CIl66cL7LIcj7yRRYZ+cgXWWTkI19kkZGPfJFFRj7yRRYZ+bXJ
56X7ULx0oyMjPwX5vHQfipfugMjIP558e/I8lD15xkRG/sHk24fvUX6zD9+AyCnIv9T0bsCRXPfh
1mzg8bDn5KX7sJvlpTsgcgryzzlbjD+kLl66l5LPS/eheOmOiVyG/H2T3HPUtfyrJ4+ql3XPxku3
ITIv3TGRM5Lfjtm+qU6jtW5H8q+r9nnpPhQv3TGR6/X57bZZ1xlg3RL8OvJ56X7nQ166QyJnvLe/
X+3PRz4v3QNzPi/d1H3+pffYbiT/Ri/dXn0+L11eumv1+b1McnvZ3UaTz0v3kHv7vHRr9PlPmuTu
/Kt2I+3bvXRvf57PS5eX7irP89eRNXwtka3hGxMZ+ceTv1m3/11Ztz8mMvKPJ3/jpfteruOlGx0Z
+SnI33jpvtfl8tINjYz8LOSLLPLIyMhHvsjIJ+SLjHwyb0RGPpk3IiOfzEiRkU8t54CIl66cL7LI
cj7yRRYZ+cgXWWTkI19kkZGPfJFFRj7yRRYZ+bXJr+gey0u37jEjPwX5Fd1jeemWPmbkH09+xV1o
7MlT/ZiRfzD5FXeesw9f9WMeR/7ONrWX/vaLfv6i33Kjl+7+eslp3GN56VY/5tHkt9vORtwIbXfR
3G5w1Nz5XdO4x/LSrX7MreTvuFO2O9XukP++He3JXHruePZ31H8Y86KXGcaQX9E9lpdu9WO+nvwr
nGofcbg1u+g8+U0L+dslZjgjya/oHstLt/oxX1Dtt1jcPOlg00J+S39+Dvj24FuAo+bJ69eTv7Gi
eywv3erHXJj8c43GpcE7kr+dcgHLljF46Rby0o075to5/1zZ/2Twduz7FvbTuMfy0q1+zJfd27/F
Vf6ivv3Gn2+Pc9Gjx+r39nnplvPSjTvm68nfrnKqvYXkWyrwRwd87t7+7V66mZ/n89It56Ubd8xD
n+eTNXyzjoY1fHQN+Zt1+/VHw7p9uob8raZ7LC/d0seM/BTkbzXdY3np1j1m5GchX2SRR0ZGPvJF
Rj4hX2Tkk3kjMvLJvBEZ+WRGiox8ajkHRLx0iShBKjIQRMgnIuQTEfKJCPlEhHwiQj4RZSefiFbT
/wGQcDQhyLFLqQAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-04-18 20:25:49 +1000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Efficacy of trastuzumab, outcome: 1.1 Overall survival - all studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqAAAADACAMAAADsiSGEAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-04-18 20:26:32 +1000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Efficacy of trastuzumab, outcome: 1.4 Overall survival - stratified by treatment line.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqAAAAFwCAMAAABQNDlFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-04-18 20:32:18 +1000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.08" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Efficacy of trastuzumab, outcome: 1.8 Progression-free survival - stratified by treatment line.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqcAAAGQCAMAAACkrDm+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAA+4ElEQVR42u19f3RcV33ndyTNe/NmZGnuSErsEBPb0gYOP1KQHcuy
5KYZGbLGZdNDgd3TljTkj5R22bI9m0NL2m34tScJlFOy5UeTc3qy2SylnA0UUkwCRCpBGsUeHNMF
ym5AsgyOrRBJ70q2RqOZkTx73+/fP2Y0I81I308iz3vv/njfe+/nfe/33vd990YIIBANjxasAgTy
FIFAniKQp4gNIp3W/gmKxP5NR3mhR7s4nghOuPUSc5xQ0iWO11ti5GlDYKz03OCydvLAALsw1ugS
F5cGd+kSH6m3xMjTeqMnwXGxbkkDMY2TjXPReJ6dJATICrGkEe0YXIOSwHNCime6SdZOHTzXuRUS
lxIcL4yrEisysZN4HEThhGl6SGASK+XhNInLPNeBPG1OLPPFXxy9ytTNKbgTblsorhyR2vrZlyE9
+M1rRrQ8a4oOsZAbXCkw3SRd6Tx0KnEwuQUSdz5TXB58kkn8UTijysSuLizBk4OnTRKPQ6tanqIm
8cipxKFO5GnTWaiSyZZv6bgHygAimRiE/Nn7OmCdXX1jFwxA/wUj6skzVyC/t+ODoDOhAB3TjL6b
L/HKb3d0wBNM4gcz/yzJtEuWKR+FD8P0jBH1gdPPG+WRcQj6p2G1LpK1Csin+mA/jM3M7IcZ8paX
X73+tTPw6OGFv4HnPvH1xPU3scsfkCJ84GEWrkT9n59sXW1NvuUPH2VRpYvsL3LT/Q/vv7i+BRL/
2svTX2MS/+11TOLkWy62yzIxiW8zS3z1Z62ffFgvjyzxpdd+oF4Soz6tN3Lwy59JRt/KaQpwEi6+
pAVMgiga5ml84COwAu97yUh4XAqPbI3EzEaGbP4FJvGKSeKMWeL59iP7LOWRyGQKR542F1pg1zn2
84Xhbyu9ea9hkZ7bb0RbfOG/l+6Gm3sVOiisONcLsS2R+HWSxLcPf4f9eze8Tpc4Cr37jGj0hXxJ
LY8qMVc/iZGn9UY8k3iW/XwDHmDG32Jmn94trr3woLn2+eHkYObXRDnFjdKFC2dP5l5c3AKJhcml
d7GfAVniwcwtuo4ce2HFLDF3LKmWJzHxGkXiB3MvLtVFpgj6oSCaoldCIJCnCATyFIE8RSCQpwgE
8hSxjXkqtvPcSCIL3dZXqT5+hdnyCMcnSiFiBsKRVnrVXKlD5AndhVMqg5Ew7ZuHVu604iBkyjkL
IpfmRMimYw4x1SPJV9QsSywtydCjJbD5aYar1lKZGymzeyvyJCWnqfaUVi6eK5dq4+uZTsdVYU+Y
hD3RXZmw2XaOu68EJU3YRwEeGVeCxk9wI+3Z2ghrer9/w/Li1Z/e/vG1I3tnzDGUF7qu+PtjX/rU
8u3/9sXgmIFwpN0PY8rFoFz1F87rpHtGY4RUhhk93YxvHlq55dfb5nj7P7360ePw2t+PPrXng8+q
Oc3YBP7FjZYUML/n5QJA2w1zq1op1pfTr66FKLBJd4wsPnLpocJje878TLrfhb9az/7dVZXB0Usn
frFQ2khNmyR4dc9FJmzuwA8MYU11GE7YLx8Wo7BYKN48eoEJe1dmdH32nY/JIbP9L1+6/+AnayOs
SZ9+GNZAGFuNas6EkvNhIkYABPbYlRQNcR/Pd0gh7TK9S/AGluIxLTZA5wmmO7LxWFJWhvG45kOp
RkinH+fjJU9ZlLilBJ+0PYK6D6T0yOr+nEwGRT4N80wgxXdSd4hU5PWHWm43TQt7YIL9ifAxsYPj
O0SlTlT5uoWY4itqxquyv1AB5oxLhp8mS56K84/rfpxSnlLFpAS+M3lvTNWZwMN8PxRZKk46W99T
huOqNkkOx1LHxnK16kzPwxD79x1mYY06ZHLlWQn1OlZ8S9PpJCt/MsZrjlxFEKfZP7tBjvREtAyv
55WQ3UNCShxbqXm/3wL9TDomJ+ie2W0DcVF6bVuCJ0G6e+e5+CnZwXDukqyM4a3CuDm38unBL8Ct
R76p6I+Fiw4fyg8ljrR5iaLGbRtIfMxOYMUHUnLhzGr+nLIMinx6Zw9R1XdSd4jU5PWvgn5rKUwM
K8Kn2d9/gtb9hxKJQ/uUOlHlm7tyNF8wVZaM6OmhccgPnY4alww/TYl100Mf0Pw4k4cSwiHpMVq7
MnTw2uePak0akd6W38WenhyfEKGlp6VUnFZC1uBntTT6UmcK3TBeOBN1q0N2cn07k0mt4w7Nt7S8
ONRfvjr0ITXB3ZKwZSZZnkssMPbcLRbOKyExeKku9umVSRh8gNlpJvAw9QOAV1hTfVB+uFdhuoMp
C4C8/Ow/b09xYRqeZvJ1UPks3+XwobwwBbyXKGpcds9BsFqWml9mlmSo7s8pyaDIp0W9JbsEKy2K
76QCXV4/GOW22aeZo6W1icGJtdJPJ1g3Pj0lax9DPhoFFxe2z8NJuB7+2lQCi5/mzB4mu+rHmYfp
83ArO3guKv9pubVBnyCVITMRH9gLwlKshz8g2X3ABEjVdHTCMVU6DFGw1aHqfwrPzbFaV+v4Vs23
dIZFn4/qdRwDoU9qjshy+8BNICQOHuD388maC2viafTyuUkYuM0cOgypw0ytZNZm1yalzqEsnUvV
qUhw+PKL1hSpFNMe1+CwUnIWaR0OW4RlETw91fS40j1VjMlf3SRv+cTXmCxw/OipKJBbrv1AOpGy
HzbFHfuXzPpVIH95TenNFP2uyesHo9xjY5aPfKLQNswd5obbWHuW4d3vhlEwyyff34E7M/9BLEzc
Y5TgR+PQB8898MV2OKYlGpLqQa8vVo/K3zE1ycUzy6kMsxsLh6eZnlosnl+deW/uj+UnB2rrNzc9
HhOF8fOGsP8yIdXhm9U6PCwJq9bxuCRsWW36KOh1/JlsRyETgdxodIqps8Xie1bnCx2yETVRS2HN
81Kpxcs/VFs1I/f/0q2ke0WH/80wpyp5EY6bUixdPsd4OQGqSLLDZCuIug3aqlwa1yJkfURX/S0j
TidG1S+ztDp5XPfnBDDkU61JYZBovpNGp2SR16P7M8ptQRvTJW2sCDH2F4GnxsaKaq/sV/+ptqnX
DrWZelIXP03dj5P9uEwMpnLFfNlkHvVyqaloWZHo5pryNMUPkaO8SZOIcUcdqsK2eHjDRpdLuXKL
ZrAA9LVFj86tK8r6dXXhaSydSj0tdTogCTTbLXfFfZJN9i32ZMnV/BXoPQeTphT51D+xFHdD9z5l
XNjLHrU8nGszOhbZI7EVepQIx/u8+33V35KHvidtIapfJhluB92fUzUV+vYZ0RYn+R7Vd7JPeS5s
8rpDK7ezCZgumWMjiyF2xEPvbFpQ+n2zfE4NN88qK2aeyjH5aeoZy36cMeg9YK0OJVH83hJhekHg
Z5XaKrwEmdLdcsjEqphPJ2rZ8Y9IBp0h7OIb+JJah7rtJNex07dUSSTwPalhgcncrQibpzA5K7NK
4P5CTKXjNefp1TM57qPZ78FTE3uBZu6RVMLa6eVHpAqdgMk98rTM2dzJs4aD4fezvxk9nl2Ewcwy
p6jPlckx1i6fIZKKle3RsydzZxeBTl79lnK75TMLXqKo/pYLp3MxLbkK1S/zMNzC6kb151TGFYp8
+rhneCWu+E5KZXDK6w6t3A77dC4DfBSik5D5GVzoz93E7ExpdGiRT/UVNSEfgcyUrOt1Muh+mlr3
qvhxzvTnDtqkkxN9+2Iif45Ce+u+5bMXpKHNHsnukyUaXduTHK2hT+rUBExYhf3ScFL1P7XWsYtv
qTz4TLQs5d4nQuJLV946yoQdb2XP9D75gZ77x2d35+R6rQHC+J+KcMPRH82Hf0bj56f+7Izb5Eka
Qnzjzcdmdt3xQj5U3NBT2jXMTJUvKFp3ropP8Hqu1ucruLrcd/bAJn5kGIanfLklXoFJPP72dYjG
51x7mWIIm2l1DVqfP8yVWwq1KiQHkZrlpckXFC0xX8UXkgnXaqs/qrpv+zPHGounCAQC0Uz47S26
bxvqU0Ql2CK+oF8fohmAPEU0H08TyvRhNsFx7SXrNcVZyebINK7O4jpDEIhawry+VGnXEcVV8H8d
+fF1/QslyzXZOxNmrK6EmvflfpiZmcHK3AHYv0XNbNand2gH6yDMq1Odd1ija36lPQLHJUqcyftS
DiEJPg9iB8/dJ2KTIurE0+xF9eDTMN6t8lS/ZsLCRbg6ONs50Fm0e19eiw99CPYf+m67eeUkBKKm
PF3uUg8GJx+4JbJmvWb6yijfBUPwe2tPOV21Z+bgCShAbApWsWoRNYSrd/3tR0/tvcURoqvOFMBH
Tg699c9Sjs6dhQyNrcOfgeypiEDUZ7yvDagk+5TzS3Z89tSZqWWrmtWHZrqrJgJRN54y2rVCXvpO
xmeqSXj34kUWTfK+HLNvdMHBuZ5a+kgiEO769Pls55Wsr9vm82f27T6d0Na9tOLC6MmlM4tYtYga
Av2lEJUgvUX7WuF7U0TT9vsIBPIUgUCeIpCnCATyFIFAniKQpwhEnWH2NqHE+Ndx2Q6qfNKl/mhp
t+w7L08Bg4vgLIx/fvJihET6JV45+99Hy0DJwk0Kkxj6DcwyUiA7mKcVsUBpI/VHqXr9rCFoapKF
BsSwFSYgtsoWOUEomtrvQwyRiDPU+qxQ1wontNbVtQiQbDqemtinP/a6MiCOupQvAkDTPuTE8uMb
x08/V3AvtwyIS95UZ2TwHTf0gdrXwqb3iDW2FTy105VYVCcJaMSGA621+jH64koLToEEpjNbH5Xk
v1GqhEq/Ve/328Ctk/Fjob/RR5tTp1Jzx+EfR68HKv1fmaWoPu7+d/C0PqSrpE5DgGSDN1Cbg4LU
5zlvFtJZTbwQ7Uo0y9Ansj2QBBOvwn6HaNZrOLMbx1FhKrlx1Slx8ramcpm6fbqxDDYh1TZBSwjl
Sd2uNk+vT0igkgrRYdS/NwmQYkfT1F2fKqaXbgsR2W6yWkZU6V1dLzYGOykEzG8aMdQjX9vPJT8l
JQkvidsNvKSwDfvdK3znAP35t3YmospefsuUK/rz70yibmqynTGOQtR9xBd2amDndYKoTxHIUwQC
eYpAniIQjTuOCjk5R+3v+K3+m2G8Oes7hg7nVlqx/ynYSlup/6nhuapfIE4/WasU9rpG/9PwL4+J
7cjqvxnGm7OeNA3rVlqZ/6lRarMLWWX+p4bnqnYf4vSTtUphfxdYL/9TCY3sg+rw5ycmx1Pd49Tm
f6o0EVjqvwHnT0hYQcJErNEjF5yNzdGVOo5C12qlZI6ESPLVLWrgNrd6sjvru/mfhvAUapjeKbQg
NMx3Jxshr7/jqVNNEudR+FqtVLjFEEkawv9Uaw2bfiGWUrs7v7s0QIU+b/UjaBhBaGBEYv1WqSr/
0xqwuY612sg+qG2O1qB6j2Hzeai0GyFbQEuHT7fsW1wLiU2aTfHSqcb/dIMmwdabUg3DU8NYt6kQ
0+d69bPeameQ1oUjji640vFMgHOJodYRNpjnT+VaN2aadFbSQI3amDVLa0lTWnW/Epr+qp8s0jRI
n5odTt38T73Uh9U3Mow3Zz2Vali3UiNiGN9OFy/Siv1PbdXsHqoKQ90/nUH/09r0iYga2QHof+rZ
7yMa2DSpRbLtNo7CEebWD/zQ/xT1KQJ5ikAgTxHIUwSiKcZRbuufUuuLU1cv08ZxN3FfSdQx5Uit
TnpB/qeOtV2psRhVxeuf+vif2ldHtaS1+K6i/6nPlIeHe2njLMzrsZIodVm1wfzaLcj/lHomqtT/
1CkQ8V0d1dN3tWr/U2k7z2TT89SmAeTX14bW8FxDriFh5oIPhYKdOh1ru1a/TKW/QCSoUkP51PjL
FgmMQZqAp7ILNLUtfErDdmqNBBruy5cwTp3E50KlT2m4yvKhaajnM0CfNqXJ0OZXVqKT17uqGnKd
Q6o79FESpomV+AHvzmuw/mmAQLTCr9N2qn0asvNovG7CTjBSoWwEXA1Ze6SNrn9KAsPrzcHktuKp
13iqkY3RrdBAVVuqAZ+f+F7emW5B1vlTYvmywn7R9aPNBi4brSVNad0Fohun+A7r982upg7HyMbw
MnWX2n0lUbtZ4OUQulnrn1oE8lodVZ2N8vBO3XGIEHyEt3S8V12lo/8p0nQrTJMtMEK2w3i/AYf0
2xLof1pDfYpAIE8RCOQpAnmKQGzJOMrj1XPAFGFDrX0KtnvTcOufGi6m4LEApat3azX+pxaB3NY/
9fA/tfjU1tD/VPJMaYLXqW3ujeJ3wRncMGufmgTS2hZCrH8KvpuH2/1Pq1//1Fk7LuufevifWnxq
yY6bmGpzYyU1rS5JlRVPdSdy65qozTJFEvSsUe8nsoqFRwMkIWGYXXlQgEr3QMQ/uFHat82NpmYF
RDQlAMS5JmqDQ6MYDemG6mog+PmoVr7+aRivbX8vlaqoQ/z7/cZXNm0u9e7eVq6roHrXK20kuob3
MaYkbC7V+J9qeVRhX+qLfeG+5rq9RavqQRxtuKUjKLB9lLRh48DVr7/CbsV4yt3XNQ62cmtO0WQT
8pTovbzv7to0uH635ol3zlTUV/fQ2j6MFLZ0ANrQaHHpXsB/L/gQNG2MTl9bUHTjg42aq/2qxaU7
lKdtzi6bGMufumxsYL/YcF6p/suNVhPRFrv69U/dasfFr9U8VAi7mOt2RwQ7ma0d4VURBOh/itj0
kd8mJttO/T5iCwd+YUei6H+KQCBPEQjkKQJ5ikA0zDjKsQdf0KDTxeN069+m+C8o6hrRtLlwUDlN
1VT1+qcmRz6n/6nrmrM2MarzP5VdTpp06R6Hn3Ronrl7nG79jIn/gqKuEf1fvzldarXcq1z/1HQf
F/9TixQevqvof2p9jit2PKWNVoM+etIhtbvwpMLMAhgbWEk+oZXsKezy0EW8HkbShDy1Ll1XqeNp
g5WYhrNFwvlVUVsPDNWuf0p8GUoC71/JE+rs95tz7tXMU1M1md1MiWfxG92zp1bO3NTqwqe/cK9+
/dMNFIbCjl//1GSfNqUB5L4Mak0tCNszXMv1T2k4/1ey4/2kqXW1OBpKzTSeMVpzOSmp3JSs8jGr
a5Umm5inLRXY4Y1O0zpOIFRUMVVWKfqfVmGfOnxPHY6Pro6njaBUPRYU9YkYwAxzOWvhfxpKCvQ/
tc5VoP9pA6nq0L0V+p8iNnnkt4nJtst4H9EYA7/AuYGNatPuq5G4uE3GUYjtinzs56/MTvPjzSRz
q4DttrMwnvg/r0q/y18gY49XnHr/zJbrU7Gd50YSWd1iTitdRNxUQrAFpgTItnPcfSUopSVAknsU
4BH1SR0/wY20Z6W4sVQzt2zyBCeMayWU64HjWD0lo6ysiQCtVLqP49rlOtXSkxh3Ylypw7Rc5+WS
Wv8cCy2VuZGy1gbZ9hGpbh0yqHJUpUtPvOkTC+rx7JubR6ea9OkNy4tXf3r7x9e0JwfkR+fIjfoT
9AvjUAkUz1wqfPmwGIXFQvHm0QszM3BXZnR99p2PKdXQ//Kl+w9+ssTiJt773Yeb14jsf3Hs775c
Kt6cfWlGroB/WMvNnvlvpbsmWVk/+1hA4oj49fMfkTxA1PSpt84vvvzlklyHY/DQsXn+6GJBjvrF
I6xSW0YWH7n0kHIBHjt2/zfKciiTgbb9vSbDjNo2ldul64s/ln678so5/5nkcrTZ9OmHYQ2EsVVZ
V8oPbDImZDl2DFDmuQ7gpcNSguMF7SnsLZyCIojT7J/dim3/RLQMr+eV0N1DQkocW5GfhqkDzatO
SxPi4WIOrgetRfPFKA8lS1k9UYSpfpB1gZq+ME6jLDcV74DzUyyO/FgPycyB+X71ArB0/VNQUGWI
FldMMlTV48d+Lj0fXQALXdrvK6t8d5ONo1qgX7D0A9e+M5hmVTYGnSOnEoc6C/LhM8XlwSfVCAV4
A9wNbOBYZhTPcwnWoZTuFgvnldAYvKTlNAWl5uXp70TifEKEdVi5N6EV4wArt7msnihDKgV3SUdq
+t9tifPGWHtUCi4rj/Vp6d+IVJ13qaF3SaEK3SMCx2S4JuWxUC1Lb5sFKa3t75Wfx/JNxdMrkzD4
gGGfAlyIwYB8cAj6p2FVPlxp6eiAJ9QI6+yZjIHQJ9V0ZLl94CYQEgcP8Pt5+U3yEJis0ibm6dTQ
5xMDewEyy4MD/0Vt8xUYtJTVE7KSVOpLST81tJA48loteFjhsmSLxuVJ0TboE/T6ndJDh4e+0M5k
KGc6Bgc+Vl0x/t2QF8HXX9NUPI1ePjcJA7cZF1KH4ftKs+jPNZC/vHZeqXy1Cj+T7ShkIpAbjUod
2GLxPavzhQ6Z0xOgq42U6qPbpLhzivUXuUL0TviiUh/Hh3/4fktZPZHRqaanz5t6lwlFhzLcrgxS
L57JpTLOUF2GuTvhb6srBB3tvV7t7i1/u1/8ldhUPIXU4uUfMh2Z0bSfKKrBLdKhghz80jDJpE4q
ulzKlVu0c4C+tujRuXXpjIPX6VMJzcxSg2pqdZXeVv6RrPyMsvrUr5g1VXKLJTeAEalmZSYO3CIN
CyCVK+TL2suXVj3UnKrqR14sduxWbFO5y5d/r9s/e7wZJmNMPI2lU6mnWccTgVnFtN73E9bZS1qR
g3O9rIPPgETc153TU7SxqhP4ntSwAPF7u/ukkRbkKUzOyrkK3F+IqbQ8rbVrQ/b/FoOHc4Jk3nBn
etkxG2F23dU5rwyoBK2snohC7x3wsJRKTc/DgX+FgvEMsJrlpOCxsTHJ/o/fWyLDnDrvxxL3KaFM
hn+VZej5CfDVF2Wx0PunoHX/7Hf3gV8tNseUoamWr57JcR/Nfg9o5h6FVa1vf+EH8OjEjXDh7IO5
F5cgnrkR4pNL79JTfA7ikGhZyr1PhMSXrrx19ALrElujwO+TB7hz//js7hzLj2Gtmd/PXjl7snN0
Adqjx1bOXpCHj1Nvlmcwx1vnILbP/0XJQn8ulx2UjtT0V84eHOlf04cA2ZO5UbPd+O2Lifw5Kpla
DM9lc8v9C6oMI7IMS29TZKhapz7We712fN3XZ2mzTGxvyF9KvIG7EipiMj/b1DP9dQHToZ5hswfy
1SYNRmp5jZH/+m/1V9EmW+UvtTG/vtTqSqh4sS++H3npsCfK+kSpA+3PHPNJyUGksKFbJ/PlxHRV
mqM5eYrYcZ0A+p8iEMhTBPIUgUCeIhDIUwTyFIGoEZzroVDbapwVwL6KjfpZpDUbl7W+vDeot1w0
r3bnlwO4rI9JidvKTNRY/9R9lVSHZPZC+klDAXfXqwdPNwziPKdu24K67OjntUE9OPZSJL45OJcY
Be/HzrLNvdvirw7J1OeAkhDlCb1AKqLafp9Sqi4EIh+ZD9mP3C56AAXzGRjx7fmB+kfDtp1pl2+i
3do9B2InozWCq0wbfQwNkiMXt0ifaosWO1Y9VbUEgC1A1zZEWxqMeKk7fbdZVw3syQvz4ni+Obgs
MaqITKixsLRtvVwbq8HDBCBGP2/audlfGqRwHXhKw6kS88pTznYgzs7ObbFHUr0+c83B1O1TN6Eg
6La6nUlC2d7B5almgVREGJ4SMHrnIOpSCMfwMMF1NJH9R30VpKxizfPKF0hFVDaOIsGtV0kju62m
SiujlUtjW3KozOYl5h4bKpHMc41S11SUUKRYfcf7PtNT1DVAPyPejW/Z6SOsVqIeszvEfYLJX6GT
gNmIAMm8J5pQaW4+T4k+Y2labtNYgFM+skxxEsfWCpbWNNK47yjiscgnJfbMvbUkVRcEt0bWFxH1
12ues0deS5dS34nRShdIRQSjKv9TuqGF5mt1mxrmUPG+JTt2An+r/E8rnuensMH9EBoRFU7H48io
8XlKahCj9mP3jeZAKs8WubqZQD8UBPIUgUCeIpCnCESDjqNcvUWNfSQrGTc43hZSx0Si2S8FXH2R
9JdGNo/U0L6irj87eE5pm/CU+O6QuKG7+L3ldvP7NDybnB6poX1FXX/URwCJug36fWryKVWdTW2u
qEYouDupWvOiqtOq4cGquKr6PQV0IzvN+z4xiObWpzbFZDihKvrH5HFq6z2dTqq2vIjFS1X+3+zB
6WYAhNbsFe6jqL8ERr42O0+drep5zeprSkJTxtV1lIRXl8ZLMeTbzuWpqtjCayrqTSoa3EH7Us3d
h8TVAwaxw3hKgsdVXrRxeJqSIPXs3u8bNybB90adujPHUergKBRDKbGrSgrBKpW6qVMio4oxEtJ0
R+pT207vlLj1sOYzq5OqpZu2JDJ5sMr5qh/WUU+uuW07H95X1PUHh/3NieZb/7QmFEOeVglc/zQs
avHJEdJ0m9inDU3UhsgCgTxFIJCnCOQpAoE8RSBPEQjkKQKBPEUgTxEI5CkCgTxFIE8RCOQpAoE8
RSBPEQjkKQJ5ikAgTxEI5CliR/E0kZZ/sgmOay9JR91xnvtj+SidTkf5eCkov3S6WkmqT4nYWTwt
xQeUg9sGljoOJ6Wj5fWO3E/Ur4nGSs8d6aifJGNj2BqIMDy9QztYB2EeitLRamHuqnIk4RhcA7HM
cx1iPF2CbFqA+3i+Q1KFjwsxwnjOE003El7Isp92AdQ4onAiyVRmOh2Pq3kwZS1r6B6B4xIlWZ9K
1+XUCT6PbYNw52n2onrwaRjv1tnZa8TJQwz2jcSXDu2PwvPwdoh2noufOtTJQv5z+9E8tB2Jr+tU
PzUo9eNzl0CN8+TgaeWD5oUlNQ9YPvKrjiO74OrgbOeAlAl0jpxKyNldiw99CNsG4c7T5S71YHDy
gVsia8pxdw4ETUmefGEeboXpPBS+CXdCCRZWYboDCixsZo6pWh6mL2h5XegAyYjIp1iwHOdpmFZy
zEfVPFiK16w9tQpD8HtrT61IQYegfxpWleyewLZBGLCuh5IG2UhMDJzae8toRKbp1aH7j2tBqbdk
CtwwO5ko8uWJobY8NzwG6fGSFMb+1B81snod+CH5WI6qxAE1j1RuCDJxSlaGoO8pkYXIcTIFIx9E
o6Gh1kMpSfYpJ5sCV+HUcf26KCd4amysCNHh249F4W4QRdDDM9KZloUIrXoyKU7EFKjmIc7+cHRo
BejsqTuncsp1Iw4C4ctTNp5phXw3RKWjWyMXBCMoz6JzcKCUjrOfAdbPfwV6z8GkFsxD7z7tuOsn
oI6EYkqcz5oC1Tzi724V4fdBePfiH0FEuX6ul8VHIELp0+eznVeySzLJjv5uWpvYTEeTp6/AhbMH
EyzsVxmYnIOZs7mTZ5e0ZAt8TtehLW9Th01anIOn8y0woRqvSh5L2St7Xvg8XDmzL3G6Xbn+YO7F
JWwURIB9Ghoi3HD0lOBtxTitS144v+uOMzmscbRPN5GnsWstsUXvYC5SsF/Kk3I5Gp/DlkaeVoO2
6pKtyv97oui8JLD4RVSniBrapwgE8hSBQJ4ikKcIBPIUgUCeIpoawfNS+r67bhuJW08tO/Badr23
/tQXxk0C7mq6rhbSPSK17RGoZxtyL0BvgaQszDelDnHtadVt2XfcThgh5k+1vSADqsa5t65li2i3
3aTrQ1P7ntZedzVdp/YLNpqZfsCy7XUomvoIZJWOOqRwpFUfEFrzapPe2iSbgqdaLarb2jmeWaVh
DFUCZp0iNRk1bVHaCM87CU9tGhhojUPqL1RAB1dFL+OLSIg4W9iqbV5Pv9GNE4WDps5dD7M1HiXQ
lHuIkRCBxNLmpErK+HbYNJSarLJ+g1ItQkNvq9VmoZmpDoh/abW+SCEx8epXK36sa22qkgq2Pg8b
UXlMla1cK7MU9ZQ+qbxDKexctG2IBRU+7qQulpXrwAgM8y+0VRw2oknDugwvg1N62cG+ofWuu+T2
5albG1HiR9g6dyyb3W/R2jKH+j4m1Zoa2wMtDvvSTQ0Sb11KlM4/lF7d5I6ryfpJQojPk7aTO303
fRrGSNPnAuwEpaYpQvlAzc36U+fm1iYsgu5qRKyg6GbzUjVSNyaQlxTKBUfanYoIbp28hfDpxP37
9y3r/Rvqe1NEg5smO88IaEOubKVJWuWYcOd1gqhPEchTBAJ5ikCeIhCNOo6iqoke4GhqXDW84sx+
kw5fTpNry+YOpYn9yCuGr/+pw4u1av9Tqo+BqJv/qeo86et/qlZ83UZSyqIMyYbmKVTn7mTzqnT4
clLDvXcTierw3PSJ4et/6nAard7/lGi3Mt7mWW7qFNelFDKb6U7Wp65KxOloalc7dgdp6tZUW1ix
JASTqHdEh18f2ejjU3lQ3XocByKeIaQReWrWGXai+XfhrvpIa+sGdaIgdWCdXwKPx5ZW8EzVq9iL
DcDJQJ4aX5fYtIe/o2nDO/GEN+f8iket3zFV438ayBvdTg6r/3Zkv0/AZrG5V1Cj15e7G2oNaGTN
pQr/U9+nWu90XM1P9fIOdevz7fe9Wog0uDqtXpqQvYX+3V2lfbChBIIdTT0u15mrjeou3RJkZbs7
mtKm6vVrQVNau/J6OJpSX3Gpb9qdpU9N9qnSy7g6mto9Ia2upo5IxN/Fv25KNdBz0+H5SV1HMtbi
ydMdVO/0K/M/DSUn+p+6YRP8T7eGp00B9D/deL9fU82GNK3pEB79T+s5rkGaVjDi2wr/01JPrlxa
izbXOAqxsyASgZ95dW5x+URnA27i1SpgCyEAxr/y0KWryo5fP158caH98sPu8fbPbLk+Fdt5biSR
1S1mZduo7rhRlgTYAlMCZNs57r4SlNISIMk9CvDIuBr/BDfSLu0aDbFUEzdhT5zn4t1StziilLrE
iszqKRllZU2MB3Sl93Fce1apMrmGeuLsQkm9INd5WT7LKsGlMjdS1tog2z4i1a2UTYKX9tQuJThe
3lo7XdMSZsvcmy6ZtqL55qXzPeXuRtWnNywvXv3p7R9f054ckB+dIzfqT9AvjEMlUDxzqfDlw2IU
FgvFm0cvzMzAXZnR9dl3PibHme1/+dL9Bz9ZYnET7/3uw807JbK+S/wNaRPh1B6lSnYNLL56+yfW
7ppkZf3sYwEWaET8+vmPSN4dMzMzP735dOnatV883r9QkutwDB46Ns8fXZQ2Mfrq7ju/yCqwZWTx
kUsPqbsaPXbs/m+U5dD2I49//eB8qWNg8Vs/n1ubUdumNv3938KDCZWkXXntd2VV3LVrubUR9emH
YQ2EsVVZV8oPbDImZDlp0zIo81wH8NKh9EQLmg7pLZyCIojT7J/dim3/RLQMr+eV0N1DQkockzeC
bp060Lz6NFeYv17yI8pqe2KtwbwA65ayeqIIU/3ahtsiGf8erBb2vAQlLfgdcH5K2cVoHT4q/fAw
369vayRA/5S8HTdcg2Pz7L5FmD/GjmtolKbikauvwIK0Uzj7s/xeu8DHUo1iqraYD/sFSy927TuD
aVZlY9A5cipxqLMgHz5TXB58Uo1QgDdIW/EyHrM6zHOJBdZB3S0WziuhMXhJy2nKaJlmxL1vmbzE
HtK4Xuzxcfi0payeKEMqBXcpxweOxg/Lv0atj0rBZeno4/AePi5K2xWDFp/9plSDKQr5cXZfHrrz
ULvx+GxHz/QlYK3m8bcwO93zSHej8fTKJAw+YNinABdiMCAfHIL+aXVfs5WWjg54Qo2wzp69GAh9
Uk1HltsHbgIhcfAAv5+X3xIPgckqbWqePnTu6F7oWdd0C+UfeGBi0FJWTwzJvYyiu/KTcqc5vgK6
sTWscJnhzzOfjx/ZC23QJ+j1O6WH/nLy5AOZNfZzy8nML2tWrjev9wRFmX+24fRp9PK5SRi4zbiQ
OgzfVwZE+nMN5C+vnVcqX63Cz2Q7CpkI5EajUge2WHzP6nyhQ+b0BOidRkr1v21SpM5L/YVemtcW
fnRq+HZLWT2R0akGfUN5qRZ7RobP6fP08sbEct0sF6LT7C4Xz+RSGWfo3qMf+9EQAXL0Rx8b2luz
cs3nfnrghm6lq3f92/Ni+Zn5RuMppBYv/5DpyIym/URRDW6RDlVjDX5pmGRSJxVdLuXKLdo5a422
6NG5demMg9fpZtA2mLk5fDIt2+qSzcns05KlrD71K2bVWrxH7pLEKy2njJ1hR6SajZithFwhX9Ze
vrTqoWuSfVpkVcrs07VaPoE0v7r/eqWb7wLr7/U3ta8eb5SJGhNPY+lU6mnW8URgVrFJ9v2E1ayk
FTk418s6+AxIxH3dOT1FG6tYge9JDQsQv7e7TxppQZ7C5Kycq8D9hZhSjLpdEG1egsb42T5W+rGx
MclAZyPMNsk+lYbCeUErqyei0HsHPCyPS1fll39fgV2CWd2ymuWkYIHvFkCqxxIZ5tR5P5a4Twlt
kezTKPtvPA+ttS1edLG4uvc3VZsUtN+e1/ykeKWBGs1Uy1fP5LiPZr8HNHOPImDr21/4ATw6cSNc
OPtg7sUliGduhPjk0rv0FJ+DOCRalnLvEyHxpStvHb3ATITWKPD75JaY+8dnd+dYfrI6aOL1gXa1
7ls+u2S6sPSmkZEzz0tlnYPYPv8XJQv9uVx2UJllkh/WPxl6s2n680L2ZG5UJsbzrVc6+2fg2xcT
eckskAe0z2Vzy/1K6JnkyJlFWMqOJM8s1byEe5Yzsd/pMs67bzjw6sqxxpoc3MirYvEG7kqoiMn8
bDPP9NcHafD2PZo9kK82adWNuX/1lS7pobguPu+tSLfKX2pjfn2p1ZVwXecX34+8tIMvu+3/rqD9
GT91xkGkUA+JSqS0Hn9pj+8T0pQ8Rey4TgDXP0UgkKcI5CkCgTxFIJCnCOQpAlEjWNY/NS/NCdWt
8kWtX/bLcOwx5diJ2nODestFbZlK3xxMi5XYRAO3HbD1I/cV+5xLl9pWgfOTJvQCqYiKeLphEOe5
s5mIc70qnw3qncwgvjnoIdTtKXLQyRTktvirc+lS50KuntKEXiAVUW2/TylVFwKRj8yH7EdpMC2A
gvkMjPj2/LR2pmHbzlg9V10DgAbn4L5JtZtMFWs6uyY1ckcubo0+VVqEmBeJJmYtAWAL0JuQaEuD
Ec8WpuZV1kJ/pW5eHM8vB2LtyHVzRFOCpkTEg7EekinlU+9CjVWefMuDFK4HT2m4Ht28Sp3bBtyO
zo64nFTRgKT6HHSR/Te6JVVIRrwrotYLpCJPTXVNrZabf6cczPAwwbVHFXqs9nSqeoFURMhxVIjF
6EkFjUydY40w/X4A8Xxz8FomNMRtq+vBXVNRQpFi9R3v+0xPua9rpp+5jnEdi3uGZijx2g+A+Ksy
txmyULetTv2h0tx8nhJ9xtK06qaxPKe6MqrraqfmzXhslprXit4BS4CGWfnTa4lRfRFRf73mOXvk
l6/PVhrUvK0BMrgWqMr/lJKNBNfTyKwyhw1OUe0gbJX/acXz/DSUNdpkqHA6HkdGjc9TUoMYm2by
kfrcitS0mIgQQD8UBPIUgUCeIpCnCESDjqNcvUXNO8VXNCC2+3bYJxLNfikQyiMVrLvgefuK2r1Y
KbqBbiee+rXmBpvZ7y23v9+n4YllDguVRnfpku+CRN12/T41+ZSqzqY2V1QjFNydVK15UdVp1fBg
VVxVPZ8Ch38BrfWepYim1ac2xWQ4oSrayORxautLnU6qtryIxUtV/t/swelnADg69VC+oi6cR4W6
3Xjqqtfcr1l9TUnoyW/ipvHsBq0l2OlLj5PtO52nqpIKv/ErdT10ntPwHbP/VupIT+Sp2UM9ZF9p
/YKDejKKhGA7qci+pEjbHd3vh3VDJ86vkKkv0ezfXpv9Vl2TOBOgYkWemjp8Yv1s3tvjFKxOqhZX
T0sikwernK/6YZ3LbKhjs3sjnxC+orYC4LB/G6D51j+tknDI05oA1z8Ni+o+OUKaNjea8P0+2bRE
COQpAoE8RSBPEQjkKQKBPEUgTxEI5CkCeYpAIE8RCOQpAnmKQCBPEQjkKQJ5ikAgTxEI5CnCjFlB
KDWFoBF0IN65KHWuLgAk16Lhk+B3J4jNZmn5Ny4xmsKi8FxT9ftpGdpZd9wUIP+kYlBq5/iyCFkl
ZiefBCjn1fgCx91XkuLGtpGKTrCii+08Vy6xZuX4dlFu4Ps4rj0LyeijLMJ4ABmUuBIIzwvd0kE8
rdW3ljdDVqv9Eq+3QbZ9RKpTo21UGUzNVDXEjr2L31QO5w5y3Y3eEK2Cfjgzsx/GZrSzIzfqh/tB
OhQv/78CufXxp47+QeSru+/84swMRDpW1kqJiByn50r00n/dtVBiceOFVx/eHiztaRlgRb9heZ4/
ulggwwvRQ/cVJcJFxK+f/0jkrsnR9dnPPuafhRqXHeV/XRRW19bYsz4o1yer1jF46JicNztT65Sp
gwHQav6xY/d/oyyHzszMXL3+TOlPBVmGmf16lGqR/OTsPECXqmRiL3ettIZKt39my/Wphvt4vgM4
9gxDSeA5IaVePjDVCqtwbBreAevwUenKtbl16IopofnhWEoYy0mHp472bhNt+uY16d9n4fwUFNl/
09NwTLpQhKl+EOCJaBlezwdkocZl6MqIcwXGizsipuB3KHkzqHUKpYIRKkD/FKjn4tVMHD6ny7Ax
EG5mHroAFrokwaTfS7EOsbnG+53n4qcOdbK6G4MOsZAbXNF6MJiCCLDCjMLH4T18XISW2RaxeF4L
/ZmWwRugsE14euay9O9eSKWgzP5jP6PSBfnoLlbmu8XC+YAstLiMiL+fuDfBOvHskil4VMmbQa1T
+IJhb7F0qZSuyIb4OSW3vRstVve953/FfhYsf/O/uC7fVDwtwHSHyrT83o4PwjWdpymIQt832OGf
Zz4fP7IXYvuEA9z/5pJS6BDoNRphumF7ICeXaUrh25B+WT56AoTEwQP8fj7pm4UaVzqa4gcHWORl
8+h6WMnbqNPuZ01qbUoPBfFQ5oKa2//YaLHWn3C/vqepeMqe2cMq05K3fOJrSlXK9AP45Z25/5hh
VV2ITsMaLBbO5y/8ce69UmgG9PpVFcS2wYRS+ox+IaNU02LxPavzhY5V38QZg2owdafSxTvzBr1O
V+93DQWhzKfAJMNGQAv7f1Pu7s1/XTflF5uKp+zZFeG4fLAC73vJxF8RUh8qrJSj2jnAOT41FJWf
zijcrCeHyLbi6QiIJVakiFQvI0qdsSOp4vraokfn1gPqV8wqlTzhVt0jUlYRUx0ffiAtjQzUQa4R
2iOvBGbIsDEs/tNN3ZJtKnf58u8NhStRaCqexqD3HEyyahXhbrjZGBJx0owKV/r+MA8C3y3Ig4N3
8tCnvM8Q+lbFfDohHe6qfJO/hkYGzl3HSs+Keg6+JU28cdDbC38t2UUCTM76z0BHofcOeFhKJUBv
H6w68+5l+UnBSp2OjY1JIwNl4ikqJZFDWQcnGQGqDBtH6spqckE9Zr/X9+ajjd0IzlqeOZs7eXYJ
Hp24EQYzvyaaarwPvt0af/CHIjzfeqWzf4YZ5C1zcDAhj2bnvra+u/Os3HOssWHpdsKF7MncKBto
jC6fzMprW83353LZgwDjrXOSje6beEGKOygdLZ1lR9Q9bwatTlXI07LPZXPL/Qqd1mX735Bhw4hG
2l/TpRx27XtFbPRGCP/eVNwTWwoVsaN4OQWIQKTB+x3k7IF8tUkrGfjnLjOWxl6uoLm26r1pBe/3
x98ebuIiHhORhCHAlx3DKh3tz/jNknIQqdHUX/dVeK6i+dgm4CkCgX4oCATyFIE8RSCQpwgE8nRn
gW4wnOGrG74TRZ4iti3MrzjtW4pVvEeIfXc09dEhjufJuQMvsRxZt6y0bmRFScgcwL6/GnVKQvRg
l12sPCWzbMPmIo1Wk1oSgvut1JKnG4bL9uTO9iEO1e/Yhdq667RtD2oSJge3DU7sopjypcS6p1uA
ZJa91ojXpq7m7bGRpnXhqaI1lP3wFLbph5J6UHcxVQJMClA6o3p8h1rSGi709r6Gftf27vPJgXhz
UknnptNIhY+g296WDmm8lPMWWZ21NVDphu9Eq1F8bV4EUbQGJXYlpxDWFmBoMbWNnKwxNatpt14S
Vj0Tk1nhloNPn649blpaZyLHQxUoGSXgXZ5gVV5ThM87SIwQYoYsiU+06uqiLRzTrds+U79KIs5e
jvhrpkobxCUH3TLWNjW1mRy6yMTTnKbeNDOTmnrssU682kTZ8pXiTmu16/c1699EWBpOe9OadU0b
1Cmq6iaVKyISGFu1eytVCATC77+NqMg+JcGtV0kjU8+xRui2c2nlCnMInaiqfF1TGZu+U2Rancb7
PtNT1H2wQkzGm5dGpVWMYKjHtA6pgNa0gtsSnwwpqSBVw2lQssHw8M1GamFOB/KU6DOWpj3sjV3t
5SPLFKfpzK1BjTSuioXo0wHGPUwGpvVWABXn4HFfI1/PaSO/fANZSE0Tv2SL7VPLPDAQ7/CgmYrg
Z888YPa7U2Woyv+Uko0E12x4WrscKr0TbbKZe9tUcUB5/AbrEPx0Er9sqq25it+bUobNoelmdoh0
kx+gLWVsPeeUgthebc1V/D6K1CBGzW5VsxxI5dk2KVdpmEFvTRqf1rKOttcnzIgwRNqk7oD4dP31
7/cRzU7TprwT8hSxubZ3dTdAnu4wGm71neiG509dvUX16YyK9LjjNSF1zCBaptncfFRNE3pkA76i
Dp9WugO9QR3zwJ7htVOa7neiVQ6vIiSA7Hbn6ap46vJ62x7u9eBRO7l0r6lwvqJ2n1bq6miKaHC4
9fuUUv2Hqn4pVLtMNS9gJRRsIWpaa14sxByo5UtD0zTMC/kGMb8QdUGbe1PaXNdtrqi23tPppGrL
i1i8VOX/idOpyeoaShy9uTvRKuxG9JfAyNdm52nA3IL1xT2xfBFSnZuCr84kbqaH8eoY+bbT+31i
78J9OlMjpmu/7xUYoiv2IC+D9qRQ9JkLATH0xa0UqDJ9SmyarAL16PA0JcGkc+v3nTf2dGnaoTpV
Xsg3/KJkN7hd/N2w9xrb2M2D7x24vFpbyIklzwkPuz3pHNW4jOyp2/dwfn6fG3zrvB1RGU2OukUv
bNLNYeP3bnHjHlW+66GmL9+Mc+eZ6ZjYnKksiYyMiTFxQGUPLOqlYdU0VLcZPF2b9Ji2AtiKs82G
/eNCNEYgloVSDEqJqLTxT1pReGkSgxTPCXlFAbL/OmPQI3DSfhTKdfmiEijv9qclTPL84/lYdJzl
Hudi0n4uPfG4Wz/dHeNZbidKUDoBoiBvK6Tlwe41znExZZ+/UizGbpqNc0JWlotLKfdO8prMFfKU
aNaf8UN05yD13DAR9RSmEELU4RQxRyPmHEDLV0trWJt2QUxSmON4Gq1gu4/LzzbTvm8XS/EV4K7A
8zx0faPEdZnCLkMuXhSJov+YBmy9DP8+UUzkQL0+pqvFsbGx+1/U012bfe6P9ly+MsJy/3ZR5nnh
5fiTLjdf/m5h8d2QuQ6um4QnY4XYa40gdq+R9uJ3l+WTLwi7BgBujRVjt0rZX27PKfd+etYhcyXj
qMZGLb412g7qVNnkNC+AOAS/+i14Ogqr/TBt2qhiOgVtpXzeuDKVgs/NS9Ft12XV+FvGovYLqWOD
51PCMMv9GNAh+cr80y43Xz0GwhScKkIpCk9Pw9QAmO8VLTz+RuUmH56eewYgNgXT0u6NMylR3Yvr
TSm7zNuIp7VQiNtBp8o7o4DYWWZtn/8deGwehlOQMm2JxLraf15P7imZL5SS8rYf1utSz5w3Pf1R
JS5DtrNdUK+Mu9xcye2Na7A+D2V283HLzRfhD/bMyidDKfXf1DU9azWSTebtxFOECa+JdH2fNfij
nax7zojabI9mTB7Oz8bbzdE7y/Pt9utS5K5no26zRb8eYRaFpG1BdCNT57VnWXAqmnxIuXnEkkc0
98qp/fJRRlT/FR10ky6WkafbHtf+75S0Jx05yHTZ6k+glweYGBf3qaFCXlNWGUV9rs3nC8b1cREy
KSlyKiJtJsGl9IQqytEpeUIoDze7dc6/t/BGybaM9n8M4FMC9H0K1PxkfHA8NaRsOtrWO8uUfvRf
odfIpU+hsyRzDHm67ZG4Z4/UhN+ZeBMj4QmuuACwlN6j7VGeeFc0p+wG2aaoz6Vd72kxrvO7IZHb
zSKvHJQMzqx8bMn90G553/bFEys/cLn54C755q9mpthxF7c6CGp+Mv7hbXynYvT+c35fnA0K7uAL
hnXx97uVB0eRORC43wmiGVAb/9PKxs+aS0rVX7WHWBDV9IbA5HdqC6bg6WwY2snVsUyVizRaVi4e
srg0asU89auyWtcl2ciSSyEWRLUu2uK2bhD4LPRSwYKoqk+M/4Ko5kUGbR6yuDRqOGzM/9RYNE33
LKW22ACaA6qWOai5UOrqu0qNvGyymNa/VWdRqe4AG7Seju3zAnNJav4wUuq9suR2fNewyfrUpjPC
+5+CaRlUau7Y7eEAehSw+qQ6D+0uq/ZV+AIWRLUvPWb3YXVbENXrtarvwmhqP29doNK5PKun9YTq
tFqeerWu4xpxuehuK9qcVv3vRNzv7rMSWsCSqq6LqFGAANUWtCBqQKURT8PcsCxwadSN8NRw+PCu
QFKr1S6o62FFstTJniY1v5HbXgW4NGrVPA3lf1qrgSoJpb2J63jdndPmzjeYShtdEJV63SCcOy0u
jbqhfj/wIbf5m9q+cna0l/2jES/KuX2FapclzIKoJIimG14QNfBxDVl9iGp5al3q0xipuq14qi0t
qsyEmhYadQ0H51qkzgVWjQACVS+Iah4w2baUAO+FWK2Pgo+54/g8PdSiAEbiRloatTlQ8/dRtVv6
qh7ABVG35Xi/ijHR9mgsQjd92IbYVH2KQNQB6C+F2Bk8FesaHYHw5Onj7QBZyXu1Xf1GIO2Tw2vM
wWn/uGD+bjvtcuSHNLYW8tSi8v5wDMTbjrKjsZVg9Tdo/po7+LvugkvccF+Dj2FrIU/N6OUOwx75
Y4DDH+w1Byjfa0M6z0nfXCvfgqsfgUsffecVnZcVtC+yPb7bVr45V78x51JgSp+N80lFb6Y7T4AY
5xPsQSkleJJW4/M86ealNCxM/l5cSYfYgTwt/gpgVpkHv7NoDlC+12YMfUX65lr5Flz7CPza7GJS
iXXrpWfV2S6P77aVb85lrF9uVz7xVtMf/9zsNfVmrV+CrywV5hmhu9pm19WL67OLhdIsy0cKWyCW
+yJ2GE9LP9Y/Xn2j5etZ5Xtt1gOnpG+u1W/BVVxICeoJTR1Tv8zy+G5b+eZcTSUOm9MXfiulfS0z
lYI/iYJwnF38buqCcZcjSj5qmOm+iG0Mt/lTXrYhlaWpzMdQ6ildGxyTz9h140z533TEFdOSPakk
k/6NlkwxxP2LwlGXVOwvWgJTKskCmCjKMlhiyYdKmHYFsfP0aVn0mEVSvteWrkrX1W/BnepY+pBb
XojA47tt5ZtzV7SKYNLgGZZLUb5f1hFTC0PsWJ5G+/RDwfJeVf1eG4j8nbj6LXjGPiXQCQKvHHl8
t61+c+4G7gB0TehnnypBSmC6ez8cn7DH/KwShtjBPL1HP7xeWSZDXdBN/V4bUsp34sq34G27bcmX
Yj2qjenx3Xbint1erxcuFEdMQYNJbuV5gIU1zhn/oBKG2Ln2qXjDZXUYJe6ZTTnD62sP5lMu80yk
mMO2Qp7akCqorEh87v1unXP97ML7/qbc+vxhu70cK0cXo9hWyFMEovnsUwQCeYpAIE8RyFMEAnmK
QCBPEchTBAJ5ikAgTxHIUwQCeYpAniIQyFMEAnmKQJ4iEMhTBMIL/x+W2SyyXkXWhQAAAABJRU5E
rkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-04-30 22:24:57 +1000" MODIFIED_BY="sara " NO="6" REF_ID="CMP-002.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Cardiac toxicity of trastuzumab, outcome: 2.1 Congestive heart failure - all studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvgAAADwCAMAAABCMOCVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-04-29 11:21:11 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-04-18 20:39:44 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-04-18 20:39:44 +1000" MODIFIED_BY="[Empty name]">Cochrane Central Register of Controlled Trials (CENTRAL)</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-21 14:48:06 +1100" MODIFIED_BY="Sharon  M Parker">
<P>#1    MeSH descriptor: [Breast Neoplasms] explode all trees <BR/>#2    breast and (cancer* or tumour* or tumor* or neoplas*)<BR/>#3    #1 or #2<BR/>#4    (adverse or toxic or side) and (effect* or event* or drug reaction*)   <BR/>#5    MeSH descriptor: [Drug Toxicity] explode all trees<BR/>#6    #4 or #5    <BR/>#7    trastuzumab or herceptin<BR/>#8    #3 and #6 and #7 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-04-18 20:39:54 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-04-18 20:39:54 +1000" MODIFIED_BY="[Empty name]">MEDLINE search strategy (1966 to current) (OVID)</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-21 14:51:05 +1100" MODIFIED_BY="Sharon  M Parker">
<TABLE COLS="2" ROWS="49">
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>exp Breast Neoplasms/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>breast.ab,ti,tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>mammary.ab,ti,tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>2 or 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>cancer*.ab,ti,tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>carcinoma*.ab,ti,tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>neoplas*.ab,ti,tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>tumo?r*.ab,ti,tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>metastas*.ab,ti,tw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>5 or 6 or 7 or 8 or 9</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>4 and 10</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>metastatic breast cancer.ab,ti,tw,kw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>advance* breast cancer.ab,ti,tw,kw.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>1 or 11 or 12 or 13</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>trastuzumab.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>herceptin.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>15 or 16</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>exp Antineoplastic Agents/ae, ct, de, to [Adverse Effects, Contraindications, Drug Effects, Toxicity]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>exp Drug Hypersensitivity/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>exp Drug Toxicity/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>exp Drug Tolerance/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>exp Causality/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>exp Risk/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>exp Product Surveillance, Postmarketing/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>18 or 19 or 20 or 21 or 22 or 23 or 24</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>safe*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>adr.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>adrs.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>tolerabilit*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>toxicit*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>adverse reaction*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P>hypersensitivit*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>adverse effect*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>undesirable effect*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>toxic effect*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>complication*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>causalit*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>risk*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>postmarketing.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>post marketing.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>side effect*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P>side event*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>side outcome*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>adverse event*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>adverse outcome*.ab,ti.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>25 or 46</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>14 and 17 and 47</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>limit 48 to (english language and humans and yr="1996 -Current")</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-04-18 20:41:52 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-04-18 20:40:23 +1000" MODIFIED_BY="[Empty name]">EMBASE (January 1996 to current) (host: Embase.com)</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-18 20:41:52 +1000" MODIFIED_BY="[Empty name]">
<P>#23 #22 AND [humans]/lim AND [english]/lim AND [embase]/lim AND [1996-2013]/py<BR/>#22 #9 AND #20 AND #21<BR/>#21 #3 OR #6<BR/>#20 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #19<BR/>#19 #17 AND #18<BR/>#18 effect*:ab,ti OR event*:ab,ti OR outcome*:ab,ti<BR/>#17 side:ab,ti OR adverse:ab,ti<BR/>#16 safe*:ab,ti OR adr:ab,ti OR adrs:ab,ti OR tolerabilit*:ab,ti OR toxicit*:ab,ti OR undesirable:ab,ti AND effect*:ab,ti OR adverse:ab,ti AND reaction*:ab,ti OR hypersensitivit*:ab,ti OR toxic:ab,ti AND effect*:ab,ti OR complication*:ab,ti OR causalit*:ab,ti OR risk:ab,ti OR postmarketing:ab,ti OR post:ab,ti AND marketing:ab,ti<BR/>#15 'postmarketing surveillance'/exp<BR/>#14 'risk'/exp<BR/>#13 'drug tolerance'/exp<BR/>#12 'drug toxicity'/exp<BR/>#11 'drug hypersensitivity'/exp<BR/>#10 'antineoplastic agent'/exp/dd_ae,dd_to<BR/>#9 #7 OR #8<BR/>#8 trastuzumab:ab,ti OR herceptin:ab,ti<BR/>#7 'trastuzumab'/exp<BR/>#6 #4 AND #5<BR/>#5 cancer*:ab,ti OR tumour*:ab,ti OR tumor*:ab,ti OR neoplasm*:ab,ti OR metastas*:ab,ti OR carcinoma*:ab,ti<BR/>#4 breast:ab,ti OR mammary:ab,ti OR mammaries:ab,ti<BR/>#3 #1 OR #2<BR/>#2 'breast tumor'/exp<BR/>#1 'breast cancer'/exp</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-04-18 20:44:22 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-01-21 15:13:02 +1100" MODIFIED_BY="Melina L Willson">WHO ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-18 20:44:22 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Basic search:</B>
</P>
<P>1. Trastuzumab containing regimens for metastatic breast cancer</P>
<P>2. Metastatic breast cancer AND trastuzumab</P>
<P>3. Advanced breast cancer AND trastuzumab</P>
<P>4. Metastatic breast cancer AND herceptin</P>
<P>5. Advanced breast cancer AND herceptin</P>
<P>
<B>Advanced search:</B>
</P>
<P>1. <U>Title</U>: Trastuzumab containing regimens for metastatic breast cancer</P>
<P>
<U>Recruitment Status</U>: All</P>
<P>2. <U>Condition</U>: metastatic breast cancer</P>
<P>
<U>Intervention</U>: trastuzumab OR herceptin OR trastuzumab containing regime*</P>
<P>
<U>Recruitment Status</U>: All</P>
<P>3. <U>Condition</U>: advanced breast cancer</P>
<P>
<U>Intervention</U>: trastuzumab OR herceptin OR trastuzumab containing regime*</P>
<P>
<U>Recruitment Status</U>: All </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-04-29 11:21:11 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-01-21 15:13:10 +1100" MODIFIED_BY="Melina L Willson">Clinicaltrials.gov</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-29 11:21:11 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Basic search:</B>
</P>
<P>1. Trastuzumab containing regimens for metastatic breast cancer[ft1] </P>
<P>2. (metastatic breast cancer OR advanced breast cancer) AND (trastuzumab OR herceptin)[ft2] </P>
<P>
<B>Advanced search:</B>
</P>
<P>1. <U>Title</U>: Trastuzumab containing regimens for metastatic breast cancer</P>
<P>
<U>Recruitment</U>: All studies</P>
<P>
<U>Study Results</U>: All studies</P>
<P>
<U>Study Type</U>: All studies</P>
<P>
<U>Gender</U>: All studies</P>
<P>2. <U>Condition</U>: (metastatic breast cancer AND advanced breast cancer)</P>
<P>
<U>Intervention</U>: trastuzumab OR herceptin OR trastuzumab containing regime*</P>
<P>
<U>Recruitment</U>: All studies</P>
<P>
<U>Study Results</U>: All studies</P>
<P>
<U>Study Type</U>: All studies</P>
<P>
<U>Gender</U>: All studies</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-04-18 20:43:46 +1000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-04-18 20:43:46 +1000" MODIFIED_BY="[Empty name]">BIOSIS (January 1996 to current) (host: ISI Web of Knowledge)</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-24 12:04:47 +1100" MODIFIED_BY="Sharon  M Parker">
<TABLE COLS="2" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P># 7</P>
</TD>
<TD VALIGN="TOP">
<P>#6 AND #5</P>
<P>
<I>Databases=BIOSIS Previews Timespan=1996-2013</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 6</P>
</TD>
<TD VALIGN="TOP">
<P>#4 AND #3</P>
<P>
<I>Databases=BIOSIS Previews Timespan=1996-2013</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 5</P>
</TD>
<TD VALIGN="TOP">
<P>#2 AND #1</P>
<P>
<I>Databases=BIOSIS Previews Timespan=1996-2013</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 4</P>
</TD>
<TD VALIGN="TOP">
<P>(TS=(advanced breast cancer*) OR TS=(advanced breast neoplasm*) OR TS=(advanced breast tumor*) OR TS=(advanced breast tumour*)) AND Language=(English) AND Taxa Notes=(Humans)</P>
<P>
<I>Databases=BIOSIS Previews Timespan=1996-2013</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 3</P>
</TD>
<TD VALIGN="TOP">
<P>(TS=(metastatic breast cancer*) OR TS=(metastatic breast neoplasm*) OR TS=(metastatic breast tumor*) OR TS=(metastatic breast tumour*)) AND Language=(English) AND Taxa Notes=(Humans)</P>
<P>
<I>Databases=BIOSIS Previews Timespan=1996-2013</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 2</P>
</TD>
<TD VALIGN="TOP">
<P>(CC=(trastuzumab OR Toxicology - Pharmacology) OR CC=(herceptin OR Toxicology - Pharmacology)) AND Language=(English) AND Taxa Notes=(Humans)</P>
<P>
<I>Databases=BIOSIS Previews Timespan=1996-2013</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 1</P>
</TD>
<TD VALIGN="TOP">
<P>(MC=(trastuzumab OR Oncology) OR MC=(herceptin OR Oncology)) AND Language=(English) AND Taxa Notes=(Humans)</P>
<P>
<I>Databases=BIOSIS Previews Timespan=1996-2013</I>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;24 full-text articles/abstracts referring to 7 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;39 full-text articles/abstracts assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;6407 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;6407 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;7660 records identified through database searching:&lt;/p&gt;&lt;p&gt;6619 records from SR, MEDLINE and EMBASE&lt;/p&gt;&lt;p&gt;310 records from BIOSIS&lt;/p&gt;&lt;p&gt;317 (all ongoing and prospectively registered) trials from WHO ICTRP&lt;/p&gt;&lt;p&gt;345 trials from ClinicalTrials.gov&lt;/p&gt;&lt;p&gt;69 trials from CENTRAL&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;6368 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;15 full-text articles excluded:&lt;/p&gt;&lt;p&gt;- 2 not randomised studies&lt;/p&gt;&lt;p&gt;- 1 study administered different chemotherapy regimens in the trastuzumab and in the control arm&lt;/p&gt;&lt;p&gt;- 12 full-text articles impossible to be found&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>